<SEC-DOCUMENT>0001493152-24-024799.txt : 20240621
<SEC-HEADER>0001493152-24-024799.hdr.sgml : 20240621
<ACCEPTANCE-DATETIME>20240621172023
ACCESSION NUMBER:		0001493152-24-024799
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		16
FILED AS OF DATE:		20240621
DATE AS OF CHANGE:		20240621

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JanOne Inc.
		CENTRAL INDEX KEY:			0000862861
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				411454591
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-278784
		FILM NUMBER:		241061415

	BUSINESS ADDRESS:	
		STREET 1:		325 E. WARM SPRINGS ROAD
		STREET 2:		SUITE 102
		CITY:			LAS VEGAS
		STATE:			NV
		ZIP:			89119
		BUSINESS PHONE:		702-997-5968

	MAIL ADDRESS:	
		STREET 1:		325 E. WARM SPRINGS ROAD
		STREET 2:		SUITE 102
		CITY:			LAS VEGAS
		STATE:			NV
		ZIP:			89119

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	APPLIANCE RECYCLING CENTERS OF AMERICA INC /MN
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>form424b5.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS
    SUPPLEMENT</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed
    Pursuant to Rule 424(b)(5)</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(To
    Prospectus dated April 25, 2024)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
    No. 333-278784</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><IMG SRC="form424b5_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JanOne
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>Up to $5,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Common Stock</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered an At The Market Offering Agreement (the &ldquo;Sales Agreement&rdquo;) with H.C. Wainwright &amp; Co., LLC (&ldquo;Wainwright&rdquo;),
relating to shares of our common stock, $0.001 par value per share (our &ldquo;Common Stock&rdquo;), offered by this
prospectus supplement and the accompanying prospectus. In accordance with the terms of the Sales Agreement, we may offer
and sell shares of our Common Stock having an aggregate offering price of up to $5,000,000 from time to time through or to Wainwright,
acting as agent or principal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of our Common Stock, if any, under this prospectus supplement will be made by any method permitted that is deemed an &ldquo;at the market&rdquo;
offering as</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> defined in Rule 415(a)(4) under
the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), including sales made directly on or through the Nasdaq
Capital Market or any other existing trading market in the United States for our Common Stock, sales made to or through a market maker
other than on an exchange or otherwise, directly to Wainwright as principal, in negotiated transactions at market prices prevailing at
the time of sale or at prices related to such prevailing market prices and/or in any other method permitted by law. Under the Sales Agreement,
Wainwright is not required to sell any specific number or dollar amount of our securities; but, Wainwright will act as our sales agent
using commercially reasonable efforts consistent with its normal trading and sales practices. There is no arrangement for funds to be
received in any escrow, trust, or similar arrangement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wainwright
will be entitled to compensation at a commission rate of 3.0% of the gross sales price per share sold under the Sales Agreement. See
&ldquo;Plan of Distribution&rdquo; beginning on page S-10 for additional information regarding the compensation to be paid to Wainwright.
In connection with the sale of the shares of our Common Stock on our behalf, Wainwright will be deemed to be an &ldquo;underwriter&rdquo;
within the meaning of the Securities Act, and the compensation of Wainwright will be deemed to be underwriting commissions or discounts.
We have also agreed to provide indemnification and contribution to Wainwright with respect to certain liabilities, including liabilities
under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 18, 2024, the aggregate market value of our outstanding Common Stock held by non-affiliates, or the public float,
was calculated based on <FONT STYLE="background-color: white">12,063,092</FONT> shares of our outstanding Common Stock held by non-affiliates
at a price of $5.10 per share, the closing price of our Common Stock on April 26, 2024. Pursuant to General Instruction I.B.6 of Form
S-3, in no event will we sell shares of our Common Stock pursuant to this prospectus with a value of more than one-third of the aggregate
market value of our Common Stock held by non-affiliates in any 12-month period, so long as the aggregate market value of our Common Stock
held by non-affiliates is less than $75,000,000. During the 12 calendar months prior to, and including, the date of this prospectus supplement,
we have sold approximately $1,092,000 of our securities pursuant to General Instruction I.B.6 of Form S-3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Common Stock is listed on the Nasdaq Capital Market under the symbol &ldquo;JAN.&rdquo; On June 18, 2024, the last reported
sale price of our Common Stock on the Nasdaq Capital Market was $2.29 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>in our securities involves a high
degree of risk. See</B> &ldquo;<B>Risk Factors</B>&rdquo; <B>beginning</B><B> on page S-5 of this prospectus supplement
and the documents incorporated by reference into this prospectus supplement for a discussion of the risks that you
should consider in connection with an investment in our securities.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus supplement. Any representation to the contrary is a criminal offense.</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>H.C. Wainwright &amp; Co.</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
date of this prospectus supplement is June 21, 2024.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prospectus
Supplement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#SJ_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>ABOUT THIS PROSPECTUS SUPPLEMENT</U></FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#SJ_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>CAUTIONARY STATEMENTS REGARDING FORWARD-LOOKING INFORMATION</U></FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#SJ_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>PROSPECTUS SUPPLEMENT SUMMARY</U></FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#SJ_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>THE OFFERING</U></FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#SJ_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>RISK FACTORS</U></FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#SJ_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>USE OF PROCEEDS</U></FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-7</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#SJ_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>DIVIDEND POLICY</U></FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-8</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#SJ_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>DESCRIPTION OF SECURITIES THAT WE ARE OFFERING</U></FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-8</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#Z_001">DILUTION</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">S-9</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#Z_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">S-10</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#SJ_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>LEGAL MATTERS</U></FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-</FONT>11</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#SJ_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>EXPERTS</U></FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-11</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#SJ_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>WHERE YOU CAN FIND MORE INFORMATION</U></FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-11</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#SJ_013"><U>INFORMATION
    INCORPORATED BY REFERENCE</U></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-12</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prospectus</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#nd_001">ABOUT THIS PROSPECTUS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#nd_002">AVAILABLE INFORMATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#nd_003">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#nd_004">FORWARD-LOOKING STATEMENTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#nd_005">RISK FACTORS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#nd_006">BUSINESS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_002">SELECTED CONSOLIDATED FINANCIAL DATA</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">31</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_003">DESCRIPTION OF SECURITIES WE MAY OFFER</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_004">DESCRIPTION OF CAPITAL STOCK</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_005">DESCRIPTION OF PREFERRED STOCK</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">36</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_006">DESCRIPTION OF DEBT SECURITIES</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">37</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_007">DESCRIPTION OF WARRANTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">43</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_008">DESCRIPTION OF RIGHTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">45</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_009">DESCRIPTION OF UNITS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">46</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_010">USE OF PROCEEDS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">46</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_011">PLAN OF DISTRIBUTION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">46</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_012">LEGAL MATTERS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">48</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_013">EXPERTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">48</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="SJ_001"></A>ABOUT
THIS PROSPECTUS SUPPLEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
document is in two parts, this prospectus supplement and the accompanying base prospectus, both of which are part of a registration statement
on Form S-3 that we filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) using a &ldquo;shelf&rdquo; registration
process. The first part is the prospectus supplement, including the documents incorporated by reference, which describes the specific
terms of this offering. The second part, the accompanying base prospectus, including the documents incorporated by reference, provides
more general information. Before you invest, you should carefully read this prospectus supplement, the accompanying base prospectus,
all information incorporated by reference herein and therein, as well as the additional information described under &ldquo;<I>Where You
Can Find More Information</I>&rdquo; on page S-11 of this prospectus supplement. These documents contain information you should consider
when making your investment decision. This prospectus supplement may add, update, or change information contained in the accompanying
base prospectus. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand,
and the information contained in the accompanying base prospectus or any document incorporated by reference therein filed prior to the
date of this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement. If any statement
in one of these documents is inconsistent with a statement in another document having a later date &mdash; for example, a document filed
after the date of this prospectus supplement and incorporated by reference in this prospectus supplement and the accompanying base prospectus
&mdash; the statement in the document having the later date modifies or supersedes the earlier statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should rely only on the information contained or incorporated by reference in this prospectus supplement, the accompanying base prospectus
and in any free writing prospectuses we may provide to you in connection with this offering. We have not authorized any other person
to provide you with any information that is different. If anyone provides you with different or inconsistent information, you should
not rely on it. We are offering to sell, and seeking offers to buy, shares of our Common Stock only in jurisdictions where offers and
sales are permitted. The distribution of this prospectus supplement and the offering of the Common Stock in certain jurisdictions may
be restricted by law. Persons outside the United States who come into possession of this prospectus supplement must inform themselves
about, and observe any restrictions relating to, the offering of the Common Stock and the distribution of this prospectus supplement
outside the United States. This prospectus supplement does not constitute, and may not be used in connection with, an offer to sell,
or a solicitation of an offer to buy, any securities offered by this prospectus supplement by any person in any jurisdiction in which
it is unlawful for such person to make such an offer or solicitation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
further note that the representations, warranties, and covenants made by us in any agreement that is filed as an exhibit to any document
that is incorporated by reference in the accompanying base prospectus were made solely for the benefit of the parties to such agreement,
including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation,
warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly,
such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
used herein, &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; or &ldquo;our&rdquo; refers to JanOne Inc., a Nevada corporation,
and our subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="SJ_002"></A>CAUTIONARY
STATEMENTS REGARDING FORWARD-LOOKING INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information included or incorporated by reference into the base prospectus and this prospectus supplement contains forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) and Section 21E of the
Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;). These forward-looking statements that relate to future
events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual
results, levels of activity, performance, or achievements to differ materially from any future results, levels of activity, performance
or achievements expressed or implied by these forward-looking statements. Words such as, but not limited to, &ldquo;believe,&rdquo; &ldquo;expect,&rdquo;
&ldquo;anticipate,&rdquo; &ldquo;estimate,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;targets,&rdquo; &ldquo;likely,&rdquo;
&ldquo;aim,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo; &ldquo;should,&rdquo; &ldquo;predict,&rdquo; &ldquo;potential,&rdquo;
&ldquo;continue,&rdquo; and similar expressions or phrases identify forward-looking statements. We have based these forward-looking statements
largely on our current expectations and future events and financial trends that we believe may affect our financial condition, results
of operation, business strategy and financial needs. Actual results may differ materially from those expressed or implied in such forward-looking
statements as a result of various factors. We do not undertake, and we disclaim, any obligation to update any forward-looking statements
or to announce any revisions to any of the forward-looking statements, except as required by law. Certain factors that could cause results
to be materially different from those projected in the forward-looking statements include, but are not limited to, statements about:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            history of losses and working capital deficit;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to continue as a going concern;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            known and unknown impact of the Covid-19 pandemic on our Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">dependence
                                            on our key personnel;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">need
                                            for additional financing to complete our Phase IIb/IIIa studies for JAN101, which is a potential
                                            treatment for Periphery Artery Disease;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 76.8pt; text-align: justify; text-indent: -41.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">need
                                            for financing for the continued development of our newly acquired JAN123, which is a potential
                                            treatment for Complex Regional Pain Syndrome;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 76.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
                                            and legal uncertainties;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            impact of quarterly results on our common stock price; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">dilution
                                            to our stockholders upon the exercise of outstanding common stock options and restricted
                                            stock unit grants.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
urge you to consider these factors before investing in our Common Stock. The forward-looking statements included in this prospectus supplement,
the accompanying base prospectus, and any other offering material, or in the documents incorporated by reference into this prospectus
supplement, the accompanying base prospectus, and any other offering material, are made only as of the date of this Prospectus Supplement,
the accompanying base prospectus, any other offering material, or the documents incorporated by reference. For more detail on these and
other risks, please see &ldquo;Risk Factors&rdquo; in this Prospectus Supplement, the base prospectus, and our Annual Report on Form
10-K for our 2023 fiscal year ended December 30, 2023, filed with the SEC on April 8, 2024, and our other filings with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="SJ_003"></A>PROSPECTUS
SUPPLEMENT SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following information below is only a summary of more detailed information included elsewhere in, or incorporated by reference in, this
prospectus supplement and the accompanying base prospectus, and should be read together with the information contained or incorporated
by reference in other parts of this prospectus supplement and the accompanying base prospectus. This summary highlights selected information
about us and this offering. This summary may not contain all of the information that may be important to you. Before making a decision
to invest in our Common Stock, you should read carefully all of the information contained in or incorporated by reference into this prospectus
supplement and the accompanying base prospectus, including the information set forth under the caption &ldquo;Risk Factors&rdquo; in
this prospectus supplement and the accompanying base prospectus, as well as the documents incorporated herein by reference, which are
described under &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Information Incorporated by Reference&rdquo; in this prospectus
supplement.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JanOne
Inc. (formerly known as Appliance Recycling Centers of America, Inc.) and subsidiaries (collectively, &ldquo;we,&rdquo; the &ldquo;Company,&rdquo;
or &ldquo;JanOne&rdquo;) is focused on being a clinical-stage pharmaceutical company committed to finding treatments for conditions that
cause severe pain and bringing drugs to market with non-addictive pain-relieving properties and, as of Mid-May, 2024 is broadening
its focus to fintech, as well.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection this broadening of our focus, on May 10, 2024, we executed and delivered a definitive Agreement and Plan of Merger (the &ldquo;Merger
Agreement&rdquo;) with ALT5 Sigma, Inc., a Delaware corporation (&ldquo;ALT5&rdquo;), pursuant to which we acquired all of the capital
stock of ALT5, which, as of the May 15, 2024, closing of that transaction, became a first-tier, wholly-owned subsidiary of ours and
ALT5&rsquo;s subsidiaries became our second-tier wholly-owned subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
that transaction, we issued approximately 1,799,100 shares of our common stock and 34,207 shares of our newly designated Series B Preferred
Stock (the &ldquo;Series B Stock&rdquo;) to the legacy equity holders of the capital stock of ALT5. The shares of our common stock represented
approximately 19.9% of our then-issued and outstanding shares of common stock. Each of the issued shares of our common stock was valued
at $4.14, which was the Nasdaq NOCP on Thursday, May 9, 2024, the day immediately prior to the date on which the parties executed and
delivered the Merger Agreement. The Series B Stock is not redeemable, is not convertible, directly or indirectly, into any class or series
of our capital stock, does not provide for the payment or accrual of any dividends, has no non-statutorily mandated voting rights, and
provides for a liquidation preference of $250 per share under certain limited circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ALT5 is a fintech that provides next generation blockchain-powered technologies to enable a migration to a new global financial paradigm.
ALT5, through its subsidiaries, offers two main platforms to its customers: &ldquo;ALT5 Pay&rdquo; and &ldquo;ALT5 Prime.&rdquo; ALT5 Pay is a crypto-currency payment gateway that enables registered and approved global merchants to accept and make crypto-currency payments
or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay&rsquo;s
checkout widgets and APIs. Merchants have the option to convert to fiat currency (US Dollars, Canadian Dollars, Euros, and British Pounds
Sterling) automatically or to receive their payment in digital assets. ALT5 Prime is an electronic over-the-counter trading platform
that enables registered and approved customers to buy and sell digital assets. Customers can purchase digital assets with fiat and, equally,
can sell digital assets and receive fiat. ALT5 Prime is available through a browser-based access, mobile phone application named &ldquo;ALT5 Pro&rdquo; that can be downloaded from the Apple App Store, from Google Play, through ALT5 Prime&rsquo;s FIX API, as well as through
Broadridge Financial Solutions&rsquo; NYFIX gateway for approved customers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to our commitment to finding treatments for conditions that cause severe pain and bringing drugs to market with non-addictive
pain-relieving properties,</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> our first drug candidate
is a treatment for Peripheral Artery Disease (&ldquo;PAD&rdquo;), a condition that can cause severe pain and affects over 8.5 million
people in the United States. The Company intends to champion new initiatives&mdash;digital technologies, educational advocacy, and revolutionary
painkilling drugs that address what we believe is a multibillion dollar a year market&mdash;to help combat the opioid crisis, which claims
tens of thousands of lives each year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2022, we entered into a Purchase Agreement (the &ldquo;Soin Purchase Agreement&rdquo;) with Soin Therapeutics, LLC. Under
the Soin Purchase Agreement, the Company acquired Soin Therapeutics and its LDN product, now known as JAN123. JAN123 is a novel formulation
of 2.0 mg of LDN that results in a biphasic release of the product. The release properties of JAN123 provide for an immediate release
of less than half the product with a slow, sustained release of the remaining product. Importantly, the rapid release of LDN has been
reported to lead to vivid and lucid unpleasant dreams, which should be eliminated with the formulation of JAN123. Initially, a single
tablet of JAN123 will be administered orally, once a day before sleep, with eventual titration up to two tablets (4 mg) before sleep.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
name of the Company, JanOne Inc., was strategically chosen to express the start of a new day in the fight against the opioid epidemic.
January one is the first day of a New Year&mdash;universally considered as a day of optimism, resolution, and hope. JanOne stands by
its strategic commitment to fresh thinking and innovative means to assist in ending the worst drug crisis in our nation&rsquo;s history.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
March 8, 2023, the Company operated its legacy businesses through its Recycling Subsidiaries, consisting of: (a) ARCA Recycling, Inc.,
a California corporation (&ldquo;ARCA Recycling&rdquo;), (b) ARCA Canada Inc., a corporation organized under the laws of Ontario, Canada
(&ldquo;ARCA Canada&rdquo;), and (c) Customer Connexx, LLC, a Nevada limited liability company (&ldquo;Connexx&rdquo;). ARCA Recycling
and ARCA Canada recycle major household appliances in North America by providing turnkey appliance recycling and replacement services
for utilities and other sponsors of energy efficiency programs. Connexx is a company that provides call center services for recycling
businesses. On March 9, 2023, we entered into a Stock Purchase Agreement (the &ldquo;Recycling Purchase Agreement&rdquo;) with VM7 Corporation,
a Delaware corporation (&ldquo;VM7&rdquo;), under which it agreed to acquire all of the outstanding equity interests of the Recycling
Subsidiaries. The principal of VM7 is Virland A. Johnson, our Chief Financial Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information contained in or accessible from our website is not incorporated into this Prospectus Supplement and it should not be considered
part of this Prospectus Supplement. We have included our website address in this Prospectus Supplement solely as an inactive textual
reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was incorporated in Minnesota in 1983, although, through its predecessors, we began operating our legacy recycling business in
1976. On March 12, 2018, we reincorporated in the State of Nevada. Effective as of September 10, 2019, we changed our name to JanOne
Inc. We run our operations through JanOne Inc., as well as through our wholly-owned subsidiaries, JanOne BioTech Holdings, Inc., and
Soin Technologies, LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Where
You Can Find Us</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive office is located at 325 E. Warm Springs Road, Suite 102, Las Vegas, Nevada 89119, and our telephone number is (702)
997-5968. We report on a 52-or 53-week fiscal year. Our 2024 fiscal year will end on December 28, 2024. Our 2023 fiscal year ended on
December 30, 2023. Our 2022 fiscal year ended on December 31, 2022. We maintain a corporate website at www.janone.com. Except as specifically
set forth herein, the information which appears on our website is not part of the prospectus or this prospectus supplement. Please see
our Annual Report on Form 10-K for the 2023 fiscal year ended December 30, 2023, as filed with the SEC on April 8, 2024, and our other
subsequent filings with the SEC for additional information about our business, operations, and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="SJ_004"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
OFFERING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary contains basic information about this offering. The summary is not intended to be complete. You should read the full
text and more specific details contained elsewhere in this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
    Stock offered by us</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    of our common stock having an aggregate offering price of up to $5,000,000.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
    Stock to be outstanding after this offering</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,183,406
    shares, assuming a sales price of $2.29 per share, the last reported sale price of our common stock on the Nasdaq Capital Market
    on June 18, 2024. The actual number of shares issued will vary depending on the sales price at which shares may be sold
    from time to time during this offering.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Plan
    of Distribution</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;At
    the market offering,&rdquo; as defined in Rule 415(a)(4) under the Securities Act, through Wainwright, as agent or principal. See section titled &ldquo;Plan
    of Distribution&rdquo; on page S-10 of this prospectus supplement.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
    of proceeds</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    intend to use the net proceeds from this offering for working capital and general corporate purposes. See &ldquo;Use of Proceeds&rdquo;
    on page S-7.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk
    factors</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    investment involves a high degree of risk. See &ldquo;Risk Factors&rdquo; and other information included or incorporated by
    reference in this prospectus supplement beginning on page S-5 and the accompanying base prospectus beginning on page 3 for
    a discussion of certain factors you should carefully consider before deciding to invest in shares of our Common Stock.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nasdaq
    Capital Market symbol</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JAN</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 8.25pt; text-align: justify"></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
discussion and table above are based on 12,171,092 shares of our Common Stock outstanding as of June 18, 2024, and excludes, as of that
date, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">114,000
    shares of our Common Stock issuable upon exercise of outstanding stock options issued under our 2016 <FONT STYLE="background-color: white">Stock
    Compensation Plan</FONT> (the &ldquo;2016 Plan&rdquo;), with a weighted-average exercise price of $5.68 per share and no shares of
    our common stock issuable upon exercise of outstanding stock options issued under our 2023 Equity Incentive Plan (the &ldquo;2023
    Plan&rdquo;);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,922,188
    shares of our Common Stock issuable upon the exercise of outstanding warrants, with a weighted-average exercise price of $0.82 per
    share; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">396,148
    shares of our Common Stock that are available for future issuance under our 2023 Plan.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="SJ_005"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Investing
in</I></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I> shares of our Common Stock involves
a high degree of risk. You should carefully consider and evaluate all of the information contained in this Prospectus Supplement, the
Base Prospectus and in the documents that we incorporate by reference into this Prospectus Supplement and the Base Prospectus before
you decide to accept any shares of our Common Stock offered hereby. In particular, you should carefully consider and evaluate the risks
and uncertainties described under the heading &ldquo;Risk Factors&rdquo; in this Prospectus Supplement and the Base Prospectus, or in
the documents incorporated by reference herein and therein. Any of the risks and uncertainties set forth in this Prospectus Supplement
and the Base Prospectus, as updated by annual, quarterly, and other reports and documents that we file with the SEC and incorporate by
reference into this Prospectus Supplement or the Base Prospectus, could materially and adversely affect our business, results of operations
and financial condition, which in turn could materially and adversely affect the value of our Common Stock.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white"><B>Risks
Relating to this Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>If you purchase
shares of our Common Stock sold in this offering, you will experience immediate and substantial dilution in the net tangible book value
of your shares. In addition, we may issue additional equity or convertible debt securities in the future, which may result in additional
dilution to investors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The price per share of
our Common Stock being offered may be higher than the net tangible book value per share of our outstanding Common Stock prior to this
offering. Assuming that an aggregate of 2,183,406 shares of our Common Stock are sold at a price of $2.29 per share, the last reported
sale price of our Common Stock on the Nasdaq Capital Market on June 18, 2024, for aggregate gross proceeds of approximately $5,000,000,
and after deducting commissions and estimated offering expenses payable by us, new investors in this offering would incur immediate dilution
of $2.04 per share. For a more detailed discussion of the foregoing, see the section entitled &ldquo;Dilution&rdquo; below. To the extent
outstanding stock options or warrants are exercised, there will be further dilution to new investors. In addition, to the extent we need
to raise additional capital in the future and we issue additional shares of our Common Stock or securities convertible, exercisable,
or exchangeable for shares of our Common Stock, our then existing stockholders may experience dilution and the new securities may have
rights senior to those of our Common Stock offered in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>The actual number
of shares of our Common Stock that we will issue under the Sales Agreement, at any one time or in total, is uncertain.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Subject to certain limitations
in the Sales Agreement and compliance with applicable law, we have the discretion to deliver instructions to Wainwright to sell shares
of our Common Stock at any time throughout the term of the Sales Agreement. The number of shares that are sold through or to Wainwright
after our instruction will fluctuate based on a number of factors, including the market price of our Common Stock during the sales period,
the limits we set with Wainwright in any instruction to sell shares, and the demand for our Common Stock during the sales period. Because
the price per share of each share sold will fluctuate during this offering, it is not currently possible to predict the number of shares
that will be sold or the gross proceeds to be raised in connection with those sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>The shares of our
Common Stock offered hereby will be sold in &ldquo;at the market offerings,&rdquo; and investors who buy shares at different times will
likely pay different prices.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Investors who purchase
shares of our Common Stock in this offering at different times will likely pay different prices for those shares, and so may experience
different levels of dilution and different outcomes in their investment results. We will have discretion, subject to market demand, to
vary the timing, prices, and numbers of shares sold in this offering. Investors may experience a decline in the value of the shares of
our Common Stock that they purchase in this offering if the market price for the shares of our Common Stock declines for any reason after
they purchase their shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to this Offering and Ownership of Our Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
market price for our Common Stock is particularly volatile given our status as a company with a small and thinly traded public float,
lack of profits, and the need for capital to fund our biopharmaceutical product development, which could and has led to wide fluctuations
in our share price.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market for our Common Stock is characterized by significant price volatility when compared to the shares of larger, more established
companies that have large public floats, and we expect that our share price will continue to be more volatile than the shares of such
larger, more established companies for the indefinite future, although such fluctuations may not reflect a material change to our financial
condition or operations during any such period. For example, from June 20, 2023 through June 18, 2024, the reported sale
price of our Common Stock has fluctuated between $0.30 and $4.78 per share. Such volatility can be attributable to a number
of factors. First, as noted above, our Common Stock is, compared to the shares of such larger, more established companies, sporadically
and thinly traded. The price for our Common Stock could, for example, decline precipitously in the event that a large number of our shares
are sold on the market without commensurate demand. Secondly, we are a speculative or &ldquo;risky&rdquo; investment due to our lack
of profits to date. As a consequence of this enhanced risk, more risk-adverse investors may, under the fear of losing all or most of
their investment in the event of negative news or lack of progress, be more inclined to sell their shares on the market more quickly
and at greater discounts than would be the case with the stock of a larger, more established company that has a large public float. Many
of these factors are beyond our control and may decrease the market price of our Common Stock regardless of our operating performance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to being highly volatile, our Common Stock could be subject to wide fluctuations in response to a number of factors that are
beyond our control, including, but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">variations
                                            in our revenues and operating expenses;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
                                            or anticipated changes in the estimates of our operating results or changes in stock market
                                            analyst recommendations regarding our Common Stock, other comparable companies or our industry
                                            generally;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">market
                                            conditions affecting our business or the economy as a whole;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
                                            in the financial markets and worldwide or regional economies;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
                                            of innovations or new products or services by us or our competitors;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
                                            of our Common Stock or other securities by us or in the open market;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in the market valuations of other comparable companies; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
                                            events or factors, many of which are beyond our control, including those resulting from such
                                            events, or the prospect of such events, including war, terrorism and other international
                                            conflicts, public health issues including health epidemics or pandemics, such as the COVID-19
                                            pandemic, and natural disasters such as fire, hurricanes, earthquakes, tornados or other
                                            adverse weather and climate conditions, whether occurring in the United States or elsewhere,
                                            could disrupt our operations, disrupt the operations of our suppliers or result in political
                                            or economic instability.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if the market for biopharmaceutical stocks or the stock market in general experiences loss of investor confidence, the trading
price of our Common Stock could decline for reasons unrelated to our business, financial condition, or operating results. The
trading price of our shares might also decline in reaction to events that affect other companies in our industry, even if these events
do not directly affect us. Each of these factors, among others, could harm the value of our Common Stock. In the past, following periods
of volatility in the market, securities class-action litigation has often been instituted against companies. Such litigation, if instituted
against us, could result in substantial costs and diversion of management&rsquo;s attention and resources, which could materially and
adversely affect our business, operating results, and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if the market for biopharmaceutical stocks or the stock market in general experiences loss of investor confidence, the trading
price of our Common Stock could decline for reasons unrelated to our business, financial condition, or operating results. The
trading price of our shares might also decline in reaction to events that affect other companies in our industry, even if these events
do not directly affect us. Each of these factors, among others, could harm the value of our Common Stock. In the past, following periods
of volatility in the market, securities class-action litigation has often been instituted against companies. Such litigation, if instituted
against us, could result in substantial costs and diversion of management&rsquo;s attention and resources, which could materially and
adversely affect our business, operating results, and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will have broad discretion as to the use of the proceeds from this offering, and we may not use the proceeds effectively.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to certain limited exceptions set forth in the offering documents, we intend to use the net proceeds from this offering for working capital
and general corporate purposes. We have considerable discretion in the application of the net proceeds of this offering. You will not
have the opportunity, as part of your investment decision, to assess whether such proceeds are being used in a manner agreeable to you.
You must rely on our judgment regarding the application of the net proceeds of this offering, which may be used for corporate purposes
that do not improve our profitability or increase the price of our shares of Common Stock. Such proceeds may also be placed in investments
that do not produce income or that lose value. The failure to use such funds by us effectively could have a material adverse effect on
our business, financial condition, operating results and cash flow.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Substantial
future sales of shares of our Common Stock could cause the market price of our Common Stock to decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that significant additional capital will be needed in the near future to continue our planned operations. Sales of a substantial
number of shares of our Common Stock in the public market, or the perception that these sales might occur, could depress the market price
of our Common Stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to
predict the effect that such sales may have on the prevailing market price of our shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have financed our operations, and we expect to continue to finance our operations, acquisitions, if any, and the development of strategic
relationships by issuing equity, warrants and/or convertible securities, which could significantly reduce the percentage ownership of
our existing stockholders. Further, any additional financing that we secure may require the granting of rights, preferences, or privileges
senior to, or pari passu with, those of our Common Stock. Additionally, we may acquire other technologies or finance strategic alliances
by issuing our equity or equity-linked securities, which may result in additional dilution. Any issuances by us of equity securities
may be at or below the prevailing market price of our Common Stock and in any event may have a dilutive impact on your ownership interest,
which could cause the market price of our Common Stock to decline. We may also raise additional funds through the incurrence of debt
or the issuance or sale of other securities or instruments senior to our shares of Common Stock. The holders of any securities or instruments
we may issue may have rights superior to the rights of our holders of our Common Stock. If we experience dilution from issuance of additional
securities and we grant superior rights to new securities over common stockholders, it may negatively impact the trading price of our
shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
do not anticipate paying dividends in the foreseeable future; you should not buy our stock if you expect dividends.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never paid a dividend on our Common Stock. The determination of whether to pay dividends on our Common Stock in the future will
depend on several factors, including without limitation, our earnings, financial condition, and other business and economic factors affecting
us at such time as our board of directors may consider relevant. If we do not pay dividends, our Common Stock may be less valuable because
a return on your investment will only occur if our stock price appreciates. We currently intend to retain our future earnings to support
operations and to finance expansion and, therefore, we do not anticipate paying any cash dividends on our Common Stock in the foreseeable
future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
could issue preferred stock without stockholder approval with the effect of diluting then current stockholder interests and impairing
their voting rights; and provisions in our charter documents could discourage a takeover that stockholders may consider favorable.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
articles of incorporation, as amended, authorize the issuance of up to 2,000,000 shares of &ldquo;blank check&rdquo; preferred stock
with designations, rights and preferences as may be determined from time to time by our board of directors. 259,729 shares of our
Series A-1 Convertible Preferred Stock are authorized, of which 117,480 shares are issued and outstanding, leaving 142,249 shares
of that series that are authorized, but unissued. 200,000 shares of our Series S Convertible Preferred Stock are authorized, of
which 100,000 shares are issued and outstanding, leaving 100,000 shares of that series that are authorized, but unissued. 34,250
shares of our Series B Preferred Stock are authorized, of which 34,208 shares are issued and outstanding, leaving 42
shares of that series that are authorized, but unissued. 3,200 shares of our Series M Preferred Stock are authorized, of
which 3,200 shares are issued and outstanding, leaving -0- shares of that series that are authorized, but unissued. 5,000 shares of
our Series V Convertible Preferred Stock are authorized, of which 5,000 shares are issued and outstanding, leaving -0-
shares of that series that are authorized, but unissued. We have 1,497,821 shares of &ldquo;blank check&rdquo; preferred stock
remaining available for designation and issuance. Our board of directors is empowered, without stockholder approval, to issue one or
more series of preferred stock with dividend, liquidation, conversion, voting, or other rights that could dilute the interest of, or
impair the voting power of, our common stockholders. The issuance of a series of preferred stock could be used as a method of
discouraging, delaying, or preventing a change in control of us. For example, it would be possible for our board of directors to
issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change control of
our Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
securities or industry analysts do not publish or cease publishing research or reports about us, our business, or our market, or if they
change their recommendations regarding our Common Stock adversely, our Common Stock price and trading volume could decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our shares of Common Stock will be influenced by many factors, including without limitation, the research reports
that industry or securities analysts may publish about us, our business, our market, or our competitors. As of the date of this Prospectus
Supplement, no analysts cover us, but, if any were to cover us and then adversely change their recommendation regarding our Common Stock,
or provide more favorable relative recommendations about our competitors, our share price would likely decline. If any analyst who may
cover us were to cease coverage of our Company or fail to publish reports on us regularly, we could lose visibility in the financial
markets, which in turn could cause our Common Stock price or trading volume to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Significant
dilution will occur if outstanding options or warrants are exercised, or restricted stock unit grants vest.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 18, 2024, we had 114,000 shares of our Common Stock underlying outstanding stock options and 1,922,188 shares of our
Common Stock underlying outstanding warrants. If outstanding stock options or warrants are exercised or if shares of our Series A-1
Convertible Preferred Stock or shares of our Series S Convertible Preferred Stock are converted, dilution will occur to our stockholders,
which may be significant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to continue to maintain compliance with the continued listing requirements of The Nasdaq Capital Market.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Common Stock is listed on The Nasdaq Capital Market. In order to maintain that listing, we must satisfy minimum financial and
other requirements including, without limitation, a requirement that our closing bid price be at least $1.00 per share and net stockholders&rsquo;
equity of not less than $2.5 million. If we fail to continue to meet all applicable continued listing requirements for The Nasdaq Global
Market in the future and Nasdaq determines to delist our Common Stock, the delisting could adversely affect the market liquidity
of our Common Stock, our ability to obtain financing to repay debt, and fund our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="SJ_006"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
that we sell all of the shares offered pursuant to this prospectus supplement, we</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
estimate that the net proceeds from the sale of the shares of our Common Stock offered under this prospectus supplement,
after deducting estimated offering expenses payable by us, will be approximately $4,735,000. <FONT>Because there is no minimum
offering amount required as a condition of this offering, the actual total public offering amount, commissions, and proceeds due to
us, if any, is not determinable at this time.</FONT> </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to use the net proceeds from the sale of the shares for working capital and other general corporate purposes, which may include
acquisitions. The amounts and timing of our use of proceeds will vary depending on a number of factors, including the amount of cash
generated or used by our operations. As a result, we will retain broad discretion in the allocation of the net proceeds of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending
our use of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation investments,
including short-term, investment-grade, interest-bearing instruments, and U.S. government securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="SJ_007"></A>DIVIDEND
POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not declared or paid cash dividends on our Common Stock since our inception. Under Nevada law, we are prohibited from paying dividends
if the distribution would result in our Company not being able to pay its debts as they become due in the normal course of business if
our total assets would be less than the sum of our total liabilities plus the amount that would be needed to pay the dividends, or if
we were to be dissolved at the time of distribution to satisfy the preferential rights upon dissolution of stockholders whose preferential
rights are superior to those receiving the distribution. Our board of directors has complete discretion on whether to pay dividends subject
to compliance with applicable Nevada law. Even if our board of directors were to decide to pay dividends, the form, the frequency, and
the amount will depend upon our future operations and earnings, capital requirements and surplus, general financial condition, contractual
restrictions, and other factors that the board of directors may deem relevant. While our board of directors will make any future decisions
regarding dividends, if, when, and as circumstances surrounding us change, it currently does not anticipate that we will pay any cash
dividends in the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="SJ_008"></A>DESCRIPTION
OF SECURITIES THAT WE ARE OFFERING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
material terms and provisions of our Common Stock are described under the caption &ldquo;Description of Capital Stock&rdquo;
beginning on page 33 of the Base Prospectus. As of the date of this Prospectus Supplement, our authorized capital consists of
200,000,000 shares of Common Stock, par value $0.001 per share, and up to 2,000,000 shares of blank check preferred stock, par value
$0.001 per share, with designations, rights, and preferences as may be determined from time to time by our board of
directors. 259,729 shares of our Series A-1 Convertible Preferred Stock&rdquo; are authorized, of which 117,480 shares are
issued and outstanding, leaving 142,249 shares of that series that are authorized, but unissued. 200,000 shares of our Series
S Convertible Preferred Stock are authorized, of which 100,000 shares are issued and outstanding, leaving 100,000 shares of that
series that are authorized, but unissued. 34,250 shares of our &ldquo;Series B Preferred Stock&rdquo; are authorized, of which
34,208 shares are issued and outstanding, leaving 42 shares of that series that are authorized, but unissued. 3,200 shares of our
&ldquo;Series M Preferred Stock are authorized, of which 3,200 shares are issued and outstanding, leaving -0- shares of that series
that are authorized, but unissued. 5,000 shares of our &ldquo;Series V Convertible Preferred Stock&rdquo; are authorized, of which
5,000 shares are issued and outstanding, leaving -0- shares of that series that are authorized, but unissued. We have 1,497,821
shares of &ldquo;blank check&rdquo; preferred stock remaining available for designation and issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The transfer agent and registrar for the Common Stock
is EQ BY EQUINITI, whose address is 1110 Centre Pointe Curve, Suite 101, Mendota Heights, Minnesota 55120, and telephone number is (855)
217-6361.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="Z_001"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you invest in our common stock in this offering, your interest will be diluted to the extent of the difference between the price per
share you pay in this offering and the net tangible book value per share of common stock immediately after this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 30, 2024, we had a net tangible book value (without taking into account the effect of the Two Post-period Equity
Transactions described below) of approximately $(9,019,000), or approximately $(1.20) per share of Common Stock. Our net tangible
book value per share represents total tangible assets, less total liabilities, divided by the number of shares of our common stock
outstanding as of March 30, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subsequent to March 30, 2024, we engaged in
two additional material equity transactions (the &ldquo;Two Post-period Equity Transactions&rdquo;): (i) the Merger Agreement with
ALT5, pursuant to which we issued approximately 1,799,100 shares of our Common Stock at a per-share price of $4.14, as well as
approximately 32,207 shares of our Series B Preferred Stock, and (ii) a registered direct offering, pursuant to which we issued
79,782 shares of our Common Stock at a per-share price of $3.63, as well as granted 79,782 common stock purchase warrants with a
per-share exercise price of $3.63, for a per-unit price of approximately $3.76. As of March 30, 2024, including the &ldquo;Two
Post-period Equity Transactions&rdquo;, on a pro forma basis, we had a net tangible book value of approximately $(1,835,000), or
approximately $(0.19) per share of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
giving effect to the sale of our common stock in the aggregate amount of $5,000,000 in this offering at an assumed offering price of
$2.29 per share, the last reported sale price of our Common Stock on The Nasdaq Capital Market on June 18, 2024, and after deducting
the commissions and estimated offering expenses payable by us, and adjusting on a pro forma basis for the Two Post-period Equity
Transactions, our net tangible book value as of March 30, 2024, would have been approximately $2,900,000, or approximately $0.25
per share of our Common Stock. This represents an immediate increase in net tangible book value of $0.44 per share to our existing
stockholders and an immediate dilution of approximately $2.04 per share to new investors participating in this offering, as
illustrated by the following table:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%">Assumed offering price per share of common stock</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">2.29</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Net tangible book value per share of common stock as of March 30, 2024 (after pro forma adjustment for the Two Post-period
    Equity Transactions)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.19</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Increase in net tangible book value per share of common stock attributable to this offering (after
    pro forma adjustment for the Two Post-period Equity Transactions)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.44</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">As adjusted net tangible book value per share of common stock as of March 30, 2024 after giving effect
    to this offering (after pro forma adjustment for the Two Post-period Equity Transactions)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.25</TD><TD STYLE="text-align: left"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Dilution in net tangible book value per share of common stock to new investors in the offering (after
    pro forma adjustment for the Two Post-period Equity Transactions)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.04</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that outstanding options or warrants are exercised, or shares of our convertible preferred stock are converted into shares
of our Common Stock, you will experience further dilution. In addition, we may choose to offer securities in other offerings due to market
conditions or strategic considerations. To the extent that we raise additional capital through the sale of shares of our Common Stock
or securities exercisable for or convertible into shares of our Common Stock, the issuance of such securities may result in further dilution
of our stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
as adjusted information is illustrative only and will adjust based on the actual price to the public, the actual number of shares sold
and other terms of the offering determined at the time shares of our Common Stock are sold pursuant to this prospectus supplement and
the accompanying prospectus. The as-adjusted information assumes that all shares of our Common Stock in the aggregate amount of $5,000,000
are sold at the assumed offering price of $2.29 per share, the last reported sale price of a shares of our Common Stock on the Nasdaq
Capital Market on June 18, 2024. The shares sold in this offering, if any, will be sold from time to time at various prices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
discussion and table above are based on 7,551,379 shares of our Common Stock outstanding as of March 30, 2024, and excludes, as of that
date, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">114,000
    shares of our Common Stock issuable upon exercise of outstanding stock options issued under our 2016 <FONT STYLE="background-color: white">Plan</FONT>,
    with a weighted-average exercise price of $5.68 per share and no shares of our common stock issuable upon exercise of outstanding
    stock options issued under our 2023 Plan;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,922,188
    shares of our Common Stock issuable upon the exercise of outstanding warrants, with a weighted-average exercise price of $0.82 per
    share; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">396,148
    shares of our Common Stock that are available for future issuance under our 2023 Plan.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Aptos; margin: 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Aptos; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="Z_002"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into a sales agreement with Wainwright, pursuant to which we may issue and sell from time to time shares of our Common Stock
having an aggregate offering price of not more than $5,000,000 through Wainwright as our sales agent. Sales of our Common Stock, if any,
will be made by any method permitted by law deemed to be an &ldquo;at the market offering&rdquo; as defined in Rule 415(a)(4) promulgated
under the Securities Act, including sales made directly on or through the Nasdaq Capital Market or any other existing trading market
in the United States for our Common Stock, sales made to or through a market maker other than on an exchange or otherwise, directly to
Wainwright as principal, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing
market prices and/or in any other method permitted by law.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wainwright
will offer shares of our Common Stock at prevailing market prices subject to the terms and conditions of the Sales Agreement as agreed
upon by us and Wainwright. We will designate the number of shares that we desire to sell, the time period during which sales are requested
to be made, any limitation on the number of shares that may be sold in one day, and any minimum price below which sales may not be made.
Subject to the terms and conditions of the Sales Agreement, Wainwright will use its commercially reasonable efforts consistent with its
normal trading and sales practices to sell on our behalf all of the shares of our Common Stock requested to be sold by us. We or Wainwright
may suspend the offering of our Common Stock being made through Wainwright under the Sales Agreement upon proper notice to the other
party.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement
for sales of our Common Stock will occur on the first business day or such shorter settlement cycle as may be in effect under Exchange
Act Rule 15c6-1 from time to time, following the date on which any sales are made, or on some other date that is agreed upon by us and
Wainwright in connection with a particular transaction, in return for payment of the net proceeds to us. Sales of our Common Stock as
contemplated in this prospectus supplement and the accompanying prospectus will be settled through the facilities of The Depository Trust
Company or by such other means as we and Wainwright may agree upon. There is no arrangement for funds to be received in an escrow, trust,
or similar arrangement.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will pay Wainwright in cash, upon each sale of shares of our Common Stock pursuant to the Sales Agreement, a commission of 3.0% of the
gross proceeds from each sale of shares of our Common Stock. Because there is no minimum offering amount required as a condition to this
offering, the actual total public offering amount, commissions, and proceeds to us, if any, are not determinable at this time. Pursuant
to the terms of the Sales Agreement, we agreed to reimburse Wainwright for the documented fees and costs of its legal counsel reasonably
incurred in connection with entering into the transactions contemplated by the sales agreement in an amount not to exceed $50,000 in
the aggregate, in addition to up to $2,500 per due diligence update session for Wainwright&rsquo;s counsel&rsquo;s fees and any incidental
expenses to be reimbursed by us. We will report at least quarterly the number of shares of our Common Stock sold through Wainwright under
the Sales Agreement, the net proceeds to us, and the compensation paid by us to Wainwright in connection with the sales of shares of
our Common Stock.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the sales of our Common Stock on our behalf, Wainwright will be deemed to be an &ldquo;underwriter&rdquo; within the
meaning of the Securities Act, and the compensation paid to Wainwright will be deemed to be underwriting commissions or discounts. We
have agreed in the Sales Agreement to provide indemnification and contribution to Wainwright against certain liabilities, including liabilities
under the Securities Act.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
offering of shares of our Common Stock pursuant to the Sales Agreement will terminate upon the earlier of the sale of all shares of our
Common Stock provided for in this prospectus supplement or the termination of the Sales Agreement as permitted therein.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent required by Regulation M, Wainwright will not engage in any market-making activities involving shares of our Common Stock
while the offering is ongoing under this prospectus supplement.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wainwright
and its affiliates may in the future provide various investment banking and other financial services for us and our affiliates, for which
services they may in the future receive customary fees.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus supplement and the accompanying prospectus may be made available in electronic format on a website maintained by Wainwright,
and Wainwright may distribute this prospectus and the accompanying prospectus electronically. A copy of the Sales Agreement is filed
with the SEC as an exhibit to a Current Report on Form 8-K filed as of the date of this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6.45pt; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Listing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
shares of Common Stock are listed on The Nasdaq Capital Market under the symbol &ldquo;JAN.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nasdaq
Capital Market Listing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Common Stock is listed on The Nasdaq Capital Market under the symbol &ldquo;JAN.&rdquo; On June 18, 2024, the last reported sale
price of our Common Stock as reported on the Nasdaq Capital Market was $2.29 per share.</FONT></P>

<P STYLE="font: 10pt Aptos; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Aptos; margin: 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Aptos; margin: 0"></P>

<P STYLE="font: 10pt Aptos; margin: 0"></P>

<P STYLE="font: 10pt Aptos; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="SJ_010"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clark
Hill LLP, Los Angeles, California, will provide us with opinions as to certain legal matters in connection with the shares of Common
Stock offered hereby. Ellenoff Grossman &amp; Schole LLP, New
York, New York, is counsel for Wainwright in connection with this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="SJ_011"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of the Registrant as of and for the year ended December 30, 2023, incorporated by reference in this prospectus,
have been audited by Hudgens, LLC, an independent registered public accounting firm, as stated in its report incorporated by reference
herein, and have been incorporated in reliance upon the authority of such firm as experts in accounting and auditing. This report on
the consolidated financial statements contains an explanatory paragraph regarding the Company&rsquo;s ability to continue as a going
concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Registrant as of and for the year ended December 31, 2022, incorporated by reference in this
prospectus, have been audited by Frazier &amp; Deeter, LLC, an independent registered public accounting firm, as stated in their report.
Such consolidated financial statements are incorporated by reference herein, and have been incorporated in reliance upon the firm given
their authority as experts in accounting and auditing. This report on the consolidated financial statements contains an explanatory paragraph
regarding the Company&rsquo;s ability to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="SJ_012"></A>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Prospectus Supplement constitutes a part of the Registration Statement. As permitted by the SEC&rsquo;s rules, this Prospectus Supplement
and the Base Prospectus, which form a part of the Registration Statement, do not contain all the information that is included in the
Registration Statement and its exhibits. You will find additional information about us in the Registration Statement and its exhibits.
Any statements made in this Prospectus Supplement concerning legal documents are not necessarily complete and you should read the documents
that are filed as exhibits to the Registration Statement or otherwise filed by us with the SEC for a more complete understanding of such
documents or matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
file annual, quarterly, and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the
public at no cost from the SEC&rsquo;s website at <I>www.sec.gov</I>. Our corporate website is <I>www.janone.com</I>. The information
on our corporate website is not incorporated by reference in this Prospectus Supplement, the Base Prospectus, or any other prospectus
supplement that we file, and you should not consider it a part of this Prospectus Supplement, the Base Prospectus or any other such prospectus
supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="SJ_013"></A>INFORMATION
INCORPORATED BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC allows us to incorporate by reference the information we file with them, which means that we can disclose important information to
you by referring you to those documents. The information incorporated by reference is considered to be part of this Prospectus Supplement
and the Base Prospectus, and later information filed with the SEC will update and supersede this information. We incorporate by reference
the documents listed below that we have previously filed with the SEC, except that information furnished under Item 2.02 or Item 7.01
of our Current Reports on Form 8-K or any other filing where we indicate that such information is being furnished and not filed under
the Exchange Act, is not deemed to be filed and not incorporated by reference herein:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            Annual Report on <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000095017023013095/jan-20221231.htm" STYLE="-sec-extract: exhibit">Form 10-K</A> for the year ended December 30, 2023, as filed with the SEC on
                                            April 8, 2024;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
Quarterly Report on <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828024020286/jan-20240330.htm" STYLE="-sec-extract: exhibit">Form 10-Q</A> for the fiscal quarter ended March 30, 2024, as filed with the SEC on May 3, 2024;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; line-height: 0.05pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">our
    Current Reports on Form 8-K (date of reports: <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828024001259/jan-20240112.htm" STYLE="-sec-extract: exhibit">January 12, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828024003865/jan-20240208.htm" STYLE="-sec-extract: exhibit">February 8, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828024007613/jan-20240223.htm" STYLE="-sec-extract: exhibit">February 23, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828024011329/jan-20240313.htm" STYLE="-sec-extract: exhibit">March 13, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828024017126/jan-20240416.htm" STYLE="-sec-extract: exhibit">April 16, 2024</A>,
    <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000149315224017936/form8-k.htm" STYLE="-sec-extract: exhibit">May 6, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000149315224020865/form8-k.htm" STYLE="-sec-extract: exhibit">May 15, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000149315224022190/form8-k.htm" STYLE="-sec-extract: exhibit">May 28, 2024</A>, and <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000149315224022580/form8-k.htm" STYLE="-sec-extract: exhibit">June 4, 2024</A>), as filed with the SEC on <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828024001259/jan-20240112.htm" STYLE="-sec-extract: exhibit">January 12, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828024003865/jan-20240208.htm" STYLE="-sec-extract: exhibit">February 8, 2024</A> with amended
    filing on <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828024004028/jan-20240208.htm" STYLE="-sec-extract: exhibit">February 9, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828024007613/jan-20240223.htm" STYLE="-sec-extract: exhibit">February 28, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828024011329/jan-20240313.htm" STYLE="-sec-extract: exhibit">March 15, 2024</A>, </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828024017126/jan-20240416.htm" STYLE="-sec-extract: exhibit">April 22, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000149315224017936/form8-k.htm" STYLE="-sec-extract: exhibit">May 6, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000149315224020865/form8-k.htm" STYLE="-sec-extract: exhibit">May 21, 2024</A> with amended filing on <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000149315224022707/form8-ka.htm" STYLE="-sec-extract: exhibit">June 5, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000149315224022190/form8-k.htm" STYLE="-sec-extract: exhibit">May 31, 2024</A>, and <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000149315224022580/form8-k.htm" STYLE="-sec-extract: exhibit">June 6, 2024</A>, respectively</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 0.05pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">the description of our Common Stock contained in <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000095017023013095/jan-ex4_1.htm" STYLE="-sec-extract: exhibit">Exhibit 4.1</A> to our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on April 17, 2023.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also incorporate by reference in this Prospectus Supplement and the Base Prospectus any future filings we make with the SEC under Sections
13(a), 13(c), 14 or 15(d) of the Exchange Act after the date hereof but before the completion or termination of this offering (excluding
any information not deemed &ldquo;filed&rdquo; with the SEC).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
statements contained in a previously filed document incorporated by reference into this this Prospectus Supplement or the Base Prospectus
is deemed to be modified or superseded for purposes of this this Prospectus Supplement and the Base Prospectus to the extent that a statement
contained in this this Prospectus Supplement or the Base Prospectus, or in a subsequently filed document also incorporated by reference
herein, modifies or supersedes that statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Prospectus Supplement and the Base Prospectus may contain information that updates, modifies or is contrary to information in one or
more of the documents incorporated by reference in this this Prospectus Supplement or the Base Prospectus. You should rely only on the
information incorporated by reference or provided in this this Prospectus Supplement or the Base Prospectus. We have not authorized anyone
else to provide you with different information. You should not assume that the information in this this Prospectus Supplement or the
Base Prospectus is accurate as of any date other than the date of this this Prospectus Supplement or the date of the documents incorporated
by reference in this this Prospectus Supplement or the Base Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will provide to each person, including any beneficial owner, to whom this this Prospectus Supplement or the Base Prospectus is delivered,
upon written or oral request, at no cost to the requester, a copy of any and all of the information that is incorporated by reference
in this registration statement. You may request a copy of these filings, at no cost to you, by telephoning us at (702) 997-5968 or by
writing us at the following address:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JanOne
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">325
E. Warm Springs Road, Suite 102</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Las
Vegas, Nevada 89119</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Corporate Secretary</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may also access the documents incorporated by reference in this this Prospectus Supplement and the Base Prospectus through our website
at www.janone.com. The reference to our website is an inactive textual reference only and, except for the specific incorporated documents
listed above, no information available on or through our website shall be deemed to be incorporated in this this Prospectus Supplement,
the Base Prospectus, or the registration statement of which it forms a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><IMG SRC="form424b5_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$100,000,000.00</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Debt
Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Units</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may offer and sell from time to time shares of our common stock, par value $0.001 per share (our &ldquo;Common Stock&rdquo;), shares
of our preferred stock, par value $0.001 per share (our &ldquo;Preferred Stock&rdquo;), debt securities, warrants, rights, and units
that include any of these securities. The Preferred Stock or warrants may be convertible into or exercisable for shares of our Common
Stock or shares of our Preferred Stock or other of our securities registered hereunder. The debt securities may be convertible into or
exchangeable for shares of our Common Stock or shares of our Preferred Stock. Our Common Stock is listed on The Nasdaq Capital Market
and trades under the symbol &ldquo;JAN.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may offer and sell these securities to or through one or more underwriters, dealers, and agents, or directly to purchasers, on a continuous
or delayed basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate market value of our outstanding Common Stock held by non-affiliates was approximately $274,320, based on 8,593,636 shares of
outstanding Common Stock as of April 8, 2024, of which approximately 108,000 shares were held by affiliates, and based on the closing
sale price of our Common Stock of $2.54 on April 8, 2024. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell
securities pursuant to this prospectus with a value of more than one-third of the aggregate market value of our Common Stock held by
non-affiliates in any 12-month period, so long as the aggregate market value of our Common Stock held by non-affiliates is less than
$75,000,000. In the event that, subsequent to the date of this prospectus, the aggregate market value of our outstanding Common Stock
held by non-affiliates equals or exceeds $75,000,000, then the one-third limitation on sales shall not apply to additional sales made
pursuant to this prospectus. During the prior 12 calendar months prior to, and including, the date of this prospectus, we have not sold
any securities pursuant to General Instruction I.B.6 of Form S-3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus describes some of the general terms that may apply to these securities and the general manner in which they may be offered.
The specific terms of any securities to be offered, and the specific manner in which they may be offered, will be described in a supplement
to this prospectus. You should read this prospectus and any applicable prospectus supplement carefully before you invest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>See
the &ldquo;Risk Factors&rdquo; section of this prospectus on page 3, our filings with the SEC, and the applicable prospectus supplement
for certain risks that you should consider before investing in our securities.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>None
of the Securities and Exchange Commission, any state securities commission, or any other regulatory body has approved or disapproved
of these securities nor passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
date of this prospectus is April 26, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#nd_001">ABOUT THIS PROSPECTUS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#nd_002">AVAILABLE INFORMATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#nd_003">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#nd_004">FORWARD-LOOKING STATEMENTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#nd_005">RISK FACTORS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#nd_006">BUSINESS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_002">SELECTED CONSOLIDATED FINANCIAL DATA</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">31</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_003">DESCRIPTION OF SECURITIES WE MAY OFFER</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_004">DESCRIPTION OF CAPITAL STOCK</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_005">DESCRIPTION OF PREFERRED STOCK</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">36</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_006">DESCRIPTION OF DEBT SECURITIES</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">37</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_007">DESCRIPTION OF WARRANTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">43</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_008">DESCRIPTION OF RIGHTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">45</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_009">DESCRIPTION OF UNITS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">46</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_010">USE OF PROCEEDS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">46</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_011">PLAN OF DISTRIBUTION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">46</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_012">LEGAL MATTERS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">48</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Su_013">EXPERTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">48</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="nd_001"></A>ABOUT
THIS PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
document is called a prospectus and is part of a Registration Statement on Form S-3 that we have filed with the Securities and Exchange
Commission (the &ldquo;SEC&rdquo;) using a &ldquo;shelf&rdquo; registration process. Under this shelf registration process, we may, from
time to time, sell any combination of the securities described in this prospectus in one or more offerings in amounts that we will determine
from time to time, up to a total dollar amount of $100,000,000.00.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities
described in this prospectus we will provide a prospectus supplement, incorporate information or document by reference into this prospectus
or a related free writing prospectus or use other offering materials, as applicable, containing more specific information about the terms
of the securities that are then being offered. We may also authorize one or more related free writing prospectuses to be provided to
you that may contain material information relating to these offerings and securities. This prospectus, together with applicable prospectus
supplements, any information or document incorporated by reference, and any related free writing prospectus or other offering materials,
as applicable, we file with the SEC, includes all material information relating to these offerings and securities. We may also add, update,
or change in the prospectus supplement any of the information contained in this prospectus or in the documents that we incorporate by
reference into this prospectus, including, without limitation, a discussion of any risk factors or other special considerations that
apply to these offerings or securities or the specific plan of distribution. If there is any inconsistency between the information in
this prospectus and a prospectus supplement or information or document incorporated by reference having a later date, you should rely
on the information in that prospectus supplement or incorporated information having a later date. We urge you to read carefully this
prospectus, any applicable prospectus supplement, and any related free writing prospectus or other offering materials, as applicable,
together with the information incorporated herein by reference as described under the heading &ldquo;Incorporation of Certain Information
by Reference,&rdquo; before buying any of the securities being offered.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should rely only on the information we have provided in, or incorporated by reference into, this prospectus, any applicable prospectus
supplement, and any related free writing prospectus or other offering materials, as applicable. We have not authorized anyone to provide
you with different information. No dealer, salesperson, or other person is authorized to give any information or to represent anything
not contained in this prospectus, any applicable prospectus supplement, any related free writing prospectus, or other offering materials,
as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the delivery of this prospectus nor any sale made under it implies that there has not been any change in our business or affairs or that
the information in this prospectus is correct as of any date after the date of this prospectus. You should assume that the information
in this prospectus, any applicable prospectus supplement, any related free writing prospectus, or other offering materials, as applicable,
is accurate only as of the date on the front of the document and that any information we have incorporated by reference is accurate only
as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus, any applicable prospectus
supplement, any related free writing prospectus, or other offering materials, as applicable, or any sale of a security.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Registration Statement containing this prospectus, including exhibits to the Registration Statement, provides additional information
about us and the securities offered under this prospectus and any prospectus supplement. We have filed and plan to continue to file other
documents with the SEC that contain information about us and our business. Also, we will file legal documents that control the terms
of the securities offered by this prospectus as exhibits to the reports that we file with the SEC. The Registration Statement and other
reports can be read at the SEC Internet site or at the SEC offices mentioned under the heading &ldquo;Available Information.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus contains summaries of certain provisions contained in some of the documents described herein; but, reference is made to the
actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some
of the documents referred to herein have been filed, will be filed, or will be incorporated by reference as exhibits to the Registration
Statement of which this prospectus is a part, and you may obtain copies of those documents as described below under &ldquo;Available
Information.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="nd_002"></A>AVAILABLE
INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a Registration Statement on Form S-3 under the Securities Act with respect to the securities covered by this
prospectus. This prospectus, which is a part of that Registration Statement, does not contain all of the information set forth in the
Registration Statement or the exhibits and schedules filed therewith. For further information with respect to us and the securities covered
by this prospectus, please see the Registration Statement and the exhibits filed with the Registration Statement. A copy of the Registration
Statement and the exhibits filed with the Registration Statement may be inspected without charge at the Public Reference Room maintained
by the SEC, located at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for more information about the
operation of the Public Reference Room. The SEC also maintains an Internet website that contains reports, proxy and information statements,
and other information regarding registrants that file electronically with the SEC. The address of the website is http://www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the information and periodic reporting requirements of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange
Act&rdquo;), and, in accordance therewith, we file periodic reports, proxy statements, and other information with the SEC. Such periodic
reports, proxy statements, and other information are available for inspection and copying at the Public Reference Room and website of
the SEC referred to above. We maintain a website at http://www.janone.com. You may access our Annual Reports on Form 10-K, Quarterly
Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports filed pursuant to Sections 13(a) or 15(d) of the Exchange
Act with the SEC free of charge at our website as soon as reasonably practicable after such material is electronically filed with, or
furnished to, the SEC. Our website and the information contained on that site, or connected to that site, are not incorporated into and
are not a part of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="nd_003"></A>INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC&rsquo;s rules allow us to incorporate by reference information into this prospectus. This means that we can disclose important information
to you by referring you to another document. Any information referred to in this way is considered part of this prospectus from the date
we file that document. Any reports filed by us with the SEC after the date of this prospectus and before the date that the offering of
the securities by means of this prospectus is terminated will automatically update and, where applicable, supersede any information contained
in this prospectus or incorporated by reference in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incorporate by reference into this prospectus the following documents or information filed with the SEC (other than, in each case, documents
or information deemed to have been furnished and not filed in accordance with SEC rules):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Annual Report on <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828024015260/jan-20231230.htm" STYLE="-sec-extract: exhibit">Form 10-K</A> for the year ended December 30, 2023, filed with the SEC on April 8, 2024;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    description of our Common Stock is filed as <A HREF="https://www.sec.gov/Archives/edgar/data/862861/000156459020015355/jan-ex41_182.htm" STYLE="-sec-extract: exhibit">Exhibit 4.1</A> to our Annual Report on Form 10-K for the year ended December 28, 2019, filed
    with the SEC on April 6, 2020. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
all documents filed by us with the SEC under Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act, after (i) the date of the initial
Registration Statement and prior to effectiveness of the Registration Statement and (ii) the date of this prospectus and before the termination
or completion of this offering, shall be deemed to be incorporated by reference into this prospectus from the respective dates of filing
of such documents, except that we do not incorporate any document or portion of a document that is &ldquo;furnished&rdquo; to the SEC,
but not deemed &ldquo;filed.&rdquo; Any information that we subsequently file with the SEC that is incorporated by reference as described
above will automatically update and supersede any previous information that is part of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will provide without charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon his or her written
or oral request, a copy of any or all documents referred to above that have been or may be incorporated by reference into this prospectus,
excluding exhibits to those documents unless they are specifically incorporated by reference into those documents. Written or telephone
requests should be directed to JanOne Inc., 325 E. Warm Springs Road, Suite 102, Las Vegas, Nevada 89119, Attention: Corporate Secretary;
telephone: (702) 997-5968.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="nd_004"></A>FORWARD-LOOKING
STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus, including the documents we incorporate by reference into it, contains forward-looking statements within the meaning of Section
27A of the Securities Act, and Section 21E of the Exchange Act, the Private Securities Litigation Reform Act of 1995 (the &ldquo;PSLRA&rdquo;)
or in releases made by the SEC. Such statements include, without limitation, statements regarding our expectations, hopes, or intentions
regarding the future. Statements that are not historical fact are forward-looking statements. These forward looking statements can often
be identified by their use of words such as &ldquo;expect,&rdquo; &ldquo;believe,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;outlook,&rdquo;
&ldquo;could,&rdquo; &ldquo;target,&rdquo; &ldquo;project,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;seek,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;may,&rdquo; and &ldquo;assume,&rdquo; as well as variations of such words and similar
expressions referring to the future. These cautionary statements are being made pursuant to the Securities Act, the Exchange Act, and
the PSLRA with the intention of obtaining the benefits of the &ldquo;safe harbor&rdquo; provisions of such laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
forward-looking statements contained in or incorporated by reference into this prospectus are largely based on our expectations, which
reflect estimates and assumptions made by our management. These estimates and assumptions reflect our best judgment based on currently
known market conditions and other factors. Although we believe such estimates and assumptions to be reasonable, they are inherently uncertain
and involve certain risks and uncertainties, many of which are beyond our control. If any of those risks and uncertainties materialize,
actual results could differ materially from those discussed in any such forward-looking statement. Among the factors that could cause
actual results to differ materially from those discussed in forward-looking statements are those discussed under the heading &ldquo;Risk
Factors&rdquo; below, those discussed under the heading &ldquo;Risk Factors&rdquo; and in other sections of our Annual Report on Form
10-K for the year ended December 30, 2023, as well as in our other reports filed from time to time with the SEC that are incorporated
by reference into this prospectus. See &ldquo;Available Information&rdquo; and &ldquo;Incorporation of Certain Information by Reference&rdquo;
for information about how to obtain copies of those documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
readers are cautioned that the forward-looking statements contained in this prospectus and in the documents incorporated by reference
into this prospectus are not guarantees of future performance, and we cannot assure any reader that such statements will be realized
or that the forward-looking events and circumstances will occur. Actual results may differ materially from those anticipated or implied
in the forward-looking statements. All forward-looking statements in this prospectus and the documents incorporated by reference into
it are made only as of the date of the document in which they are contained, based on information available to us as of the date of that
document, and we caution you not to place undue reliance on forward-looking statements in light of the risks and uncertainties associated
with them. Except as required by law, we undertake no obligation to update any forward-looking statements, whether as a result of new
information, future events, or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="nd_005"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing
in our securities involves significant risks. You should review carefully the risks and uncertainties described under the heading &ldquo;Risk
Factors&rdquo; contained in, or incorporated into, the applicable prospectus supplement, any related free writing prospectus, or other
offering materials, as applicable, and under similar headings in the other documents that are incorporated by reference herein or therein.
Each of the referenced risks and uncertainties could adversely affect our business, operating results, and financial condition, as well
as adversely affect the value of an investment in our securities. When we offer and sell any securities pursuant to a prospectus supplement,
we may include additional risk factors relevant to such securities in the prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="nd_006"></A>BUSINESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>General</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JanOne
Inc. (formerly known as Appliance Recycling Centers of America, Inc.) and subsidiaries (collectively, &ldquo;we,&rdquo; the &ldquo;Company,&rdquo;
or &ldquo;JanOne&rdquo;) is focused on being a clinical-stage pharmaceutical company committed to finding treatments for conditions that
cause severe pain and bringing drugs to market with non-addictive pain-relieving properties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
of the Company&rsquo;s goals is to reduce the need for prescriptions for dangerous opioid drugs by treating underlying diseases that
cause severe pain. The Company&rsquo;s first drug candidate is a treatment for Peripheral Artery Disease (&ldquo;PAD&rdquo;), a condition
that can cause severe pain and affects over 8.5 million people in the United States. The Company intends to champion new initiatives&mdash;digital
technologies, educational advocacy, and revolutionary painkilling drugs that address what we believe is a multibillion dollar a year
market&mdash;to help combat the opioid crisis, which claims tens of thousands of lives each year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2022, we entered into a Purchase Agreement (the &ldquo;Soin Purchase Agreement&rdquo;) with Soin Therapeutics, LLC. Under
the Soin Purchase Agreement, the Company acquired Soin Therapeutics and its LDN product, now known as JAN123. JAN123 is a novel formulation
of 2.0 mg of LDN that results in a biphasic release of the product. The release properties of JAN123 provide for an immediate release
of less than half the product with a slow, sustained release of the remaining product. Importantly, the rapid release of LDN has been
reported to lead to vivid and lucid unpleasant dreams, which should be eliminated with the formulation of JAN123. Initially, a single
tablet of JAN123 will be administered orally, once a day before sleep, with eventual titration up to two tablets (4 mg) before sleep.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
name of the Company, JanOne Inc., was strategically chosen to express the start of a new day in the fight against the opioid epidemic.
January one is the first day of a New Year&mdash;universally considered as a day of optimism, resolution, and hope. JanOne stands by
its strategic commitment to fresh thinking and innovative means to assist in ending the worst drug crisis in our nation&rsquo;s history.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
March 8, 2023, the Company operated its legacy businesses through its Recycling Subsidiaries, consisting of: (a) ARCA Recycling, Inc.,
a California corporation (&ldquo;ARCA Recycling&rdquo;), (b) ARCA Canada Inc., a corporation organized under the laws of Ontario, Canada
(&ldquo;ARCA Canada&rdquo;), and (c) Customer Connexx, LLC, a Nevada limited liability company (&ldquo;Connexx&rdquo;). ARCA Recycling
and ARCA Canada recycle major household appliances in North America by providing turnkey appliance recycling and replacement services
for utilities and other sponsors of energy efficiency programs. Connexx is a company that provides call center services for recycling
businesses. On March 9, 2023, we entered into a Stock Purchase Agreement (the &ldquo;Recycling Purchase Agreement&rdquo;) with VM7 Corporation,
a Delaware corporation (&ldquo;VM7&rdquo;), under which it agreed to acquire all of the outstanding equity interests of the Recycling
Subsidiaries. The principal of VM7 is Virland A. Johnson, our Chief Financial Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information contained in or accessible from our website is not incorporated into this Annual Report on Form 10-K (the &ldquo;Form 10-K&rdquo;),
and it should not be considered part of this Form 10-K. We have included our website address in this Form 10-K solely as an inactive
textual reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was incorporated in Minnesota in 1983, although, through its predecessors, began operating its legacy recycling business in 1976.
In 2018, the Company reincorporated in the State of Nevada. The Company&rsquo;s principal office is located at 325 E. Warm Springs Road,
Suite 102, Las Vegas, Nevada 89119.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Biotechnology</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Overview</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biopharmaceutical company focused on becoming the leader in identifying, acquiring, licensing, developing, partnering,
and commercializing novel, non-opioid, and non-addictive therapies to address the large, unmet medical need for the treatment of pain
and addiction. JAN101 (formerly known as TV1001SR) is a potential treatment for PAD, a vascular disease that affects more than 8.5 million
people in the U.S. and more than 60 million people worldwide. We expect to commence Phase IIb/III clinical trials for the treatment of
PAD in 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>JAN101</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Generally</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JAN101,
formerly known as TV1001SR, is a patented oral, sustained-release pharmaceutical composition of sodium nitrite that targets poor blood
flow to the extremities, such as those with vascular complications of diabetes or PAD and treats pain. A conclusion from a round of human
studies found JAN101 prevents the prevalent reports of headaches by patients treated with an immediate release formulation of sodium
nitrite. In a previous study of patients with PAD, a 40 mg BID treatment with immediate release sodium nitrite led to a statistically
significant reduction in reported pain, while an 80 mg BID treatment had a more pronounced effect on bioactivity and Flow Mediated Dilation,
a measure of vascular function. However, a number of subjects in both treatment groups reported headaches and dizziness following treatment.
Although this did not result in subjects discontinuing treatment, JAN101 was developed to overcome this side effect. JAN101 was tested
in a bridging study of diabetic neuropathy subjects and, during that bridging study, the subjects did not report headaches or dizziness.
Subjects in this bridging study also reported less pain following treatment and improvements in bioactivity (quantitative sensory testing,
a measure of nerve function) were similar to the PAD study, where the 80 mg dosing group had the greatest improvement in Flow Mediated
Dilation. The ability to alleviate pain with BID treatment of JAN101 offers promise for a new non-addictive, non-sedating treatment of
chronic pain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Clinical
Studies in Humans JAN101 Attributes</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Well-established
    safety profile</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excellent
    bioavailability</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lack
    of induced tolerance</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-narcotic</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JAN101
does not mask pain, but instead treats the cause of pain by improving tissue and vascular function.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Benefits
of Sodium Nitrite on Vascular Health</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
initial research studies, sodium nitrite effectively restored ischemic tissue blood flow and was effective in a wide range of pathologies
involving alterations of angiogenesis &ndash; development of new blood vessels &ndash; including diabetes, wound healing, and tissue
necrosis. Beneficial effects include enhancing angiogenesis, endothelial cell proliferation, and arteriogenesis. There is also a strong
association between reduced circulating nitrite levels and cardiovascular diseases in humans. We describe some of the associations and
beneficial effects of sodium nitrite/nitrite below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Plasma
nitrite levels are negatively correlated to cardiovascular disease</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><IMG SRC="form424b5_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><IMG SRC="form424b5_003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plasma
nitrite levels were inversely related to number of cardiovascular risk factors a subject had and decreased plasma nitrite was associated
with decreased flow mediated vasodilation (FMD) and increased intimal medial thickness (IMT) (both are indicators of vascular pathology).
Kleinbongard, et al. (2006) Free Radic Biol and Medicine 40:295-302.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Plasma
nitrite levels are reduced in diabetic and PAD patients</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><IMG SRC="form424b5_004.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
is a well-known stimulator of endothelial nitric oxide synthase activity, an enzyme that enhances nitric oxide (NO) production, which
leads to increased plasma nitrite. In the study by Allen, et al., these authors revealed that baseline plasma levels of nitrite were
less in patients with diabetes mellitus (DM) or DM + PAD. Importantly, increases in plasma nitrite levels were not observed in either
DM, PAD, or DM + PAD patients after supervised exercise. These data reveal that baseline nitrite availability is compromised in DM patients
and that supervised exercise is unable to increase plasma nitrite levels but actually results in a decrease in nitrite, highlighting
a physiological efficiency of this molecule. Allen, et al., Nitric Oxide 2009 20:231-2377.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Skeletal
Muscle Nitrite and Metabolite Levels are Reduced in Critical Limb Ischemia (CLI) Patients</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><IMG SRC="form424b5_005.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Skeletal
muscle nitrite, nitrosothiol (RSNO), nitric oxide-heme, and cGMP are all significantly reduced in CLI (the most severe form of PAD) patients.
Diabetic patients with CLI show even further nitrite reductions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
summary, nitrite levels in various cardiovascular and vascular diseases appear to be inversely related to the severity of the disease
in humans:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lower
    nitrite levels are associated with higher level of heart failure;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lower
    nitrite levels are observed in diabetic patients with PAD and are not compensated by exercise; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nitrite
    levels are lower in the muscles of patients with critical limb ischemia and are further reduced in diabetic subjects with critical
    limb ischemia.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the association between low levels of circulating nitrite and human diseases, supplementation with sodium nitrite has been studied preclinically
in animals. Below are summaries of some of the more important findings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promotes
    angiogenesis</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stimulates
    wound healing</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prevents
    tissue necrosis</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
Arya, et al.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nitrite
Therapy Selectively Increases Ischemic Tissue Vascular Density in a NO-dependent Manner</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b5_006.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chronic
sodium nitrite therapy increases ischemic tissue vascular density in a NO-dependent manner. A and B show representative images of CD31
(red) and DAPI nuclear (blue) staining from sodium nitrite and sodium nitrate ischemic gastrocnemius muscle tissue at day 7. C and D
report the vascular density of ischemic gastrocnemius muscle tissue at days 3 and 7 for 165 &mu;g/kg sodium nitrite and nitrate treatments,
respectively. E and F demonstrate the vascular density of ischemic gastrocnemius muscle tissue at days 3 and 7 from 165 &mu;g/kg sodium
nitrite plus carboxy PTIO. (Scale bar, 150 &mu;m.) n = 10 mice per treatment group. Kumar D., et al., PNAS; 2008; 105:7540-7545.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nitrite
Therapy Augments Arterial Perfusion of Ischemic Tissue</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><IMG SRC="form424b5_007.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chronic
sodium nitrite therapy acutely increases ischemic tissue blood flow and stimulates arteriogenesis. A and B report 165 &mu;g/kg sodium
nitrite-induced acute changes in blood flow of chronically ischemic tissues at various time points with or without cPTIO, respectively.
C reports the number of arterial branches between PBS and nitrite therapies. D and E illustrate vascular casting of the arterial vasculature
in ischemic hind limbs of day 7 nitrite or PBS-treated mice, respectively. *, P &lt; 0.01 vs. sodium nitrite. N = 10 mice per treatment
group. Kumar D., et.al., PNAS;2008; 105:7540-7545.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nitrite
Therapy Restores Diabetic Ischemic Hind-Limb Blood Flow and Promotes Wound Heal</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><IMG SRC="form424b5_008.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unilateral
femoral artery ligation was performed on 18-20 week old male Db/Db mice. Mice were randomized to PBS or sodium nitrite (165 &mu;g/kg)
therapy twice daily via I.P. injection. Laser doppler flowmetry was performed at the indicated time points. Increased wound dehiscence
was noted in the PBS treated animals at day 7 but not in nitrite treated animals. (Bir, et al., Diabetes 2014, 63(1):270-81).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nitrite
Therapy Increases Diabetic Ischemia Induced Angiogenesis</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><IMG SRC="form424b5_009.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nitrite
therapy prevented ischemia mediated endothelial cell density loss in normal C57BL/6J ischemic limbs. Nitrite therapy significantly restored
endothelial cell density in ischemic limbs of diabetic mice to normal C57BL/6J levels compared to PBS therapy of non-ischemic and ischemic
conditions. These data suggest that nitrite therapy may be useful in attenuating microvascular rarefaction due to loss of nitric oxide
that is observed during metabolic dysfunction (Frisbee JC AJP Integr Comp Physiol 2005 289(2):R307-16; Stepp et al. Microcirculation
2007 14(4-5): 311-6).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delayed
Nitrite Therapy Restores Ischemic Hind-Limb Blood Flow</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><IMG SRC="form424b5_010.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Studies
were performed to determine whether nitrite mediated therapy would be effective in tissue that had been left ischemic for 5 days after
femoral artery ligation. Femoral artery ligation was performed in C57BL/6J mice and the animals randomized to either PBS or sodium nitrite
therapy 5 days after artery ligation. Treatments were given b.i.d. via I.P. injection. Ischemic limb blood flow was measured using laser
doppler flowmetry. (Bir, et al., Diabetes 2014, 63(1):270-81).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delayed
nitrite therapy increases SPY angiogram arteriogenesis</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><IMG SRC="form424b5_011.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delayed
nitrite therapy increases SPY angiogram arteriogenesis. Representative temporal SPY angiogram image stills (3&ndash;6s) are shown at
11 days following ligation and 6 days after beginning therapy (either PBS or sodium nitrite). <I>Left</I>: PBS control angiogram. <I>Right</I>:
sodium nitrite angiogram following injection of ICG. <I>n </I>= 5 animals per cohort. Circles identify limb anatomical regions of vascular
blush, whereas arrows indicate perfused vessels that progressively occur over time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bir,
et al., Am J Physiol Heart Circ Physiol 2012;303:H178-H188.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nitrite
Therapy Prevents Tissue Necrosis in Aged Db/Db Mice</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b5_012.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delayed
sodium nitrite (165 ug/kg) or control PBS therapy was stated 5 days post-femoral artery ligation in nine-month old Db/Db mice. Nitrite
therapy significantly prevented tissue necrosis (panel B) compared to control PBS therapy (panel A). Panel D reports tissue necrosis
severity as a function of degree of limb and digit involvement. Nitrite therapy, but not PBS control or sodium nitrate, significantly
prevented tissue necrosis. (Bir, et al., Diabetes 2014, 63(1):270-81).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Nitrite
and Hind Limb Ischemia Summary</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sodium
nitrite has long been known to be a potent vasodilator (transiently increasing blood vessel diameter) that can lead to a drop in blood
pressure when given acutely. The above studies indicate that chronic administration at low doses promotes angiogenesis, unlike one-time
nitrite therapy, which does not stimulate angiogenesis. In addition, these studies and a large number of other studies not reviewed above
show:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nitrite
    therapy is very specific, acting only in damaged, ischemic tissue;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delayed
    nitrite therapy effectively restores ischemic tissue blood flow;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nitrite
    therapy is effective in a wide range of pathologies involving alterations of angiogenesis including critical limb ischemia, heart
    failure, and tissue necrosis;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nitrite
    supplementation has had positive effects in various diabetes models, including diabetic nephropathy and diabetic wound healing;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
    effects center on enhancing angiogenesis, endothelial cell proliferation, and arteriogenesis; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sustained
    release nitrite therapy, unlike immediate release therapy, does not lead to vasodilation or a drop in blood pressure.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>JAN101</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JAN
101 is designed to treat diseases associated with poor vascular function. The following table summarizes our current product candidate:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><IMG SRC="form424b5_013.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Pain</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pain
is a protective reaction that alerts the body to the presence of actual or potential tissue damage so that necessary corrective responses
can be mounted. The National Institutes of Health (the &ldquo;NIH&rdquo;) defines chronic pain as pain that persists beyond the normal
healing time of an injury or that persists longer than three months. It is estimated that chronic pain affects 100 million individuals
in the United States and over 1.5 billion people worldwide; thus, more people suffer from chronic pain than diabetes, heart disease,
and cancer combined (Cowen Therapeutic Categories Outlook, March 2019). Chronic pain exacts a tremendous cost in terms of direct treatment
and rehabilitation expenditures, lost worker productivity, prevalent addiction to opioid-based drugs, and emotional and financial burden
for patients and their families. According to an Institute of Medicine of the National Academies report, pain is a significant public
health problem in the United States that costs society between $560 billion and $635 billion annually. Despite the magnitude of the pain
problem, innovation in the development of therapeutic solutions has been largely absent. Since 2010, there have been 20 approvals by
the FDA for the treatment of pain, of which 12 were opioid variants, one was an extended-release generic corticosteroid, five were variants
of aspirin, and two were variants of other existing drugs. We are developing a novel product candidate designed to overcome the limitations
of current treatment options for patients with PAD who suffer from chronic pain. According to a research study by Stanford University,
more than 24% of patients with PAD are at risk of high opioid use. By treating pain at the source and presenting patients and physicians
with better and safer treatment alternatives, we expect to minimize opioids at the prescription pad. Given the properties of JAN101,
we have made the strategic decision to focus initially on pain associated with PAD by treating the underlying cause of PAD.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Peripheral
artery disease</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peripheral
artery disease (&ldquo;PAD&rdquo;) is a general term for conditions in which arterial blood flow to the limbs is partially blocked. When
there is less blood present in the extremities relative to demand, muscle pain and fatigue result, especially in the calf, which is also
known as &ldquo;intermittent claudication.&rdquo; In many patients, pain and fatigue are relieved through rest. Roughly half of patients
with PAD are asymptomatic. The most common cause of PAD / intermittent claudication is atherosclerosis. Diabetes, chronic kidney disease,
hypertension, and smoking are all risk factors that can increase the likelihood of PAD. In atherosclerosis, fat deposits (plaques) build
up along arterial walls, resulting in a reduction in blood flow in the legs. This same process can cause strokes if the arteries leading
up to the brain are affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the high rate of asymptomatic patients, prevalence figures vary widely. Some estimate that up to 200 million people worldwide have
PAD, ranging from asymptomatic disease to severe. Prevalence increases as a function of patient age, rising sharply after the age of
60. Thus, in countries with an aging population, it is expected that the prevalence of PAD will only increase. There is also a strong
ethnic and racial component to PAD prevalence, which may be due to cultural differences in diet and exercise, along with genetic differences.
Some suggest a prevalence of eight to 12 million in the United States alone, with roughly one-third experiencing pain when walking, which
improves upon resting. The diagnosis of PAD usually begins with patient complaints of pain in the extremities. If the patient is already
being treated or monitored for diabetes or other risk factors, then the physician will check for a weak or absent pulse in the extremity.
Decreased blood pressure, poor wound healing, and whooshing sounds (via stethoscope) in the legs are also tell-tale signs of PAD / intermittent
claudication. Angiograms, electrocardiograms, and ultrasounds can also be used to image and confirm the diagnosis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><IMG SRC="form424b5_014.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Figure
1: Ethnic-specific prevalence of PAD in men in the US, by age. NHW = Non-Hispanic Whites, AA = African American, HS = Hispanics, AS
= Asian Americans, AI = American Indians. Source: (Criqui, 2015)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
non-drug treatment of PAD / intermittent claudication may be divided into four general categories:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Lifestyle
    </I>&ndash; Primarily changes in diet and smoking cessation.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exercise
    </I>&ndash; Patients who walk, cycle, stretch, or swim can experience marked improvement. Formal programs involving treadmills and
    track walking (usually three to five times per week) are frequently provided to patients. However, if the pain is triggered by exercise
    (claudication) and is significant, it can discourage the patient from exercise.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Angioplasty
    </I>&ndash; A procedure by which the affected artery is stretched with a balloon-like device. This procedure has limited effectiveness
    and is reserved for severely blocked arteries.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Bypass
    Surgery </I>&ndash; Arteries that are beyond angioplasty can be bypassed entirely. This procedure is typically reserved for cases
    where the blockage is considered very long (~10 centimeters) and nearly complete.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underlying condition is not addressed by surgery. Surgical approaches will not, in the long run, improve exercise capacity and walking
distance. Only exercise itself, coupled with lifestyle changes and drug approaches, has this benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prescription
drugs for the treatment of the underlying PAD may be divided into multiple categories, depending on the underlying condition and severity:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cholesterol-Lowering
                                            Agents &ndash;</I> Statins and bile acid sequestrants.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Antiplatelet
    Medications </I>&ndash; Aspirin and related drugs, such as clopidogrel. Cilostazol also has antiplatelet properties.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Antihypertensives
    </I>&ndash; Patients with underlying high blood pressure can and will receive any number of medications to reduce blood pressure,
    such as ACE inhibitors and diuretics.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Diabetes
    Therapies </I>&ndash; While a substantial portion of PAD patients may have pre-diabetes or fulminant diabetes, it is unknown if aggressive
    treatment of diabetes has a positive effect on PAD.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Pain
    </I>&ndash; To our knowledge, no drugs are specifically indicated for PAD-associated pain. Pentoxifylline, for example, is indicated
    &ldquo;&hellip;for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of
    the limbs.&rdquo; (Sanofi-Aventis U.S. LLC, 2010). However, the evidence supporting the effectiveness of pentoxifylline is mixed.
    Short-term courses of NSAIDs, such as ibuprofen, may be used, provided the patient is not on another anticoagulant, like aspirin.
    Non-drug pain relievers, such as TENS and massage therapy, may also be used in these patients. Opioids may also be used, which creates
    a risk for addiction and potential misuse at the medicine cabinet by family members.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><IMG SRC="form424b5_015.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lack of any truly effective treatment of PAD, along with encouraging early trial results using JAN101 on both improving vascular function
and reducing pain in PAD patients, has created an opportunity potentially to treat this large unmet medical need. By improving vascular
function, JAN101 has the potential to reduce associated pain and improve PAD patients&rsquo; quality of life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Our
Strategy</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
focus is to develop and commercialize novel, non-opioid, and non-addictive therapies to address, safely and effectively, the significant
unmet medical need of chronic pain or treat conditions that cause pain. The principal elements of our strategy to achieve this mission
are the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>License,
    acquire, develop, and create novel, non-opioid and non-addictive therapies by leveraging our understanding of pain biology to address
    the large and growing problem of pain.</B> While innovation in medical sciences has led to exciting new treatment options in many
    disease areas, pain has seen limited innovation in recent years. We have a deep understanding of the pathophysiology of pain and
    diseases that cause pain. We intend to leverage this understanding to bring innovation in the pain treatment paradigm through targeted
    acquisitions of companies or assets in development. Our advisors and doctors have years of collective experience in leadership positions
    at institutions and substantial scientific experience and understand the complexity of designing and executing clinical trials for
    and developing therapies.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Advance
    the development of JAN101, designed for the treatment of patients with PAD and pain associated with the disease.</B> There are limited
    therapeutic options available for patients with PAD and we believe that JAN101 has the potential to transform the standard of care
    to a twice-a-day pill to improve moderate-to-severe PAD substantially.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Leverage
    clinical activity of JAN101 possibly to expand into new indications. </B>The Company is in discussion with multiple researchers about
    expanding JAN101&rsquo;s use into other indications. JanOne will provide the researchers previously manufactured clinical supplies
    of JAN101 for use in their clinical trials.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Advance
    JAN101 through clinical development and pursue development of additional product candidates through acquisitions.</B> Our objective
    is to build a well-balanced, multi-asset portfolio targeting the large population of patients with chronic and acute pain. To achieve
    this, in addition to JAN101, we intend to pursue partnerships, licensing agreements, and potential acquisitions of other pharma companies.
    We continue our search for assets with indications where we believe they could have meaningful impact and address the large unmet
    medical need. In addition, we may choose to selectively in-license or acquire complementary product candidates by leveraging the
    insights, network, and experience of our team.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Maximize
    the commercial potential of all our product candidates. </B>We currently intend to retain all commercial rights to JAN101 in the
    United States and selectively partner outside of the United States. Because we believe that PAD is an attractive market for many
    major pharmaceutical companies, we may sub-license or partner certain indications if we believe it may enhance stockholder value.
    As we continue to build and develop our product portfolio, we may opportunistically pursue strategic partnerships that maximize the
    value of our pipeline while seeking to develop other indications.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Leverage
    our management team background and expertise. </B>We have assembled a team with extensive experience described above.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Chronic
Pain</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NIH defines chronic pain as pain that persists either beyond the normal healing time of an injury or longer than three months. We believe
that chronic pain represents a significant public health crisis. It is estimated that chronic pain affects 100 million individuals in
the United States and over 1.5 billion people worldwide; thus, more people suffer from chronic pain than diabetes, heart disease, and
cancer combined (Cowen Therapeutic Categories Outlook, March 2019). Chronic pain exacts a tremendous cost in terms of direct treatment
and rehabilitation expenditures, lost worker productivity, prevalent addiction to opioid-based drugs, and emotional and financial burden
for patients and their families. According to an Institute of Medicine of the National Academies report, pain is a significant public
health problem in the United States that costs society between $560 billion and $635 billion annually. Chronic pain is the leading cause
of long-term disability in the United States, and approximately 23 million adults in the United States experience severe pain over a
three-month period. Globally, the prevalence of chronic pain is even larger, with over one billion people worldwide affected each year.
Common types of chronic pain include those of neuropathic and inflammatory origin and may involve the skin, muscles, joints, bones, tendons,
ligaments, and other soft tissues. Chronic pain is associated with a variety of clinical conditions including, but not limited to, arthritis,
spinal conditions, cancer, fibromyalgia, diabetes, surgical recovery, visceral injury, and general trauma.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pain
is a necessary protective reaction that alerts the body to the presence of actual or potential tissue damage so that necessary corrective
responses can be mounted. Pain is signaled by specialized cells in the peripheral nervous system called nociceptors, or pain-sensing
fibers. These pain-sensing fibers normally transmit information about stimuli that approach or exceed harmful intensity from different
locations in the body to the brain, which registers this information as a sensation of pain. In the case of tissue injury due to trauma
or infection, pain accompanies the associated inflammation, persists for the duration of the inflammatory response, and aids healing
by inhibiting use of the affected body part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pain
also can modify the central nervous system, such that the brain becomes sensitized and registers more pain with less provocation. This
is called central sensitization. When central sensitization occurs, the nervous system goes through a process called wind-up and gets
regulated in a persistent state of high reactivity. This persistent, or up-regulated, state of reactivity lowers the threshold for what
triggers the sensation of pain and can result in the sensation of pain even after the initial injury might have healed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
there is dysfunction in pain signaling, injury to the nervous system, or an unhealed injury, pain becomes no longer just a symptom, but
a disease in itself.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Current
Therapeutic Approaches to Treating Chronic Pain and Their Limitations</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>NSAIDs</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the most widely used therapies to treat chronic inflammatory pain are non-steroidal anti-inflammatory drugs (&ldquo;NSAIDs&rdquo;).
NSAIDs can have significant side effects that include gastrointestinal bleeding, gastritis, high blood pressure, fluid retention, kidney
problems, heart problems, and rashes. On April 7, 2005, the FDA announced a decision to require boxed warnings of potential cardiovascular
risk for all NSAIDs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Corticosteroids</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corticosteroids,
or steroids, also possess anti-inflammatory properties and are commonly used in the practice of pain management, either systemically
or locally, depending on the condition. Steroids work by decreasing inflammation and reducing the activity of the immune system. While
steroids are commonly used, they may have numerous and serious side effects. These side effects may include allergic or hypersensitivity
reactions, increased risk for infection, adrenal insufficiency, diabetes or decreased glucose tolerance, hypertension, loss of bone density,
and loss of joint cartilage volume. In addition, steroids should not be administered when there is an infection present because steroids
can inhibit the body&rsquo;s natural infection-fighting immune response. Also, if a joint is already damaged or is subject to chronic
deterioration, intra-articular, or IA steroid injections are not likely to provide any long-term restorative benefit. For the above reasons,
IA steroid injections are generally recommended to be administered no more often than every six weeks and not more than three to four
times per year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Opioids</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opioids
are some of the most widely prescribed therapeutics for chronic and acute pain, and sales of these drugs have quadrupled between 1999
and 2010. According to a National Survey on Drug Use and Health report, in 2016 more than one-third of adult Americans were prescribed
opioids and 230 million opioid prescriptions were written that year in the United States. Opioids act by binding to specific receptors
located on neurons in both the central and peripheral nervous system throughout the body including in the brain, spinal cord, and other
nervous tissue. Although they can be effective in providing pain relief, the increased medical use of opioids has been accompanied by
an increase in the abuse and misuse of prescription opioids. In addition, for most patients, chronic opioid use is a poor option due
to an intolerance to the many side effects, including nausea, vomiting, drowsiness, and constipation, and the propensity for opioids
to become less effective with long-term use. According to the Centers for Disease Control and Prevention (the &ldquo;CDC&rdquo;), almost
two million individuals abused or were dependent on prescription opioids in 2014. CDC figures show that the number of opioid-related
overdose deaths has quadrupled between 1999 and 2010, and currently approximately 40% of opioid overdose deaths in the United States
involve a prescription opioid. This increase in prescription opioid-related deaths in the United States prompted former President Trump
to declare the opioid crisis a national Public Health Emergency in October 2017. Opioid abuse has become an epidemic in the United States,
ranking as the nation&rsquo;s second most prevalent illegal drug problem. These major issues create the need to find new approaches to
treating chronic pain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Our
Approach to Treating PAD and Chronic Pain</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unmet medical need for treating PAD and chronic pain reflects the historic failure to develop novel classes of analgesics with comparable
or greater efficacy, an acceptable level of adverse effects and a lower abuse liability than those currently available. Some of the reasons
for this include the heterogeneity of chronic pain and its related conditions, and the complexity and diversity of the underlying pathophysiological
mechanisms for pain. However, recent advances in the understanding of the neurobiology of pain are beginning to offer opportunities to
identify new drug targets and develop new therapeutic strategies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have taken an innovative and targeted approach to identifying treatments for chronic pain that leverages our understanding of the pathophysiology
of pain. Pain is variable. For example, it can be inflammatory or neuropathic in nature, and it may be localized to a specific area of
the body or it may be generalized throughout. We believe that the most effective way to treat chronic pain is through therapies that
specifically target the origin of the pain signal. We strive to maximize JAN 101&rsquo;s potential based on its unique mechanism of action
related to the origin of the pain signal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>A
Randomized, Double-Blind Study of the Effects of a Sustained Release Formulation of Sodium Nitrite (SR-nitrite) on Patients with Diabetic
Neuropathy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Background:
</B>Sodium nitrite has been reported to be effective in reducing chronic peripheral pain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Objectives:
</B>To evaluate the safety and efficacy of 40 and 80 mg, BID, of an oral sustained-release formulation of sodium nitrite (SR-nitrite)
in patients suffering from diabetic neuropathy, and to determine whether SR-nitrite would reduce the frequency of headaches reported
previously by subjects receiving the same doses of an immediate release formulation. Study Design: Phase II, single-center, randomized,
double-blind, placebo-controlled clinical trial. Setting: The Ohio Pain Clinic and Kettering Medical Center.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Methods:
</B>Twenty-four patients were randomized to 40 mg or 80 mg SR-nitrite or placebo twice daily for 12 weeks. The primary objective was
to determine whether headaches would be reduced using SR-nitrite. The primary efficacy endpoint was the mean difference in the change
of the Neuropathic Pain Symptom Inventory (NPSI) pain score from baseline to that reported after 12 weeks of treatment. Secondary endpoints
included changes from baseline for the Brief Pain Inventory (BPI) Scale, the RAND 36 questionnaire, Short-Form McGill Questionnaire,
daily patient reported score for neuropathic pain, changes in HbA1c, PulseOx, and quantitative sensory testing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results:
</B>The number of subjects reporting adverse events and the number of adverse events did not change with dose. There were no reports
of treatment-related headaches. Although no significant differences were identified in patient responses to the questionnaires, a trend
was observed. In the NPSI assessment, patients in the 40 mg and 80 mg dosing groups reported a 12.7% and 22.0% reduction in pain, respectively,
compared to an 8.4% reduction by patients in the placebo group. A trend was also observed with the BPI total severity score. However,
the 40 mg dosing group reported the greatest reduction in pain using the McGill Pain index and via patient logs of daily pain scores,
where the mean of pain scores reported by subjects in the 40 mg group dropped by day 41 and generally stayed lower than the mean of scores
reported by subjects in either of the other two groups. Patients in the 80 mg SR-nitrite group had an improvement in both Nerve Sensory
Conductance and Nerve Sensory Velocity. No changes were observed in HbA1c levels or PulseOx.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limitations:
</B>Small sample size.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Conclusion:
</B>Sustained release sodium nitrite prevents the prevalent reports of headaches by patients treated with an immediate release formulation
of sodium nitrite. In a previous study of patients with peripheral arterial disease (PAD), 40 mg BID treatment led to a statistically
significant reduction in reported pain. Similar trends were observed at the end of the trial period for most of the pain questionnaires
used in the study. The 80 mg BID treatment had the more pronounced effect on bioactivity (quantitative sensory testing), which was similar
to the PAD study, where this dosing group had the greatest improvement in Flow Mediated Dilation . The ability to alleviate pain with
BID treatment of SR-nitrite offers promise for a new non-addictive, non-sedating treatment of chronic pain and warrants further study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microcirculatory
injury, which is common in diabetic patients, can lead to a number of problems. Prominent among these is diabetic peripheral neuropathy
(DPN). About 10% of patients will have evidence of DPN at the time they are initially evaluated, and almost 50% of diabetic patients
will ultimately develop DPN. Of diabetic patients with DPN, 40% to 50% suffer from chronic pain, as well as paresthesia, sensory loss,
and weakness, and have at least an eight-fold increased risk of undergoing a distal lower extremity amputation compared to similar non-diabetics.
Endothelial cells play an important part in the regulation of microcirculation, as they maintain vascular tone by secreting both vasodilators
and vasoconstrictors. A central feature of diabetic microvascular disease (MVD) is endothelial dysfunction, which, in turn, plays an
important role in the development and progression of DPN. The pathophysiological factors leading to endothelial dysfunction in diabetes
include chronic hyperglycemia and protein glycosylation, insulin resistance, inflammation, and increased oxidative stress. Studies have
now shown a close relationship between endothelial dysfunction and diminished nitric oxide (NO) bioavailability. Endogenously produced
NO has a half-life measured in seconds, and is rapidly oxidized to nitrite (NO<SUB>2</SUB>&ndash;) and nitrate (NO<SUB>3</SUB>&ndash;)
end-products, the latter of which is biologically inert. In the presence of microcirculatory ischemia and endothelial cell dysfunction,
however, endogenous NO production by eNOS is much more limited. In such circumstances, circulating NO<SUB>2</SUB> can be non-enzymatically
reduced to increase NO availability. In addition to serving as a circulating NO reservoir, nitrite itself has also been shown to have
direct and potent vasodilatory effects in vitro and in vivo. The findings that NO<SUB>2</SUB>&ndash; mediates vasodilatation, both directly
and through NO generation, has led to growing interest in the potential effectiveness of nitrite as a therapeutic agent in conditions
associated with DPN and endothelial dysfunction. Such conditions include diabetic microvascular disease, DPN, and retinopathy, in which
low levels of NO and NO<SUB>2</SUB>&ndash;, as well as elevated levels of nitrate (NO<SUB>3</SUB>&ndash;), suggest that the complete
oxidation of NO occurs during diabetes with insufficient NO<SUB>2</SUB>&ndash; reserves to restore NO bioavailability. Previous human
studies with an oral formulation of NaNO<SUB>2</SUB> have shown that administration twice daily improves vascular function. In the peripheral
arterial disease study, subjects who received the lower dose of NaNO<SUB>2</SUB> reported a significant reduction in pain. Although side
effects were minimal, headaches and dizziness were reported by a large number of subjects, likely due to the rapid release of NaNO<SUB>2
</SUB>leading to vasodilation. An oral, sustained-release formulation of NaNO<SUB>2</SUB> (SR-nitrite) was developed in an attempt to
overcome these problems and was tested in a porcine model of metabolic syndrome with critical limb ischemia. SR-nitrite-treated animals
showed increased myocardial NO bioavailability, diminished oxidative stress, and cytoprotection in ischemic tissue. Importantly, 24-hour
telemetry recordings of blood pressure showed no evidence of vasodilation. In the above study, we hypothesized that the SR-nitrite would
reduce or eliminate headaches reported in patients following administration of the immediate release formulation. Given the promising
results on reducing pain in diabetic patients with PAD reported in the previous study, patients with diabetic neuropathy were utilized
in this study to determine whether any trends in reducing pain could be observed. The study design was a randomized, placebo controlled,
double-blind phase II study was carried out to investigate the safety and potential biological activity of multiple doses of an oral,
sustained-release formulation of sodium nitrite (SR-nitrite; TheraVasc Inc., Cleveland, OH, USA), BID in doses of 40 mg and 80 mg over
a 12-week treatment period, in human subjects with diabetes and neuropathic pain in the lower extremities and feet. The trial was approved
by the Copernicus Group Institutional Review Board and listed on ClinicalTrials.gov: www.clinicaltrials.gov/ct2/show/NCT02412852. The
study was funded by TheraVasc Inc. (&ldquo;TheraVasc&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>JAN101&mdash;Regulatory
Strategy</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sodium
nitrite has been previously approved as one of the active components of cyanide poisoning antidote. This means the approval path for
JAN101 is through a 505(b)(2) (&ldquo;NDA&rdquo;), which we intend to pursue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>JAN101&mdash;Commercial
Strategy</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently intend to use third-party providers and manufacturers to support the commercialization JAN101, if we are successful in obtaining
FDA approval. We believe that we can promote JAN101 to the patients suffering from PAD in a cost effective manner. We anticipate our
commercial operation will include outside sales management, outside sales support, distribution support, and an internal marketing group.
Additional requisite capabilities will include focused management of key accounts, such as managed-care organizations, group purchasing
organizations, and government accounts. We intend selectively to partner with third parties with vast experience in the space, as we
have been partnering for every aspect of development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Competition</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology and pharmaceutical industries are characterized by extensive research and development efforts, rapidly advancing technologies,
intense competition, and a strong emphasis on proprietary products. We are currently focused on the development and commercialization
of our asset pipeline of novel, non-opioid, and non-addictive therapies for PAD. The number of patients suffering from chronic PAD is
large and growing. While we believe that JAN 101 and our Chief Scientific Officer&rsquo;s development experience and scientific knowledge
provide us with competitive advantages, we face potential competition from many different sources, including pharmaceutical, biotechnology,
and specialty pharmaceutical companies that market or develop therapeutics to treat chronic pain. Academic research institutions, governmental
agencies, as well as public and private institutions are also potential sources of competitive products and technologies. Our competitors
may have significantly greater financial resources, robust drug pipelines, established presence in the market, and expertise in research
and development, manufacturing, pre-clinical and clinical testing, obtaining regulatory approvals and reimbursement, and marketing approved
products than we do. These competitors also compete with us in recruiting and retaining qualified clinical, regulatory, scientific, sales,
marketing, and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring
technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors,
particularly through collaborative arrangements with large and established companies. The key competitive factors affecting the success
of JAN 101 (as well as other subsequent product candidates), if and when approved, is likely to be its efficacy, durability, safety,
price, and the availability of reimbursement from government and other third-party payors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
competition exists in the PAD pain field. Although we believe our approach to developing novel treatments for pain is unique from most
other existing or investigational therapies, such as NSAIDs, corticosteroids, and opioids, we will need to compete with all currently
available and future therapies within the indications where our development is focused. With respect to JAN101, the main classes of marketed
products that are available for the treatment of PAD pain include NSAIDs and opioids. Furthermore, numerous monoclonal antibodies targeting
nerve growth factor, or NGF inhibitors, are in clinical development, including two product candidates in Phase III.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are a number of companies developing or marketing therapies for the treatment and management of pain that may compete with JAN 101, including
many major pharmaceutical and biotechnology companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Intellectual
Property</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends in large part upon our ability to obtain and maintain proprietary protection for our products and technologies, and to
operate without infringing or otherwise violating the proprietary rights of others. We endeavor to protect our products using a combination
of intellectual property protections and available government regulatory and marketing exclusivities afforded to new medicines. For example,
we endeavor to protect our products by, among other methods, filing United States and foreign patent applications related to our proprietary
technology, inventions, and improvements that are important to the development and implementation of our business. We also use other
forms of protection, such as confidential information, trade secrets, and know-how, and trademarks to protect our intellectual property,
particularly where we do not believe patent protection is appropriate or obtainable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proprietary nature of, and protection for, JAN 101, processes, and know-how are important to our business. Our policy is to pursue, maintain,
and defend intellectual property rights, and to protect the technology, inventions, and improvements that are commercially important
to our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Trade
Secrets and Other Proprietary Information</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to patents, we rely on trade secrets and know-how to develop and maintain our competitive position. For example, we have developed
methods for more efficient manufacture of sustained released sodium nitrite tablets. We seek to protect our proprietary information,
in part, by confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors,
and commercial partners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>License
Agreement</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 19, 2019, we entered into a Patent and Know How License Agreement (the &ldquo;License Agreement&rdquo;) with UAB Research Foundation
(&ldquo;UABRF&rdquo;), TheraPAD, and the Board of Supervisors of Louisiana State University and Agricultural and Mechanical College,
acting on behalf of LSU Health Shreveport, together with UABRF and TheraPAD collectively, the &ldquo;Licensors&rdquo;). Under the License
Agreement, the Licensors have agreed to grant to JanOne an exclusive, worldwide license, including the right to sublicense, to the Licensors&rsquo;
patent rights and know-how related to the Licensors&rsquo; sustained release formulation of sodium nitrite. Under the License Agreement,
we have agreed to pay a non-refundable upfront license fee and certain milestone payments upon the achievement of certain milestones
of up to approximately $6.5 million and certain royalty payments and annual license maintenance fees. The License Agreement requires
us to use commercially reasonable efforts to develop and commercialize JAN101.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Soin
Therapeutics</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JanOne
acquired Soin Therapeutics, a company focused on the development of a novel formulation of low-dose naltrexone (&ldquo;LDN&rdquo;) for
the treatment of chronic regional pain syndrome (&ldquo;CRPS&rdquo;) in 2022. CRPS is a rare pain disorder, characterized by a complex
set of symptoms, affecting approximately 200,000 patients annually in the US. There are currently no approved treatments for patients
with CRPS. Prior to the acquisition, Soin Therapeutics received Orphan Drug Designation for the product, which provides a variety of
incentives for developing the product in this indication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>JAN123</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Generally</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JAN123
is a novel formulation of 2.0 mg of LDN that results in a biphasic release of the product. The release properties of JAN123 provide for
an immediate release of less than half the product with a slow, sustained release of the remaining product. Importantly, the rapid release
of LDN has been reported to lead to vivid and lucid unpleasant dreams, which should be eliminated with the formulation of JAN123. Initially,
a single tablet of JAN123 will be administered orally, once a day before sleep, with eventual titration up to two tablets (4 mg) before
sleep.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Naltrexone</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Naltrexone
was first synthesized in 1965 and approved by the FDA for the oral treatment of opioid dependence in 1984, with the brand name Trexan.
Later it was approved for the oral treatment of alcohol dependence in 1995, when the brand name was changed by DuPont to ReVia. A depot
formulation for intramuscular injection was approved by the FDA under the brand name Vivitrol for alcohol dependence in 2006 and opioid
dependence in 2010. Typical oral doses are 50 to 100 mg daily, with a once-monthly intramuscular formulation also available. At these
doses, Naltrexone has been shown to function as a nonselective opioid antagonist with a high affinity for &micro; opioid receptors, which
decreases addiction cravings (Schumacher, Basbaum et al. 2017, Opioid Agonists &amp;amp; Antagonists. <U>Basic &amp;amp; Clinical Pharmacology,
14e</U>. B. G. Katzung. New York, NY, McGraw-Hill Education). However, there is a risk that patients who are non-compliant with oral
naltrexone may experience opioid intoxication simply by skipping doses of naltrexone. Oral bioavailability is also variable from patient
to patient, largely due to first-pass metabolism. Thus, naltrexone is pharmacologically effective, but may be ineffective in a real world
setting without counseling and strong patient support (Minozzi, 2011, Oral naltrexone maintenance treatment for opioid dependence. <I>Chchrane
Database Syst Rev</I>(4), CD001333). There are also multiple generic Naltrexone tablets available on the market for oral administration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Low-Dose
Naltrexone (LDN)</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compared
to the standard dose, LDN is defined as a daily dose of Naltrexone of 1 to 5 mg, which is 10- to 100-fold lower than the dose used to
manage substance use disorders (LDN Research Trust, Toljan and Vrooman 2018, Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization.
<U>Med Sci (Basel)</U> 6(4)). Off-label uses of Naltrexone at lower doses have been explored based on a different mechanism of action
for the treatment of inflammatory, rheumatologic, and neurologic conditions. These include multiple sclerosis, fibromyalgia, Crohn disease,
chronic fatigue syndrome (CFS), and, more recently, CRPS. At the low doses used for these conditions, Naltrexone is thought to act as
an immune modulator. Some speculate that this effect is related to reduced neuroinflammation in the case of disorders like CFS (Cant,
Dalgleish et al. 2017, Naltrexone Inhibits IL-6 and TNFalpha Production in Human Immune Cell Subsets following Stimulation with Ligands
for Intracellular Toll-Like Receptors. <U>Front Immunol</U> 8: 809).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evidence
suggests that, at low doses, Naltrexone antagonizes TLR4 on activated glial cells without the previously mentioned function as a mu-opioid
receptor antagonist (Chopra and Cooper 2013, Treatment of Complex Regional Pain Syndrome (CRPS) using low-dose naltrexone LDN). <U>J
Neuroimmune Pharmacol</U> <B>8</B>(3): 470-476.). TLR4 has been shown to be a key mediator of microglial activation, which has been identified
as a causal mechanism of neuropathic pain in CRPS. Microglial activation is associated with the release of pro-inflammatory cytokines,
reactive oxygen species, and prostaglandins, which amplify the inflammatory response (Carniglia, Ram&iacute;rez et al. 2017, Neuropeptides
and Microglial Activation in Inflammation, Pain, and Neurodegenerative Diseases. <U>Mediators of Inflammation</U> <B>2017</B>: 5048616).
Thus, LDN presents a promising therapeutic avenue for the treatment of CRPS, a condition in which TLR4 upregulation is a primary pathway,
through attenuation of glial activation and direct targeting of TLR4 activity (Del Valle, Schwartzman et al. 2009, Spinal cord histopathological
alterations in a patient with longstanding complex regional pain syndrome. <U>Brain Behav Immun</U> 23(1): 85-91. By downregulating the
inflammatory cytokine release, LDN should be beneficial for CRPS patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRPS
patients suffer from severe debilitating pain, and even light touch or benign stimulation elicits extreme amounts of pain. Microglial
cells and glial cells oftentimes are involved in this pain-signaling pathway. By reducing glial cell activation, Low-dose Naltrexone
can treat this pain syndrome. Another potential mechanism of action of LDN treatment on pain is a paradoxical upregulation of opioid
signaling. It is noted that, when taken at bedtime, the short-acting low-dose Naltrexone binds to receptors, which leads to a brief blockade
of opioid receptors between 2 and 4 a.m. This blockade is believed to upregulate vital life elements of the body and cause an increase
in endorphin and enkephalin production. This increase in endorphins and enkephalins will likely cause a decrease in pain that the patient
experiences overall. Therefore, LDN leads to transient opioid receptor blockade, which triggers a positive feedback mechanism that increases
the production of endogenous opioids (endogenous endorphins and enkephalins) and opioid signaling (Ludwig, Zagon et al. 2017, Serum [Met(5)]-enkephalin
levels are reduced in multiple sclerosis and restored by low-dose naltrexone. <U>Exp Biol Med (Maywood)</U> 242(15): 1524-1533; Toljan
and Vrooman 2018, Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization. <U>Med Sci (Basel)</U> 6(4)). Together, these mechanisms
may work to alleviate pain associated with CRPS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interestingly,
low-dose Naltrexone also has effects on the peripheral nervous system. In the peripheral nervous system, it was found that low-dose Naltrexone
can modulate T and B lymphocyte production. And it was noticed that low-dose Naltrexone could reduce interleukin 6, interleukin 12, and
tumor necrosis factor alpha in the periphery regarding peripheral nervous systems. CRPS patients often have an increase in inflammatory
cytokines and may often note an increase in interleukin 6, 12, and tumor necrosis factor alpha. By reducing these inflammatory cytokines
back to a normal state, it is predicted that low-dose Naltrexone could treat the actual disease state of CRPS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
summary, low-dose Naltrexone has a very specific mechanism of action that will distinctly treat CRPS through inhibition of inflammatory
cytokines, glial cell activation, neuroinflammation, and increase of endogenous enkephalins and endorphins. In other words, low-dose
Naltrexone is not just treating the symptoms with this medication but also treating the underlying disease state and process specific
to CRPS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Chronic
Regional Pain Syndrome (CRPS)</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRPS,
also termed reflex sympathetic dystrophy (RSD), is a chronic, orphan neurologic condition that typically affects the extremities after
trauma or nerve injury, and can cause severe pain. As the most common and prominent symptom of CRPS, the pain is often deep inside the
limbs with a burning, stinging, or tearing sensation. Sensory changes are also common and may include increased sensitivity to painful
stimuli, feeling pain from stimuli that are usually non-painful, and in some instances, sensory loss (<I>e.g.</I>, numbness). In addition
to pain, patients commonly experience an affected extremity that is warm, red, and swollen, at least initially. As CRPS progresses, it
becomes refractory to sympathetic nerve blocks, conventional analgesics, anticonvulsants, and antidepressants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRPS
is a rare neurologic disease. It is a painful progressive condition and is listed in the rare disease database of the National Organization
for Rare Disorders (NORD). CRPS is subdivided into two categories: type I and type II CRPS. In CRPS type I, there are no nerve injuries
or lesions identified. CRPS type I is also known as &ldquo;reflex sympathetic dystrophy,&rdquo; and it comprises about 90 percent of
all cases of CRPS. CRPS type II (causalgia), on the other hand, is diagnosed when there is evidence of nerve damage. As described in
the NORD, it was found that CRPS type I developed in 5.46 persons out of every 100,000 per year and the incidence rate of CRPS type 2
was 0.82 persons out of every 100,000 per year, giving rise to a combined incidence rate for both CRPS types I and II of 6.28 per 100,000
person-years (Sandroni, Benrud-Larson et al. 2003, Complex regional pain syndrome type I: incidence and prevalence in Olmsted county,
a population-based study. <U>Pain</U> 103(1-2): 199-207; Goh, Chidambaram et al. 2017, Complex regional pain syndrome: a recent update.
<U>Burns Trauma</U> 5:2.).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underlying cause of CRPS is not well understood. In most cases, it occurs after an illness or injury that did not directly damage the
nerves in the affected area (Type I). In some cases, it occurs after a specific nerve injury (Type II). The exact trigger of CRPS after
an injury is not known, but it may be due to abnormal interactions between the central and peripheral nervous systems and/or inappropriate
inflammatory responses. There are multiple factors that may contribute to CRPS development, including immobilization, alterations to
the nervous system of the body, and inflammation. Genetic factors and psychological factors, such as anxiety, depression, and anger,
may also contribute to the symptoms of CRPS. However, there is no evidence that CRPS is a disease that can be caused by genetic factors
alone, and the role of psychological factors in CRPS development remains unproven.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CRPS
is treated by approaching it from different areas: physical therapy (PT), occupational therapy (OT), medications for pain management,
neuromodulation through implantable devices, and/or nerve blocks targeting the sympathetic chain. Neridronate and zoledronate D,L-lysine
monohydrate (ZLM) has been designated as an orphan drugs for the treatment of CRPS in 2013 and 2015, respectively. However, neither of
them has been approved. Thus, there is no current FDA-approved drug for CRPS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Clinical
Studies of LDN on CRPS</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LDN
has been widely used for chronic pain and inflammatory condition and has been shown to alleviate symptoms of pain in patients with chronic
pain. A number of case studies have also reported positive effects for LDN in the treatment of CRPS. Chopra et al. reported 2 patient
case studies with CRPS who experienced significantly less pain with 4.5 mg daily LDN treatment (Chopra and Cooper 2013, Treatment of
Complex Regional Pain Syndrome (CRPS) using low-dose naltrexone (LDN). <U>J Neuroimmune Pharmacol</U> 8(3): 470-476). The remission of
pain and dystonic spasms in Case 1, as well as remission of all CRPS symptoms (including fixed dystonia) in Case 2, provide evidence
that a multi-modal interventional approach, which includes low-dose Naltrexone (a known glial attenuator), should be considered as a
treatment option for the treatment of CRPS patients, particularly those patients with dystonic movement disorders. In another CRPS case
study, Sturn and Collin found alleviation of pain symptoms as early as 2 days after beginning LDN therapy, with significantly less pain
at 4 weeks (Sturn and Collin 2016, Low-Dose Naltrexone: A New Therapy Option for Complex Regional Pain Syndrome Type I Patients. <U>Int
J Pharm Compd</U> 20(3): 197-201). Weinstock et al. reported alleviation of pain symptoms within one month of LDN treatment, with complete
remission of CRPS leg symptoms by 16 months (Weinstock, Myers et al. 2016, Identification and Treatment of New Inflammatory Triggers
for Complex Regional Pain Syndrome: Small Intestinal Bacterial Overgrowth and Obstructive Sleep Apnea. <U>A A Case Rep</U> 6(9): 272-276).
In a recent case study, an CRPS patient was able to discontinue gabapentin and amitriptyline via the use of LDN, while simultaneously
achieving superior pain relied (Soin, 2021, Management of pediatric complex regional pain syndrome with low-dose naltrexone. <I>Pain
Medicine Case Reports, 5</I>(3), 109-113). LDN has been reported to have benefits related to other symptoms of chronic pain syndromes
as well, including dystonic spasms, CRPS flares, energy, sleep disturbances, and mood.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Systematic
literature review of LDN use showed that the most commonly reported AEs with LDN use were dizziness, vomiting, nausea, and vivid dreams
(Soin et al. 2021, Low-Dose Naltrexone Use for Patients with Chronic Regional Pain Syndrome: A Systematic Literature Review. <U>Pain
Physician</U> 24(4): E393-E406.). Other reported AEs included headaches, abdominal pain, gastrointestinal issues, peripheral edema, restlessness,
falls, somnolence, irritability, hematological abnormalities, urinary infection, difficulty concentrating, anxiety, sleepiness, hot flashes/sweating,
tachycardia, depression, muscle and joint pain, fatigue, tinnitus, heartburn, dry mouth, and joint pain. Another systematic review also
evaluated occurrence of adverse events (AEs) and serious adverse events (SAEs) with LDN use and found that only mild AEs reported among
the included studies (89 studies), including nausea, vomiting, and dizziness (Bolton, Hodkinson et al. 2019, Serious adverse events reported
in placebo randomized controlled trials of oral naltrexone: a systematic review and meta-analysis. <U>BMC Med</U> 17(1): 10). Although
119 patients reported at least one SAE in the naltrexone study arm, meta-analysis found no difference between occurrence of SAEs in naltrexone
and placebo groups. Furthermore, secondary analysis found only 6 AEs that were statistically significant: decreased appetite, dizziness,
nausea, sleepiness, sweating, and vomiting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Efficacy
of low-dose naltrexone treatment on CRPS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 14%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Author
    (year)</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; width: 2%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 30%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Symptoms</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; width: 2%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 16%; vertical-align: bottom"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Symptoms</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">alleviated</FONT></P></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; width: 2%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 10%; vertical-align: bottom"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Time
                                            to</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">alleviation&nbsp;of
                                            symptoms</FONT></P></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; width: 2%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 10%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dose</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; width: 2%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 10%; vertical-align: bottom"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AEs
                                            and</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SAEs</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chopra
    et al. (2013)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">swelling,
    allodynia, color change, temperature change, some weakness, blisters, skin ulceration, dystonic spasms, dysesthesia</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dystonic
    spasms, CRPS flares, energy, pain tolerance, sleep disturbances, pain, mood</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&lt;
    2 months</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
    mg/day</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sturn
    et al. (2016)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pain</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pain</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2
    days</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5
    mg</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weinstock
    et al. (2016)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severe
    leg pain, episodic pain in arms and nose, asymmetric and shiny skin with fluctuating temperature changes, color change, edema, IBS,
    atypical chest pain and fatigue, edema, blue discoloration, tenderness, joint hypermobility with EDS diagnosis</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leg
    and bowel symptoms; all CRPS pain, bowel symptoms, and fatigue</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&lt;
    1 month</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
    mg/day</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Orphan
Drug Designation</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
orphan disease is a rare disease affecting fewer than 200,000 people in the US. It is often a serious or fatal condition for which there
are no effective therapies. In 1983, the Orphan Drug Act was passed to incentivize companies to develop drugs for patients with rare
diseases. Orphan drug designation provides incentives to companies, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    credits for qualifies clinical trials</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exemption
    from user fees</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential
    for seven years of market exclusivity after approval</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, given the small number of patients with a disease and the severity of the disease, approvals are often granted with fewer and
smaller trials, saving costs and time. JAN123 was granted Orphan Status for the treatment of CRPS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Clinical
Development Plan</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LDN
can be rapidly developed in the US via the 505(b)(2) regulatory pathway. This pathway is used for candidates that contain drugs that
are already approved but come in a dosage form or delivery system that is different than the original, approved product. In this case,
JAN123 fits these criteria perfectly. LDN has the added benefit of being developed at a much lower dose (&lt; 5 milligrams) compared
to approved naltrexone products, which are 50 milligrams per tablet. Therefore, it is likely that product development will consist of
the following general steps:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing
    and approval of clinical batches of LDN tablets prior to clinical studies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    I pharmacokinetic study(ies) to confirm the release profile of LDN; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    single Phase III study to demonstrate efficacy in CRPS.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
protocol synopsis of the development plan is presented below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title
    of study </B></FONT></TD>
    <TD STYLE="width: 0.1in">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            I: The Pharmacokinetincs of LDN in the fed and fasted state of a Single Oral Dose of LDN,
                                            4 mg</FONT></P>
                                                                                          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    III: Double-Blind Placebo-Controlled Trial of Low-Dose Naltrexone to Treat Complex Regional Pain Syndrome (CRPS)</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Clinical
    Phase </B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            I: The Pharmacokinetincs of LDN in the fed and fasted state</FONT></P>
                                                                              <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    III: Registration/Efficacy Study to hopefully facilitate an NDA application for the use of low-dose naltrexone to treat CRPS</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Objectives:</B></FONT></TD>
    <TD STYLE="width: 0.1in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            I: To determine pharmacokinetics of single oral low-dose naltrexone in healthy participants
                                            in fasting and fed state</FONT></P>
                                                         <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase3:
    The primary objective is to assess the efficacy of low-dose naltrexone in treating complex regional pain syndrome symptoms (CRPS).</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    plan to conduct a double-blind, randomized, placebo-controlled trial to treat CRPS using low-dose naltrexone.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    Efficacy:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1-
    Assess daily NRS (numerical pain scale 0 &ndash; 10) scores through the 3-month study</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-
    Study the possible changes or improvement in the Brief Pain Inventory (BPI) and Oswestry Disability Index (ODI) over the three-month
    study</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    Safety:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will also monitor safety labs on enrollment and termination of the study. However, we would like to point out that this drug has
    been available and FDA approved at much higher doses (50 &ndash; 150mg or higher) orally with a long-standing proven safety track
    record. The drug has been available with multiple different embodiments, route of administration and at much higher doses for quite
    a long time and the safety of the drug has already been extensively established and published.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investigational
    product </B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JAN123</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Study
    Design</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            1: Single-center, dual-arm, cross-over, open-label study</FONT></P>
                                                         <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    3: Study Description</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    plan to conduct a randomized, double blind placebo controlled trial to treat Complex Regional Pain Syndrome. The study duration will
    be three months long. Patients in the treatment group will receive a single tablet for the first month of a 2mg dose of Naltrexone.
    Then, after 1 month, the patient will take 2 tablets for a total of 4mg for months 2 and 3. Study conclusion will be after 3 months.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
    in the placebo group will take a single tablet for 1 month followed by 2 tablets for month 2 and 3.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    total number of 200 patients with a 1:1 randomization will used. Since CRPS is an orphan disease, we will likely have to use a total
    of 25 clinical sites or more to be able to adequately recruit the study.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Safety
    labs will be completed prior to first dose and upon study completion.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    clinical efficacy, we will be assessing daily NRS (1-10) pain scores, a brief pain inventory (BPI) at enrollment and at months 1,
    2, and 3 (study completion) and Oswestry Disability Index (ODI) at enrollment and at months 1, 2, and 3 (study completion). Statistically
    significant improvement in pain scores or any scales in the BPI or ODI are desired outcomes.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Treatment
    Regimen and Route of Administration</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Study
                                            Drugs are as follows:</FONT></P>
                                                         <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    I: Single Oral dose of JAN123, 4 mg given on separate days with and without food separated by a washout period of no less than 7
    days</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    III: Patients will be dosed with either the low-dose naltrexone or placebo for three months. Initially for the first month patients
    will take 1 tablet at bedtime (typically in the evenings) for the first month and then increase to 2 tablets for month 2 and 3. Specifically
    the Naltrexone will be 2mg tablets, such that for the first month with the 1 tablet per day the patient will be on 2mg doses and
    subsequently increase to 2 tablets in the evening for a total of 4mg.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Duration
    of treatment: </B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            I: One day for each dose. Two doses of 2 mg each, in total, separated by a washout period
                                            of no less than 7 days.</FONT></P>
                                                         <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    III: This will be a 3 month trial or approximately 90 days. Upon enrollment, patients will be on either low-dose naltrexone or placebo
    for 90 days.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Participant
    duration is expected to be 121 days, and at the conclusion of the study (approximately day 90 post-treatment) patients will come
    in for a final site visit to complete remaining surveys and within 7 days of completion the patients will obtain final safety labs
    which are anticipated to be a complete blood count and a comprehensive metabolic panel. Since Naltrexone is non-opioid based and
    does not have withdrawal issues, patients can immediately discontinue the therapy without concerns. As referenced earlier, the safety
    of Naltrexone orally is already well established and our tested doses are low.</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of Centers </B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            1: Single Center Clinical Trial</FONT></P>
                                                                     <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    3: Multicenter Clinical Trial</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Likely
    25 total sites. Keeping in mind this is an Orphan Disease state and recruitment may be quite difficult, we feel the need to have
    25 clinical sites to enroll 200 patients.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    sites will be likely Pain Management Centers, both academic and private practice facilities that have access to patients who suffer
    from CRPS and also include local PIs who have the skill set and ability to properly diagnose CRPS.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Local
    or regional clinical trial coordinators will be assigned to each site as well.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enrolling
    participants are those who meet the diagnosis criteria of CRPS. Typically CRPS is diagnosed using the Budapest Criteria. Age range
    of 18 - 65 for enrollment, negative pregnancy test, and stable therapy for 3 months.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subjects:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            I: Adult male and female healthy subjects, 18-65 years of age, satisfying all inclusion and
                                            exclusion criteria.</FONT></P>
                                                                                             <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    III: Patients diagnosed with CRPS (Complex Regional Pain Syndrome), Adult male and female patients, 18-65 years of age.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
                                            of</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subjects</B></FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            I: 10 patients</FONT></P>
                                                                                             <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    III: 200 patients</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Endpoints</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase1:
    Primary Outcome Measure:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PK
    profile for low-dose naltrexone (Time Frame: Day 1: predose and at multiple time points after low-dose naltrexone administration).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.1in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C<SUB>max
    </SUB>(Maximum observed plasma concentration)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">T<SUB>max
    </SUB>(Time to reach maximum plasma concentration)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AUC<SUB>0-t
    </SUB>(Area under the plasma concentration-time curve from 0 hour to the time of the last quantifiable concentration)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AUC<SUB>0-inf
    </SUB>(Area under the plasma concentration-time curve from 0 hour extrapolated to infinity)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CL/F
    (Oral clearance)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            3:</FONT></P>
                                                                                             <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
    Outcome Measure: Improvement in NRS pain scores over a 3-month time period.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Secondary
    Outcome Measure: Improvement in Brief Pain Inventory and Oswestry Disability Index (ODI) or other verified pain scales.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">End
    of Study will occur upon completion of the 90-day trial of the low-dose naltrexone or placebo. It is expected that patients will
    complete all required surveys and testing requirements of the study. Through March 8, 2023, the Company operated its legacy businesses,
    ARCA Recycling, Inc. (&ldquo;ARCA Recycling&rdquo;), ARCA Canada Inc. (&ldquo;ARCA Canada&rdquo;), and Customer Connexx, LLC (&ldquo;Connexx&rdquo;),
    in its Recycling segment. ARCA Recycling and ARCA Canada recycle major household appliances in North America by providing turnkey
    appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs. Connexx is a company
    that provides call center services for recycling businesses. On March 9, 2023, we entered into a Stock Purchase Agreement with VM7
    Corporation, a Delaware corporation, under which the Buyer agreed to acquire all of the outstanding equity interests of (a) ARCA
    Recycling, Inc., a California corporation, (b) Customer Connexx LLC, a Nevada limited liability company, and (c) ARCA Canada Inc.,
    a corporation organized under the laws of Ontario, Canada. The principal of the Buyer is Virland A. Johnson, our Chief Financial
    Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Early
    termination is also a possible way to end the study due to issues such as side effects, adverse events, or patient desire to withdraw
    from the study, among other reasons.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Safety</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assessments
    </B></FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Standard
    clinical evaluation and objective measures will be employed to monitor and assess safety during the conduct of the trial. Furthermore,
    the results of safety assessments will be used during the trial to monitor and protect the safety of enrolled subjects. Strict subject
    and study stopping criteria will be implemented to protect the subject&rsquo;s well-being.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Intellectual
Property</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
composition of Naltrexone is off-patent and generic versions of the drug are available at 50 mg doses. LDN has been routinely compounded
in compounding pharmacies and used clinically off-label. However, the 4.5 mg compounded tablets are associated with sleep disturbances,
manifested in vivid and lucid unpleasant dreams. For these reasons, JAN-123 was developed as a biphasic release, orally available tablet
to reduce the likelihood of unpleasant dreams. A provisional patent was filed in December 2020 and converted to a PCT application in
November 2021 (Pub. No. US 2022/0202807 A1). US Patent number 11,752,143 B2 issued on September 12, 2023. The issued claims in this patent
cover the use of the biphasic LDN formulation for treatment of patients with chronic pain. In addition, claims are made to the titration
of the LDN for treating chronic pain. While there is no guarantee that the pending applications or future pending claims will issue,
the issued US patent will provide protection of JAN123 through 2040 and the Orphan Drug Designation provides 7 years of market exclusivity
after drug approval in the event that there are any challenges to this patent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Trade
Secrets and Other Proprietary Information</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to patents, we rely on trade secrets and know-how to develop and maintain our competitive position. For example, we have developed
methods for more efficient manufacture of the biphasic LDN. We seek to protect our proprietary information, in part, by confidentiality
agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors, and commercial partners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Soin
Purchase Agreement</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2022, we entered into a Purchase Agreement (the &ldquo;Soin Purchase Agreement&rdquo;) with Soin Therapeutics, LLC. Under
the Soin Purchase Agreement, JanOne acquired Soin Therapeutics and its LDN product, now known as JAN123. This all- stock transaction
has a value of $13M, with up to an additional $17M depending on revenues generated by the product, for a total value of up to $30M. The
transaction includes restrictions on the maximum number of shares of preferred stock and common stock that can be issued to or transferred
by Soin Therapeutics at any given time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Our
Team</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tony
Giordano, Ph.D.</B>, our Chief Scientific Officer, joined the Company in December 2019 from the Cleveland Clinic, the No.2 rated hospital
in the country, where he served as Senior Director of Special Projects in the Business Development group. Dr. Giordano has extensive
experience in drug development, having served as Vice President or President of seven different biotechnology companies he co-founded,
including companies developing platform technologies, a cancer vaccine, and Alzheimer&rsquo;s Disease and cardiovascular therapies. He
has managed numerous clinical trials and the launch of a medical food product. Dr. Giordano has also served as an Associate Professor
and Assistant Dean of Research and Business Development at LSU Health Sciences Center in Shreveport, Louisiana (&ldquo;LSU Health Shreveport&rdquo;),
at which he led the licensing efforts at the campus and at Abbott Labs, where, in addition to serving as a Senior Research Scientist,
he was involved in technology assessment activities. Dr. Giordano has a Ph.D. focused in Molecular Genetics from The Ohio State University
and completed Fellowships at the NIH National Cancer Institute and the NIH National Institute of Aging.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2019, we formed a Scientific Board of Advisors (the &ldquo;SBA&rdquo;) and the following doctors and scientists currently are
members of our SBA:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chris
Kevil, Ph.D., Chair of the Scientific Board of Advisors &ndash; </B>Dr. Kevil, an internationally known expert in vascular pathophysiology,
PAD, and nitric oxide biology, discovered the role of sodium nitrite in promoting angiogenesis that led to the development of TV1001,
now known as JAN101. Dr. Kevil earned his Ph.D. from LSU Health Shreveport in Molecular and Cellular Physiology, followed by a fellowship
at the University of Alabama at Birmingham (UAB) with an emphasis on redox pathophysiology. Returning to LSU Health Shreveport in the
Department of Pathology, he established cutting edge research programs regarding redox biology regulation of peripheral vascular diseases.
This led to ground-breaking insights on how glutathione, nitrite/nitric oxide, and hydrogen sulfide regulate vascular health during ischemia.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Edgar
Ross, MD &ndash;</B> Dr. Ross is the current Director of the Pain Management Center at Brigham and Women&rsquo;s Hospital and a professor
of anesthesia at Harvard Medical School. Dr. Ross is recognized as Castle Connolly&rsquo;s America&rsquo;s top doctors for the fifth
year in a row. In addition to serving as chairman of Pfizer&rsquo;s partnership on pain, Dr. Ross also has served as a member of the
Blue Cross and Blue Shield Opioid Prescribing Policy Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>John
Cooke, MD, Ph.D. &ndash; </B>Dr. Cooke is the Chair of the Department of Cardiovascular Sciences at the Houston Methodist Research Institute,
Director of the Center for Cardiovascular Regeneration, and Medical Director of the RNA Therapeutics Program in the Houston Methodist
DeBakey Heart &amp; Vascular Center in Houston, Texas. He trained in cardiovascular medicine and obtained a Ph.D. in physiology at the
Mayo Clinic. He was recruited to Harvard Medical School as an assistant professor of medicine. In 1990, he was recruited to Stanford
University to spearhead its program in vascular biology and medicine, and was appointed professor in the Division of Cardiovascular Medicine
at Stanford University School of Medicine, and associate director of the Stanford Cardiovascular Institute until his recruitment to Houston
Methodist in 2013. Dr. Cooke has published over 500 research papers, position papers, reviews, book chapters, and patents in the arena
of vascular medicine and biology with over 30,000 citations. He has served on national and international committees that deal with cardiovascular
diseases, including the American Heart Association, American College of Cardiology, Society for Vascular Medicine, and the National Heart,
Lung and Blood Institute. He has served as president of the Society for Vascular Medicine, as a director of the American Board of Vascular
Medicine, and as an associate editor of Vascular Medicine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Joshua
Beckman, MD &ndash; </B>Dr. Beckman is the Director of Vascular Medicine and the Gayle and Paul Stoffel Distinguished Chair in Cardiology
at UT Southwestern Medical Center. Prior to this, he founded and is director of the Section of Vascular Medicine in the Division of Cardiovascular
and is Professor of Medicine at Vanderbilt University Medical Center. The overriding theme linking all of his career activities is vascular
function in health and disease. Dr. Beckman&rsquo;s primary research focuses on the mechanisms by which diabetes mellitus impairs vascular
function. Secondary investigations involve studying the effect on endothelial function of non-diabetes-related insulin resistance, androgen
deprivation, and vascular function in venous bypass grafts. Dr. Beckman has been involved in numerous clinical studies and has published
over 300 research papers with over 30,000 citations. In addition to a number of other journals, Dr. Beckman serves in editorial roles
at <I>Vascular Medicine </I>and <I>Circulation, </I>two of the premier journals in the cardiovascular space.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nicolas
Goeders, Ph.D. &ndash;</B> Dr. Goeders is a Professor and Head of the Department of Pharmacology, Toxicology and Neuroscience at LSU
Health Shreveport. He has conducted addiction research for the past 30 years and is regarded as one of the world&rsquo;s leaders on the
role for stress in substance abuse disorder. His work has helped to determine the mechanisms responsible for how stress contributes to
relapse to drug use. He has published over 100 manuscripts, has written 15 book chapters, and was issued five patents, one of which is
a drug currently in clinical development. Dr. Goeders also serves as the Executive Director of the Louisiana Addiction Research Center.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Commercial
Operations</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently do not have any marketing and sales organization. We have retained global rights to JAN-101 and JAN123, and, if either of them
or one of our potential subsequent product candidates is approved by the FDA to market in the United States, we expect that our sales
force will be supported by sales management, internal sales support, an outside marketing group, and distribution support. We intend
to invest in our commercial capabilities prudently by focusing our marketing efforts on the physician subspecialties that treat patients
with PAD. These physicians include, but are not limited to, pain management specialists, rheumatologist, surgeons, and sports medicine
physicians. We will also evaluate licensing and partnering with third parties to help us reach other sales channels and geographic markets
inside and outside of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Government
Regulation</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements
upon companies involved in the clinical development, manufacture, marketing, and distribution of drugs, such as those we are developing.
These agencies, and other federal, state, and local entities regulate, among other things, the research and development, testing, manufacture,
quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion, distribution, post-approval
monitoring and reporting, sampling, and export and import of product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>U.S.
Government Regulation of Drug Products</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (the &ldquo;FDCA&rdquo;) and its implementing
regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local, and foreign
statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable
United States requirements at any time during the product development process, the approval process, or thereafter, may subject an applicant
to a variety of administrative or judicial sanctions, such as the FDA&rsquo;s refusal to approve pending applications, withdrawal of
an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension
of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal
penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process required by the FDA before a drug may be marketed in the United States generally involves the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
    of pre-clinical laboratory tests, animal studies, and formulation studies in compliance with the FDA&rsquo;s good laboratory practice
    (&ldquo;GLP&rdquo;), regulations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an Investigational New Drug Application (&ldquo;IND&rdquo;), which must become effective before human clinical trials
    may begin;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
    by an institutional research board (&ldquo;IRB&rdquo;) at each clinical site before each trial may be initiated;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    of adequate and well-controlled human clinical trials in accordance with good clinical practice (&ldquo;GCP&rdquo;) requirements
    to establish the safety and efficacy of the proposed drug product for each indication;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of a new drug application (NDA);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA advisory committee review, if applicable;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance
    with current good manufacturing practices (&ldquo;cGMP&rdquo;) requirements and to assure that the facilities, methods, and controls
    are adequate to preserve the drug&rsquo;s identity, strength, quality, and purity;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">payment
    of user fees and securing FDA and approval of the NDA; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
    with any post-approval requirements, including the potential requirement to implement a risk evaluation and mitigation strategy (&ldquo;REMS&rdquo;),
    and the potential requirement to conduct post-approval studies.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Pre-clinical
Studies</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-clinical
studies include laboratory evaluation of product chemistry, toxicity, and formulation, as well as animal studies to assess potential
safety and efficacy. An IND sponsor must submit the results of the pre-clinical tests, together with manufacturing information, analytical
data, and any available clinical data or literature, among other things, to the FDA as part of an IND. Some pre-clinical testing may
continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that
time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical
hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result,
submission of an IND may not result in the FDA allowing clinical trials to commence. Clinical holds also may be imposed by the FDA at
any time before or during clinical trials, due to safety concerns about on-going or proposed clinical trials, or non-compliance with
specific FDA requirements, and the trials may not begin or continue until the FDA notifies the sponsor that the hold has been lifted.
Through the 505(b)2 regulatory path, the FDA allows a sponsor to rely on well documented, published studies to support the clinical development
of the product. The FDA has indicated that it will accept published data in support of the Company&rsquo;s development program for JAN101
but prior to filing an NDA would require the Company to complete developmental and reproductive toxicology studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Clinical
Trials</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators
in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing
for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives
of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical
trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution
participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution.
Information about certain clinical trials must be submitted within specific timeframes to the NIH for public dissemination on their www.clinicaltrials.gov
website. The information contained in, or accessible through, this website does not constitute a part of this Annual Report. We have
included this website address solely as an inactive, textual reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
clinical trials are typically conducted in three sequential phases, which may overlap or be combined:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    I: The drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety,
    dosage tolerance, absorption, metabolism, distribution, and excretion and, if possible, to gain an early indication of its effectiveness.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    II: The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to evaluate the
    efficacy of the product for specific targeted diseases preliminarily, and to determine dosage tolerance and optimal dosage.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    III: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled
    clinical trials to generate sufficient data statistically to evaluate the efficacy and safety of the product for approval, to establish
    the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-approval
trials, sometimes referred to as Phase IV clinical trials, may be conducted after initial marketing approval. These trials are used to
gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate
the performance of Phase IV clinical trials as a condition of approval of an NDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients
are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution
if the clinical trial is not being conducted in accordance with the IRB&rsquo;s requirements or if the drug has been associated with
unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized
by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial
may move forward at designated check points based on access to certain data from the trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to
submission of an IND, at the end of Phase II, and before an NDA is submitted. Meetings at other times may be requested. These meetings
can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for
the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the meetings at the end of the Phase
II clinical trial to discuss Phase II clinical results and present plans for the pivotal Phase III clinical trials that they believe
will support approval of the new drug. JanOne submitted briefing materials in 2021 describing the previous research and development activities
and planned clinical trials. The Company is now working to implement suggestions by the FDA to be ready to submit a protocol amendment
in late 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrently
with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry
and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance
with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of product candidates and,
among other things, the manufacturer must develop methods for testing the identity, strength, quality, and purity of the final drug.
In addition, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product
candidate does not undergo unacceptable deterioration over its shelf life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the IND is active and before approval, progress reports summarizing the results of the clinical trials and non-clinical studies performed
since the last progress report must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the
FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk
to humans exposed to the same or similar drugs, findings from animal or in vitro testing suggesting a significant risk to humans, and
any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator
brochure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>United
States Review and Approval Process</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results of product development, pre-clinical, and other non-clinical studies and clinical trials, along with descriptions of the manufacturing
process, analytical tests conducted on the chemistry of the drug, proposed labeling, and other relevant information are submitted to
the FDA as part of an NDA requesting approval to market the product. The submission of an NDA is subject to the payment of substantial
user fees; a waiver of such fees may be obtained under certain limited circumstances. The FDA reviews an NDA to determine, among other
things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve
the product&rsquo;s identity, strength, quality, and purity. Under the Prescription Drug User Fee Act (the &ldquo;PDUFA&rdquo;), guidelines
that are currently in effect, the FDA has a goal of 10 months from the date of &ldquo;filing&rdquo; of a standard NDA for a new molecular
entity to review and act on the submission. This review typically takes 12 months from the date the NDA is submitted to FDA because the
FDA has approximately two months to make a &ldquo;filing&rdquo; decision after the application is submitted. The FDA conducts a preliminary
review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently
complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event,
the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts
it for filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including
clinicians and other scientific experts, that reviews, evaluates, and provides a recommendation as to whether the application should
be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee; but, it considers such recommendations
carefully when making decisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application
unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure
consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or
more clinical trial sites to assure compliance with GCP requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing
of the drug with prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the
application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes the
specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an additional Phase III trial
or other significant and time-consuming requirements related to clinical trials, non-clinical studies, or manufacturing. If a Complete
Response Letter is issued, the sponsor must resubmit the NDA that addresses all of the deficiencies identified in the letter, or withdraw
the application. Even if such additional data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria
for approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications
for use may otherwise be limited, which could restrict the commercial value of the product. In addition, the FDA may require a sponsor
to conduct Phase IV clinical testing, which involves clinical trials designed to assess a drug&rsquo;s safety and effectiveness further
after NDA approval, and may require testing and surveillance programs to monitor the safety of approved products that already have been
commercialized. The FDA may also place other conditions on approval, including the requirement for REMS, to assure the safe use of the
drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS. The FDA will not approve the NDA without
an approved REMS, if required. A REMS could include medication guides, physician communication plans, or elements to assure safe use,
such as restricted distribution methods, patient registries, and other risk minimization tools. Any of these limitations on approval
or marketing could restrict the commercial promotion, distribution, prescription, or dispensing of products. Marketing approval may be
withdrawn for non-compliance with regulatory requirements or if problems occur following initial marketing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Food and Drug Administration Safety and Innovation Act (the &ldquo;FDASIA&rdquo;) made permanent the Pediatric Research Equity Act (the
&ldquo;PREA&rdquo;), which requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication,
new dosage form, new dosing regimen, or new route of administration. Under PREA, original NDAs and supplements must contain a pediatric
assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of
the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric
subpopulation for which the product is safe and effective. The sponsor or the FDA may request a deferral of pediatric clinical trials
for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is
ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs
to be collected before the pediatric clinical trials begin. The FDA must send a non-compliance letter to any sponsor that fails to submit
the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Special
FDA Expedited Review and Approval Programs</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has various programs, including Fast Track Designation, accelerated approval, priority review, and breakthrough therapy designation,
which are intended to expedite or simplify the process for the development and FDA review of drugs that are intended for the treatment
of serious or life-threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these
programs is to provide important new drugs to patients earlier than under standard FDA review procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
be eligible for a Fast Track Designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat
a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need. The FDA will determine
that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially
superior to existing therapy based on efficacy or safety factors. The FDA may review sections of the NDA for a fast track product on
a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of
the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required
user fees upon submission of the first section of the NDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may give a priority review designation to drugs that offer major advances in treatment, or provide a treatment where no adequate
therapy exists. A priority review means that the goal for the FDA to review an application is six months, rather than the standard review
of 10 months under current PDUFA guidelines. Under the new PDUFA agreement, these six- and 10-month review periods are measured from
the &ldquo;filing&rdquo; date, rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two
months to the timeline for review and decision from the date of submission. Most products that are eligible for Fast Track Designation
are also likely to be considered appropriate to receive a priority review.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful
therapeutic benefit over existing treatments may be eligible for accelerated approval and may be approved on the basis of adequate and
well-controlled clinical trials that establish that the drug product has an effect (i) on a surrogate endpoint that is reasonably likely
to predict clinical benefit or (ii) on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality that
is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, including taking into account
the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval,
the FDA may require a sponsor of a drug receiving accelerated approval to perform post-marketing studies to verify and describe the predicted
effect on irreversible morbidity or mortality or other clinical endpoint, and the drug may be subject to accelerated withdrawal procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
under the provisions of the FDASIA, a sponsor can request designation of a product candidate as a &ldquo;breakthrough therapy.&rdquo;
A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious
or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement
over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical
development. Drugs designated as breakthrough therapies are also eligible for accelerated approval. The FDA must take certain actions,
such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval
of a breakthrough therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for
qualification or decide that the time period for FDA review or approval will not be shortened. We may explore some of these opportunities
for our initial (or subsequent) product candidates, as appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Post-Approval
Requirements</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drugs
manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among
other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion
and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications
or other labeling claims are subject to prior FDA review and approval. There also are continuing, annual user program fee requirements
for any marketed products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing
testing, including Phase IV clinical trials, and surveillance to assess further and monitor the product&rsquo;s safety and effectiveness
after commercialization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register
their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state
agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA
approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements
and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to
use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain
cGMP compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
an approval of a drug or medical device is granted, the FDA may withdraw the approval if compliance with regulatory requirements and
standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems
with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply
with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of
post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program.
Other potential consequences include, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
    warning letters or holds on post-approval clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    seizure or detention, or refusal to permit the import or export of products; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
    or the imposition of civil or criminal penalties.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. Drugs or devices may
be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies
actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have promoted off-label
uses improperly may be subject to significant liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>The
Hatch-Waxman Amendments</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Drug Price Competition and Patent Term Restoration Act of 1984, known as the Hatch-Waxman Act, added two pathways for FDA drug approval.
First, the Hatch-Waxman amendments to the FDCA authorized the FDA to approve an alternative type of NDA under Section 505(b)(2) of the
FDCA. Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from trials not
conducted by or for the applicant and for which the applicant has not obtained a right of reference from the data owner. The applicant
may rely upon the FDA&rsquo;s findings of safety and efficacy for an approved product that acts as the &ldquo;listed drug.&rdquo; The
FDA may also require 505(b)(2) applicants to perform additional studies or measurements to support the change from the listed drug. The
FDA may then approve a new product candidate for all, or some, of the label indications for which the branded reference drug has been
approved, as well as for any new indication sought by the 505(b)(2) applicant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second,
the Hatch-Waxman amendments to the FDCA also established a statutory procedure for submission and FDA review and approval of abbreviated
new drug applications (&ldquo;ANDAs&rdquo;) for generic versions of branded drugs previously approved by the FDA (such previously approved
drugs are referred to as &ldquo;listed drugs&rdquo;). An ANDA is a comprehensive submission that contains, among other things, data and
information pertaining to the active pharmaceutical ingredient, drug product formulation, specifications, and stability of the generic
drug, as well as analytical methods, manufacturing process validation data and quality control procedures. Premarket applications for
generic drugs are termed abbreviated because they generally do not include pre-clinical and clinical data to demonstrate safety and effectiveness.
However, a generic manufacturer is typically required to conduct bioequivalence studies of its test product against the listed drug.
The bioequivalence studies for orally administered, systemically available drug products assess the rate and extent to which the active
pharmaceutical ingredient (the &ldquo;API&rdquo;) is absorbed into the bloodstream from the drug product and becomes available at the
site of action. Bioequivalence is established when there is an absence of a significant difference in the rate and extent for absorption
of the generic product and the listed drug. For some drugs, other means of demonstrating bioequivalence may be required by the FDA, especially
where rate and/or extent of absorption are difficult or impossible to measure. The FDA will approve the generic product as suitable for
an ANDA application if it finds that the generic product does not raise new questions of safety and effectiveness as compared to the
innovator product. A product is not eligible for ANDA approval if the FDA determines that it is not bioequivalent to the referenced innovator
drug, if it is intended for a different use, or if it is not subject to an approved Suitability Petition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
seeking approval for a drug through an NDA, including a 505(b)(2) NDA, applicants are required to list with the FDA certain patents whose
claims cover the applicant&rsquo;s product. Upon approval of an NDA, each of the patents listed in the application for the drug is then
published in the Orange Book. Any applicant who files an ANDA seeking approval of a generic equivalent version of a drug listed in the
Orange Book or a 505(b)(2) NDA that references a drug listed in the Orange Book must certify to the FDA that (1) no patent information
on the drug product that is the subject of the application has been submitted to the FDA; (2) such patent has expired; (3) the date on
which such patent expires; or (4) such patent is invalid or will not be infringed upon by the manufacture, use, or sale of the drug product
for which the application is submitted. This last certification is known as a paragraph IV certification. A notice of the paragraph IV
certification must be provided to each owner of the patent that is the subject of the certification and to the holder of the approved
NDA to which the ANDA or 505(b)(2) application refers. The applicant may also elect to submit a &ldquo;section viii&rdquo; statement
certifying that its proposed label does not contain (or carves out) any language regarding the patented method-of-use rather than certify
to a listed method-of-use patent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the referenced NDA holder and patent owners assert a patent challenge directed to one of the Orange Book-listed patents within 45 days
of the receipt of the paragraph IV certification notice, the FDA is prohibited from approving the application until the earlier of 30
months from the receipt of the paragraph IV certification expiration of the patent, settlement of the lawsuit, or a decision in the infringement
case that is favorable to the applicant. The ANDA or 505(b)(2) application also will not be approved until any applicable non-patent
exclusivity listed in the Orange Book for the branded reference drug has expired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Marketing
Exclusivity</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
exclusivity provisions under the FDCA can delay the submission or the approval of certain marketing applications. The FDCA provides a
five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for
a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same
active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA
may not approve or even accept for review an abbreviated new drug application, or ANDA, or a NDA submitted under Section 505(b)(2), or
505(b)(2) NDA, submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended
for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right
of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification
of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder. The FDCA alternatively
provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than
bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the
application, for example new indications, dosages, or strengths of an existing drug. This three-year exclusivity covers only the modification
for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs
or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity
will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or
obtain a right of reference to all of the pre-clinical studies and adequate and well-controlled clinical trials necessary to demonstrate
safety and effectiveness. Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity
provides for an additional six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical
trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake
the described clinical trials. In addition, orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity,
except in certain circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>United
States Coverage and Reimbursement</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
uncertainty exists as to the coverage and reimbursement status of any therapeutic product candidate for which we may seek regulatory
approval. Sales in the United States will depend in part on the availability of adequate financial coverage and reimbursement from third-party
payors, which include government health programs such as Medicare, Medicaid, TRICARE, and the Veterans Administration, as well as managed
care organizations and private health insurers. Prices at which we or our customers seek reimbursement for our initial or subsequent
therapeutic product candidates can be subject to challenge, reduction, or denial by payors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process for determining whether a payor will provide coverage for a product is typically separate from the process for setting the reimbursement
rate that the payor will pay for the product. A payor&rsquo;s decision to provide coverage for a product does not imply that an adequate
reimbursement rate will be available. Third-party payors are increasingly challenging the price and examining the medical necessity and
cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement
for any product that might be approved for marketing, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate
the medical necessity and cost-effectiveness of any products, which would be in addition to the costs expended to obtain regulatory approvals.
Third-party payors may not consider our initial or subsequent product candidates to be medically necessary or cost-effective compared
to other available therapies, or the rebate percentages required to secure favorable coverage may not yield an adequate margin over cost
or may not enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Healthcare
Reform</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and
proposed changes regarding the healthcare system that could prevent or delay marketing approval of drug product candidates, restrict
or regulate post-approval activities, and affect the profitable sale of drug product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Among
policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems
with the stated goals of containing healthcare costs, improving quality, and/or expanding access. In the United States, the pharmaceutical
industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. In March
2010, the Affordable Care Act, formally known as the Patient Protection and Affordable Care Act (the &ldquo;ACA&rdquo;), was enacted
by Congress, and signed into law by the President. It substantially changed the methods by which healthcare is financed by both the government
and private insurers, and significantly impacted the United States pharmaceutical industry. The ACA, among other things: (i) increased
the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals
enrolled in Medicaid-managed care organizations; (ii) established an annual, nondeductible fee on any entity that manufactures or imports
certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in
some government healthcare programs; (iii) expanded the availability of lower pricing under the 340B drug pricing program by adding new
entities to the program; (iv) increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;
(v) expanded the eligibility criteria for Medicaid programs; (vi) created a new Patient-Centered Outcomes Research Institute to oversee,
identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and (vii) established
a Center for Medicare &amp; Medicaid Innovation to test innovative payment and service delivery models to lower Medicare and Medicaid
spending, potentially including prescription drugs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the provisions of the ACA have yet to be implemented, and there have been judicial and Congressional challenges to certain aspects
of the ACA. While Congress has not passed comprehensive repeal legislation, bills affecting the implementation of certain taxes under
the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017 includes a provision repealing, effective January 1, 2019, the tax-based
shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part
of a year that is commonly referred to as the &ldquo;individual mandate.&rdquo; Additionally, on January 22, 2018, former President Trump
signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain ACA-mandated fees, including
the so-called &ldquo;Cadillac&rdquo; tax on certain high-cost employer-sponsored insurance plans, the annual fee imposed on certain health
insurance providers based on market share, and the medical device excise tax on non-exempt medical devices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to
providers of two percent per fiscal year and reduced payments to several types of Medicare providers. Moreover, there has recently been
heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in
several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency
to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement
methodologies for drug products. At the state level, legislatures have increasingly passed legislation and implemented regulations designed
to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product
access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries
and bulk purchasing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>United
States Healthcare Fraud and Abuse Laws and Compliance Requirements</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
and state healthcare laws and regulations restrict business practices in the pharmaceutical industry. The United States laws that may
affect our ability to operate include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            federal Anti-Kickback Statute, which prohibits, among other things, persons from soliciting,
                                            receiving, offering, or paying remuneration, directly or indirectly, to induce, or in return
                                            for, the purchase or recommendation of an item or service reimbursable under a federal healthcare
                                            program, such as the Medicare and Medicaid programs;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 81pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit,
                                            among other things, individuals, or entities from knowingly presenting, or causing to be
                                            presented, claims for payment from Medicare, Medicaid or other third-party payors that are
                                            false or fraudulent;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 81pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
                                            which created new federal criminal statutes that prohibit executing a scheme to defraud any
                                            healthcare benefit program and making false statements relating to healthcare matters;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 81pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
                                            as amended by the federal Health Information Technology for Economic and Clinical Health
                                            Act and its implementing regulations, also imposes certain requirements relating to the privacy,
                                            security, and transmission of individually identifiable health information;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 81pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            federal Physician Payments Sunshine Act, which among other things, requires certain manufacturers
                                            of drugs, devices, and biologics that are reimbursable by a federal healthcare program to
                                            report annually to the United States Department of Health and Human Services information
                                            related to payments and other transfers of value to physicians and teaching hospitals, and
                                            ownership and investment interests held by physicians and their immediate family members;
                                            and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 81pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">similar
                                            federal laws and state law equivalents of each of the above federal laws.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 81pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Regulation
Outside of the United States</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that our initial or subsequent product candidates, if and when approved, are sold in a foreign country, we may be subject
to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance,
anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or other transfers of value to
healthcare professionals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to market our future products in the European Economic Area (the &ldquo;EEA&rdquo;) and many other foreign jurisdictions, we must
obtain separate regulatory approvals. More concretely, in the EEA, medicinal products can only be commercialized after obtaining a Marketing
Authorization (an &ldquo;MA&rdquo;). There are two types of Marketing Authorizations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Community MA, which is issued by the European Commission through the Centralized Procedure,
                                            based on the opinion of the Committee for Medicinal Products for Human Use of the European
                                            Medicines Agency (the &ldquo;EMA&rdquo;) and which is valid throughout the entire territory
                                            of the EEA. The Centralized Procedure is mandatory for certain types of products, such as
                                            biotechnology medicinal products, orphan medicinal products, advanced therapy products, and
                                            medicinal products containing a new active substance indicated for the treatment certain
                                            diseases, such as AIDS, cancer, neurodegenerative disorders, diabetes, and auto-immune and
                                            viral diseases. The Centralized Procedure is optional for products that contain a new active
                                            substance not yet authorized in the EEA, or for products that constitute a significant therapeutic,
                                            scientific, or technical innovation or that are in the interest of public health in the EU;
                                            and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 81pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">National
                                            MAs, which are issued by the competent authorities of the Member States of the EEA and only
                                            cover their respective territory, are available for products not falling within the mandatory
                                            scope of the Centralized Procedure. Where a product has already been authorized for marketing
                                            in a Member State of the EEA, a National MA can be recognized in another Member State through
                                            the Mutual Recognition Procedure. If the product has not received a National MA in any Member
                                            State at the time of application, it can be approved simultaneously in various Member States
                                            through the Decentralized Procedure.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 81pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the above-described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an
assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety, and efficacy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Data
and Marketing Exclusivity</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EEA, new products authorized for marketing, or reference products, qualify for eight years of data exclusivity and an additional
two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from
relying on the pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or
biosimilar marketing authorization in the EU during a period of eight years from the date on which the reference product was first authorized
in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the
EU until 10 years have elapsed from the initial authorization of the reference product in the EU. The 10-year market exclusivity period
can be extended to a maximum of 11 years if, during the first eight years of those 10 years, the marketing authorization holder obtains
an authorization for one or more new therapeutic indications that, during the scientific evaluation prior to their authorization, are
held to bring a significant clinical benefit in comparison with existing therapies. In Japan, medicinal products approved for administration
to a patient via a new route of administration qualify for six years of market exclusivity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Clinical
Trials</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials of medicinal products in the European Union must be conducted in accordance with European Union and national regulations and the
International Conference on Harmonization (the &ldquo;ICH&rdquo;) guidelines on GCPs. Additional GCP guidelines from the European Commission,
focusing in particular on traceability, apply to clinical trials of advanced therapy medicinal products. If the sponsor of the clinical
trial is not established within the European Union, it must appoint an entity within the European Union to act as its legal representative.
The sponsor must purchase a clinical trial insurance policy and, in most EU countries, the sponsor is liable to provide &ldquo;no fault&rdquo;
compensation to any study subject injured in the clinical trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to commencing a clinical trial, the sponsor must obtain a clinical trial authorization from the competent authority, and a positive opinion
from an IEC. The application for a clinical trial authorization must include, among other things, a copy of the trial protocol and an
investigational medicinal product dossier that contains information about the manufacture and quality of the medicinal product under
investigation. Currently, clinical trial authorization applications must be submitted to the competent authority in each EU Member State
in which the trial will be conducted. Under the new Clinical Trials Regulation (Regulation (EU) No 536/2014), which took effect on January
31, 2022, there will be a centralized application procedure where one national authority takes the lead in reviewing the application
and the other national authorities have only a limited involvement. Any substantial changes to the trial protocol or other information
submitted with the clinical trial applications must be notified to or approved by the relevant competent authorities and ethics committees.
Medicines used in clinical trials must be manufactured in accordance with cGMP. Other national and European Union-wide regulatory requirements
also apply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Recycling</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
started our business in 1976 as a used appliance retailer that reconditioned old appliances to sell in our stores. Under contracts with
national and regional retailers of new appliances, we collected the replaced appliance from the retailer&rsquo;s customer&rsquo;s residence
when one of their stores delivered a new appliance. Any old appliances that we could not sell in our stores were sold to scrap metal
processors. In the late 1980s, stricter environmental regulations began to affect the disposal of unwanted appliances and we were no
longer able to take appliances that contained hazardous components to scrap metal processors. At that time, we began to develop systems
and equipment to remove the harmful materials so that metal processors would accept the appliance shells for processing. We then offered
our services for disposing of appliances in an environmentally sound manner to appliance manufacturers and retailers, waste hauling companies,
rental property managers, local governments, and the public. In 1989, we began contracting with electric utility companies to provide
turnkey appliance recycling services to support their energy conservation efforts. Since that time, through March 8, 2023, we provided
our services to approximately 400 utilities and other providers of energy efficiency programs throughout North America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
March 8, 2023, when we disposed of our recycling business, we had contracts to recycle, or to replace and recycle, major household appliances
for approximately 100 utilities and other providers of energy efficiency services across North America. We operate 17 recycling centers
in the United States and Canada to process and recycle old appliances according to all federal, state, provincial, and local rules, and
regulations. We used United States Environmental Protection Agency (the &ldquo;EPA&rdquo;) Responsible Appliance Disposal (&ldquo;RAD&rdquo;)
Program-compliant methods to remove and manage hazardous components and materials properly, including CFC refrigerants, mercury, polyurethane
foam insulation, and recyclable materials, such as ferrous and nonferrous metals, plastics, and glass. During our operations of the recycling
business, all of our facilities complied with licensing and permitting requirements, and employees who process appliances receive extensive
safety and hazardous materials training.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
wholly-owned Recycling Subsidiaries in our Recycling segment included ARCA Recycling and ARCA Canada, which recycle major household appliances
in North America by providing turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency
programs, and Connexx, which provides call center services for the recycling segment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Disposition
of our Recycling Business</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 19, 2023, the Company entered into a Stock Purchase Agreement (the &ldquo;Recycling Purchase Agreement&rdquo;) with VM7 Corporation
(&ldquo;VM7&rdquo;), under which it agreed to acquire all of the outstanding equity interests of the Recycling Subsidiaries, consisting
of: (a) ARCA Recycling, (b) ARCA Canada, and (c) Connexx. The principal of VM7 is Virland A. Johnson, our Chief Financial Officer. The
sale of all of the outstanding equity interests of the Recycling Subsidiaries to VM7 under the Recycling Purchase Agreement (the &ldquo;Disposition
Transaction&rdquo;) was consummated simultaneously with the execution of the Recycling Purchase Agreement. Our Board of Directors unanimously
approved the Recycling Purchase Agreement and the Disposition Transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
economic aspects of the Disposition Transaction are: (i) we reduced the liabilities on our consolidated balance sheets by approximately
$17.6 million (excluding those related to the California Business Fee and Tax Division, as discussed below); (ii) we will receive not
less than $24.0 million in aggregate monthly payments from VM7, which payments are subject to potential increase due to the Recycling
Subsidiaries&rsquo; future performance; and (iii) during the next five years, we may request that VM7 prepay aggregate monthly payments
in the aggregate amount of $1 million. We also received one thousand dollars for the equity of each of the Recycling Subsidiaries at
the closing. Each monthly payment is to be the greater of (a) $140,000 (or $100,000 for each January and February during the 15-year
payment period) or (b) a monthly percentage-based payment, which is an amount calculated as follows: (i) 5% of the Recycling Subsidiaries&rsquo;
aggregate gross revenues up to $2,000,000 for the relevant month, plus (ii) 4% of the Recycling Subsidiaries&rsquo; aggregate gross revenues
between $2,000,000 and $3,000,000 for the relevant month, plus (iii) 3% of the Recycling Subsidiaries aggregate gross revenues over $3,000,000
for the relevant month. VM7 will receive credit toward the payment of the first monthly payment (March of 2023) for any payments, distributions,
or cash dividends paid by any of the Recycling Subsidiaries to the Company on or after March 19, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VM7
may prepay, at any time and in total, the estimated aggregate of the future monthly payments. That amount will be an amount equal to
the then-present value of the estimated future monthly payments, discounted at the rate of 5% per annum (the &ldquo;Prepayment Price&rdquo;).
Furthermore, VM7 will be required to pay the Prepayment Price upon the earliest of (i) Mr. Johnson holding less than 75% of the capital
stock of VM7, (ii) VM7 selling substantially all of its assets, (iii) VM7 holding less than 50% of the capital stock of the Recycling
Subsidiaries, or (iv) the Recycling Subsidiaries selling substantially all of their respective assets. Upon payment of the Prepayment
Price, VM7 will have no further purchase price payment obligations to the Company.&zwnj;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
terms of the Disposition Transaction are: (i) we have the right to appoint one member of VM7&rsquo;s board of directors until the sooner
of VM7 having paid the Prepayment Price or having tendered all of the monthly payments; (ii) Mr. Johnson&rsquo;s annual salary as Chief
Executive Officer of VM7 shall be $400,000, prorated, for the remainder of the 2023 calendar year, and then adjusted annually to an amount
equal to 1% of the Recycling Subsidiaries&rsquo; aggregate gross revenues, until the sooner of VM7 having paid the Prepayment Price or
having tendered all of the monthly payments; and (iii) we will receive additional payments from VM7 (that are not related to the on-going
monthly payments) that relate to certain taxing agency issues. Upon settlement of the continuing dispute between ARCA Recycling and the
California Business Fee and Tax Division (as to which settlement, there can be no assurance), ARCA Recycling will pay to us 50% of the
amount of the reduction between the current assessment and any such settlement. The payment will be memorialized by a three-year promissory
note with interest at five percent per annum. The first payment under the note will be on the last day of VM7&rsquo;s fiscal year in
which the settlement occurs and the remaining payments each year thereafter. If ARCA Recycling receives a refund from the agency for
payments previously made, it shall pay to us an amount equivalent to 25% of such refund after reduction for the legal fees payable to
counsel for this proceeding. ARCA Recycling and Connexx are due to receive from the Internal Revenue Service two payments in the aggregate
amount of approximately $931,000 in connection with the Employee Retention Credit provisions of the Coronavirus Aid, Relief, and Economic
Security Act and the Taxpayer Certainty and Disaster Tax Relief Act of 2020. Those payments are to be tendered to us within 10 days of
receipt by ARCA Recycling or Connexx.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
secure VM7&rsquo;s obligations under the Recycling Purchase Agreement and pursuant to a Stock and Membership Interests Pledge Agreement
dated March 19, 2023 (the &ldquo;Pledge Agreement&rdquo;), Mr. Johnson pledged to us all of the capital stock in VM7 (&ldquo;VM7&rsquo;s
Capital Stock&rdquo;) and VM7 pledged to us all of the equity interests of the Recycling Subsidiaries (the &ldquo;Subject Securities&rdquo;).
Under the terms of the Pledge Agreement, upon an Event of Default (as defined in the Pledge Agreement), among other remedies in our favor,
we may foreclose on any or all of VM7&rsquo;s Capital Stock and the Subject Securities. We may also cause the ownership of VM7&rsquo;s
Capital Stock and of the Subject Securities to be transferred to us automatically, pursuant to an irrevocable transfer entered in our
favor, as referenced in the Pledge Agreement. In the event of an automatic transfer, all of the monthly payments previously made by VM7
pursuant to the terms of the Recycling Purchase Agreement will then be characterized as contributions to the capital of the Company without
dilution of the Company&rsquo;s capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
parties have made customary representations, warranties, covenants, and indemnities in connection with the Disposition Transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Recycling Purchase Agreement contains certain representations and warranties that the parties made to each other as of the date of the
Recycling Purchase Agreement or such other date as explicitly referenced therein. The representations and warranties were made solely
for purposes of the Recycling Purchase Agreement and (i) are subject to limitations agreed by the parties in negotiating the terms and
conditions thereof, (ii) may not be accurate or complete as of any specified date, (iii) will be qualified by the underlying disclosure
schedules, (iv) may be subject to a contractual standard of materiality different from those generally applicable to investors, and (v)
may have been used for the purpose of allocating risk among the parties thereto, rather than for establishing any matters as facts. Information
concerning the subject matter of the representations and warranties may change after March 8, 2023, and subsequent information may or
may not be fully reflected in JanOne&rsquo;s public disclosures. For the foregoing reasons, the representations and warranties contained
in the Recycling Purchase Agreement should not be relied upon as statements of factual information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to the closing of the Disposition Transaction, VM7 determined that, after expending significant amounts of time and resources, it was
unable to obtain sufficient equity or debt financing to continue the operations of the Recycling Subsidiaries. Accordingly, we were advised
that the operations of the Recycling Subsidiaries were wound down and, ultimately, ceased. Because we did not receive all of the economic
benefits of the Disposition Transaction and understand that we will not receive any future benefits of the Disposition Transaction, we
determined to fully impair the approximately $5.3 million carrying value of the Disposition Transaction on our balance sheet. We also
determined not to exercise any of our remedies under the Recycling Purchase Agreement so that we could maintain our focus on our clinical-stage
biopharmaceutical activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Technology</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended January 1, 2022, the Company took a full write-down of the unamortized portion of the GeoTraq intangible asset of approximately
$9.8 million, and then on May 24, 2022, the Company entered into an Asset Purchase Agreement with SPYR Technologies Inc., pursuant to
which the Company sold to SPYR substantially all the assets and assigned none of the liabilities of the Company&rsquo;s wholly-owned
subsidiary, GeoTraq Inc. The aggregate purchase price for the GeoTraq assets was $13.5 million, payable in cash and shares of SPYR&rsquo;s
capital stock. As of the closing of the transaction on May 24, 2022, SPYR issued to the Company 30,000,000 shares of its common stock
at $0.03 per share, and delivered a five-year Promissory Note in the initial principal amount of $12.6 million. The Promissory Note bears
simple interest at the rate of 8% per annum, provides quarterly interest payments due the first day of each calendar quarter, and may
be prepaid at any time without penalty. Quarterly interest payments may be made in cash or in shares of SPYR&rsquo;s restricted common
stock or preferred stock. The Promissory Note matures on May 23, 2027.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Employees</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of April 8, 2024, the Company had five employees, all of whom were full-time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Su_002"></A>SELECTED
CONSOLIDATED FINANCIAL DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables set forth selected consolidated financial data for the periods ended or as of the dates indicated. Such historical consolidated
financial data should be read in conjunction with the information set forth in our <U>Annual Report on Form 10-K for the year ended December
30, 2023</U>, filed with the SEC on April 8, 2024, and incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
statement of operations data presented below for each of the years ended December 30, 2023 and December 31, 2022, and the balance sheet
data as of December 30, 2023 and December 31, 2022, are derived from the audited &ldquo;Consolidated Financial Statements&rdquo; contained
in our Annual Report on Form 10-K for the year ended December 30, 2023. Our historical results are not necessarily indicative of the
results to be expected for any future periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in
thousands, except per share)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">For the 52-Week Period Ended</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December 30, 2023</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2022</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Cost of revenues</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Gross profit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; width: 64%; text-align: left">Sales, general and administrative expenses</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">4,746</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">3,149</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Impairment expense</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">15,100</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">19,486</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,149</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(19,486</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,149</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Interest expense, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,250</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">468</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Gain on litigation settlement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,950</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Gain on reversal of contingent liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">637</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Unrealized loss on marketable securities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(926</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(631</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other income, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">998</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,124</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total other income, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,322</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,548</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">(Loss) Income before income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(17,524</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,399</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Income tax benefit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(429</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6,621</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net (loss) income from continuing operations</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(17,095</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,020</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Income from discontinued operations</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,254</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,081</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Income tax provision for discontinued operations</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">971</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,109</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net income from discontinued operations</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,283</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,972</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net (Loss) income</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(7,812</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10,992</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Income (Loss) per share:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Net (loss) income per share from continuing operations, basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.27</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.55</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Net income per share from discontinued operations, basic</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.32</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.94</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Net income per share from discontinued operations, diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.09</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.94</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Net (loss) income per share, basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1.95</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3.49</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Weighted average common shares outstanding:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">Basic</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,005,334</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,150,230</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,444,361</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,150,230</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(7,812</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,992</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Effect of foreign currency translation adjustments</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Total other comprehensive loss, net of tax</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Comprehensive (loss) income</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(7,812</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10,988</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December 30, 2023</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2022</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Balance Sheet Data</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; text-align: left">Total assets</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">18,847</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">46,756</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,905</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,938</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Total liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,285</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,939</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Mezzanine equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,510</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,510</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total stockholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,308</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,307</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Total liabilities, mezzanine equity, and stockholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">18,487</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">46,756</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Su_003"></A>DESCRIPTION
OF SECURITIES WE MAY OFFER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue from time to time, in one or more offerings the following securities:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
    of Common Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
    of Preferred Stock, which may be convertible into shares of Common Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">debt
    securities, which may be senior or subordinated and may be convertible into or exchangeable for shares of Common Stock or shares
    of Preferred Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants
    exercisable for debt securities, shares of Common Stock, or shares of Preferred Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">rights
    to purchase any of such securities; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">units
    composed of our debt securities, shares of Common Stock, shares of Preferred Stock, and warrants, in any combination.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus contains a summary of the material general terms of the various securities that we may offer. The specific terms of the securities
will be described in a prospectus supplement, information or document incorporated by reference, related free writing prospectus, or
other offering materials, which may be in addition to or different from the general terms summarized in this prospectus. Where applicable,
the prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials
will also describe any material United States federal income tax considerations relating to the securities offered and indicate whether
the securities offered are or will be listed on any securities exchange. The summaries contained in this prospectus and in any prospectus
supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials, as applicable,
may not contain all of the information that you would find useful. Accordingly, you should read the actual documents relating to any
securities sold pursuant to this prospectus. See &ldquo;Available Information&rdquo; and &ldquo;Incorporation of Certain Information
by Reference&rdquo; for information about how to obtain copies of those documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms of any particular offering, the initial offering price, and the net proceeds to us will be contained in the prospectus supplement,
information or document incorporated by reference, related free writing prospectus, or other offering materials, as applicable, relating
to such offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Su_004"></A>DESCRIPTION
OF CAPITAL STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following summary of terms of our Common Stock and our Preferred Stock is based upon our Articles of Incorporation (our &ldquo;Charter&rdquo;)
and Bylaws (our &ldquo;Bylaws&rdquo;), currently in effect, and under Chapter 78 of the Nevada Revised Statutes (the &ldquo;NRS&rdquo;).
This summary is not complete and is subject to, and qualified in its entirety by reference to, our Charter and our Bylaws. For a complete
description of the terms and provisions of our Common Stock, please refer to our Charter and Bylaws, which are filed as exhibits to Registration
Statement of which this prospectus forms a part. Throughout this section, references to &ldquo;we,&rdquo; &ldquo;our,&rdquo; and &ldquo;us&rdquo;
refer to JanOne Inc. and its subsidiaries. We encourage you to carefully read these documents and the applicable provisions of the NRS.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
authorized capital stock consists of 200,000,000 shares of Common Stock, par value $0.001 per share, and 2,000,000 shares of Preferred
Stock, par value $0.001 per share, of which 259,729 shares are designated as Series A-1 Convertible Preferred Stock (our &ldquo;Series
A-1 Preferred Stock&rdquo;), and 200,000 shares are designated as Series S Convertible Preferred Stock (our &ldquo;Series S Preferred
Stock&rdquo;), which have a stated value of $300.00 per share (the &ldquo;Stated Value&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of April 8, 2024, we had 8,593,636 shares of our Common Stock issued and outstanding, 156,630 shares of our Series A-1 Preferred Stock
issued and outstanding, and 100,000 shares of our Series S Preferred Stock issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
authorized and unissued shares of Common Stock and Preferred Stock are available for issuance without further action by our stockholders,
unless such action is required by applicable law or the rules of any stock exchange on which our securities may then be listed. Unless
approval of our stockholders is so required, our Board of Directors (our &ldquo;Board&rdquo;) does not currently intend to seek stockholder
approval for the issuance and sale of our Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our issued and outstanding shares of our capital stock are fully paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting,
Dividend, and Liquidation Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
holder of our Common Stock is entitled to one vote for each share issued and outstanding held on all matters to be voted upon by the
stockholders. Each holder of our Series A-1 Preferred Stock is entitled to 17 votes for each share issued and outstanding held on all
matters to be voted upon by the stockholders. Each holder of our Series S Preferred Stock is entitled to one vote for each share issued
and outstanding held on all matters to be voted upon by the stockholders. Our Charter does not provide for cumulative voting in the election
of directors. Subject to the rights of the holders of the Series A-1 Preferred Stock to their preferential dividend in accordance with
the provisions of our Charter, the holders of shares of our Common Stock and Series A-1 Preferred Stock (on an as-if-converted to Common
Stock basis in accordance with the terms of our Charter) will be entitled to such cash dividends as may be declared from time to time
by our Board from funds available therefor. Upon liquidation, dissolution, or winding up of the Company, and after all liquidation preferences
payable to any series of Preferred Stock entitled thereto have been satisfied, our remaining assets shall be distributed to all holders
of Common Stock and any similarly situated stockholders who are not entitled to any liquidation preference or, if there be an insufficient
amount to pay all such stockholders, then ratably among such holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Preemptive,
Conversion, or Other Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
shares of Common Stock do not have any preemptive, conversion, or redemption rights. Our shares of Series A-1 Preferred Stock do not
have any preemptive or redemption rights and each share of which is convertible into 20 shares of our Common Stock. Our shares of Series
S Preferred do not have any preemptive or redemption rights and, subject to the provisions of the Certificate of Designation in respect
of the Series S Preferred Stock, each share of which is convertible into shares of our Common Stock at a conversion price of $1.66 per
share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Stockholder
Action; Special Meetings</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders&rsquo;
actions can only be taken at an annual or special meeting of our stockholders. Our Bylaws provide that special meetings of the stockholders
may be called at any time only by (i) our Chief Executive Officer, (ii) two of the members of the Board, or (iii) upon a written request
of stockholders holding 10% or more of the capital stock entitled to vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Board
of Directors; Removal; Vacancies</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Bylaws specify that the number of directors is to be determined by a majority vote of the Board. Our Board is currently composed of four
directors. We do not have a classified Board. Pursuant to our Bylaws and the NRS, a director serves until the regular meeting next following
or closely coinciding with the expiration of his or her term of office and until his or her successor has been elected and qualified,
or until his or her earlier death, removal, or resignation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Newly
created directorships resulting from an increase in the number of directors and vacancies occurring on our Board for any reason may be
filled by a vote of a majority of the directors then in office, although less than a quorum exists. A director that is appointed or elected
to fill a vacancy shall hold office for the remaining term of his or her predecessor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Limitation
of Liability and Indemnification</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Charter provides that none of our directors and officers shall be personally liable to us or our stockholders for damages for breach
of fiduciary duty as a director or officer, except for liability for (i) acts or omissions that involve intentional misconduct, fraud,
or knowing violation of law or (ii) for authorizing any distribution in violation of Section 78.300 of the NRS. Our Bylaws provide that
any officer or director who is made a party or witness to an action, suit, or proceeding, whether civil, criminal, administrative, or
investigative, by reason of the fact that he or she is or was one of our directors or officers or serving at our request as a director,
officer, employee, or agent, shall be indemnified and held harmless by us to the fullest extent authorized by the NRS. The right to indemnification
shall include the right of advancement of expenses to the extent permitted under the NRS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Listing
and Transfer Agent</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on The Nasdaq Capital Market under the symbol &ldquo;JAN.&rdquo; The transfer agent and registrar for our common
stock is EQ Shareowner Services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Series
A-1 Convertible Preferred Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividends</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot declare, pay, or set aside any dividends on shares of any other class or series of our capital stock unless (in addition to the
obtaining of any consents required by our Articles of Incorporation) the holders of the Series A-1 Preferred Stock then outstanding shall
first receive, or simultaneously receive, a dividend in the aggregate amount of $1.00, regardless of the number of then-issued and outstanding
shares of Series A-1 Preferred Stock. Any remaining dividends allocated by the Board of Directors shall be distributed in an equal amount
per share to the holders of outstanding Common Stock and Series A-1 Preferred Stock (on an as-if-converted to Common Stock basis pursuant
to the Conversion Ratio as defined below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Conversion</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
share of Series A-1 Preferred Stock has the right to be converted into 20 shares of Common Stock of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Redemption</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of Series A-1 Preferred Stock have no redemption rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Preemptive
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of shares of Series A-1 Preferred Stock are not entitled to any preemptive rights in respect to any securities of the Company, except
as set forth in the Series A-1 Certificate of Designation or any other document agreed to by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
holder of a share of Series A-1 Preferred Stock has that number of votes as is determined by multiplying (i) the number of shares of
Series A Preferred Stock held by such holder and (ii) 17. The holders of Series A-1 Preferred Stock vote together with all other classes
and series of Common Stock and Preferred Stock of the Company as a single class on all actions to be taken by the holders of Common Stock
of the Company, except to the extent that voting as a separate class or series is required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Protective
Provisions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
first obtaining the affirmative approval of a majority of the holders of the shares of Series A-1 Preferred Stock, we may not directly
or indirectly (i) increase or decrease (other than by redemption or conversion) the total number of authorized shares of Series A-1 Preferred
Stock; (ii) effect an exchange, reclassification, or cancellation of all or a part of the Series A-1 Preferred Stock, but excluding a
stock split or reverse stock split or combination of the Common Stock or preferred stock; (iii) effect an exchange, or create a right
of exchange, of all or part of the shares of another class of shares into shares of Series A-1 Preferred Stock; or (iv) alter or change
the rights, preferences, or privileges of the shares of Series A-1 Preferred Stock so as to affect adversely the shares of such series,
including the rights set forth in the Series A-1 Certificate of Designation; <I>provided</I>, <I>however</I>, that we may, without any
vote of the holders of shares of the Series A-1 Preferred Stock, make technical, corrective, administrative, or similar changes to the
Series A-1 Certificate of Designation that do not, individually or in the aggregate, materially adversely affect the rights or preferences
of the holders of shares of the Series A-1 Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Series
S Convertible Preferred Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2022 the Company acquired Soin Therapeutics LLC, a Delaware limited liability company (&ldquo;STLLC&rdquo;) by way of merger.
In connection with this transaction, with a potential value of up to $30 million, the Company tendered 100,000 shares of the Company&rsquo;s
Series S Convertible Preferred Stock to Amol Soin, M.D., the sole stockholder of STLLC (&ldquo;Dr. Soin&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividends</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of Series S Preferred Stock have no dividend rights.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Conversion</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Soin may convert up to $10 million of value of the Series S Preferred Stock into shares of the Company&rsquo;s Common Stock from and
after the sooner of (y) the issuance by the FDA of New Drug Approval for low-dose naltrexone for treating pain or (z) 10 years from the
closing of the acquisition of STLLC. Further, during the 10-year period following the closing, Dr. Soin may convert up to an additional
$17 million of value of shares of Series S Preferred Stock at a rate of five percent of the gross revenues that the Company receives
in connection with sales or license revenue from STLLC-related products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Soin further agreed to certain restrictions on the maximum number of shares of Series S Preferred Stock that he may ultimately keep or
that he may convert into shares of our Common Stock or sell into the public markets at any given time: (i) Dr. Soin may not convert shares
of Series S Preferred Stock into shares of the Company&rsquo;s Common Stock in an amount such that, upon any such conversion, he beneficially
own shares of the Company&rsquo;s Common Stock in excess of 4.99% of the Company&rsquo;s then-outstanding Common Stock and (ii) during
the five-year period that commences on the date that Dr. Soin is first eligible to convert any shares of Series S Preferred Stock into
shares of the Company&rsquo;s Common Stock, he will not dispose of any of such shares into the public markets in an amount that exceeds
five percent of the daily trading volume of the Company&rsquo;s common stock during any trading day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
lieu of Dr. Soin exercising his initial conversion rights in respect of up to $3 million in value of his Series S Preferred Stock, Dr.
Soin and we agreed that we will tender to him $3 million in three payments: the first payment of $100,000 was made in March 2024, the
second payment in the amount of $100,000 is due on July 31, 2024, and the third payment of $2,800,000 is due on December 31, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Redemption</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of Series S Preferred Stock have no redemption rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Preemptive
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of shares of Series S Preferred Stock are not entitled to any preemptive rights in respect to any securities of the Company, except as
set forth in the Series S Certificate of Designation or any other document agreed to by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
share of Series S Preferred Stock has one vote. The holders of Series S Preferred Stock vote together with all other classes and series
of Common Stock and Preferred Stock of the Company as a single class on all actions to be taken by the holders of Common Stock of the
Company, except to the extent that voting as a separate class or series is required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Liquidation
Preference</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
a voluntary or involuntary liquidation, dissolution or winding up of the Company, the Holders of Series S Preferred Stock have preferential
rights to holders of junior securities and shall be entitled to payments in an amount equal to the Stated Value for each share of Series
S Preferred Stock that is eligible to be converted into the Company&rsquo;s Common Stock at such time, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Protective
Provisions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
first obtaining the affirmative approval of a majority of the holders of the shares of Series S Preferred Stock, we may not directly
or indirectly (i) increase or decrease (other than by redemption or conversion) the total number of authorized shares of Series S Preferred
Stock; (ii) effect an exchange, reclassification, or cancellation of all or a part of the Series S Preferred Stock, but excluding a stock
split or reverse stock split or combination of the Common Stock or preferred stock; (iii) effect an exchange, or create a right of exchange,
of all or part of the shares of another class of shares into shares of Series S Preferred Stock; or (iv) alter or change the rights,
preferences, or privileges of the shares of Series S Preferred Stock so as to affect adversely the shares of such series, including the
rights set forth in the Series S Certificate of Designation; <I>provided</I>, <I>however</I>, that we may, without any vote of the holders
of shares of the Series S Preferred Stock, make technical, corrective, administrative, or similar changes to the Series S Certificate
of Designation that do not, individually or in the aggregate, materially adversely affect the rights or preferences of the holders of
shares of the Series S Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anti-Takeover
Effects of Certain Provisions of our Charter, our Bylaws, and the NRS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
provisions of the NRS and our Charter and Bylaws could make more difficult the acquisition of us by means of a tender offer or otherwise,
and the removal of incumbent officers and directors. These provisions are expected to discourage certain types of coercive takeover practices
and inadequate takeover bids and to encourage persons seeking to acquire control of us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Advance
Notice of Stockholder Proposals</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholder
proposals must be submitted to the Chairman of our Board, our Chief Executive Officer, our President, or our Secretary not less than
120 days before the one-year anniversary of the date on which we released our proxy statement in connection with the previous year&rsquo;s
annual meeting of stockholders. In the event that our annual meeting date has been changed by more than 30 days from the date of the
prior year&rsquo;s annual meeting, written proposals must be submitted within a reasonable time before we begin to print and mail our
proxy materials. To be in proper form, a stockholder&rsquo;s written proposal must be in compliance with Rule 14a-8 under the Exchange
Act and must include: (i) a brief description of the business desired to be brought before the annual meeting and the reasons for conducting
such business at the annual meeting, (ii) the name and record address of such stockholder, (iii) the class or series and number of shares
of our capital stock that are owned beneficially or of record by such stockholder, (iv) a description of all arrangements or understandings
between such stockholder and any other person or persons (including their names) in connection with the proposal of such business by
such stockholder and any material interest of such stockholder in such business, and (v) a representation that such stockholder intends
to appear in person or by proxy at the annual meeting to bring such business before the meeting. This provision could make it more difficult
for stockholders to submit proposals for consideration and nominees for director at an annual meeting of our stockholders<I>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Business
Combinations</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
&ldquo;business combination&rdquo; provisions of Sections 78.411 to 78.444, inclusive, of the NRS prohibit a Nevada corporation with
at least 200 stockholders (at least 100 of whom are stockholders of record and residents of the State of Nevada) from engaging in various
&ldquo;combination&rdquo; transactions with any interested stockholder for a period of three years after the date of the transaction
in which the person became an interested stockholder, unless the transaction is approved by the entity&rsquo;s board of directors prior
to the date the interested stockholder obtained such status; or after the expiration of the three-year period, unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    transaction is approved by the entity&rsquo;s board of directors or a majority of the voting power held by disinterested stockholders
    of the entity, or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the consideration to be paid by the interested stockholder is at least equal to the highest of: (a) the highest price per share paid
    by the interested stockholder within the three years immediately preceding the date of the announcement of the combination or in
    the transaction in which it became an interested stockholder, whichever is higher, (b) the market value per share of common stock
    on the date of announcement of the combination and the date the interested stockholder acquired the shares, whichever is higher,
    or (c) for holders of preferred stock, the highest liquidation value of the preferred stock, if it is higher.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
&ldquo;combination&rdquo; is defined to include mergers or consolidations or any sale, lease exchange, mortgage, pledge, transfer, or
other disposition, in one transaction or a series of transactions, with an &ldquo;interested stockholder&rdquo; having: (a) an aggregate
market value equal to 5% or more of the aggregate market value of the assets of the corporation, (b) an aggregate market value equal
to 5% or more of the aggregate market value of all outstanding shares of the corporation, or (c) 10% or more of the earning power or
net income of the corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, an &ldquo;interested stockholder&rdquo; is a person who, together with affiliates and associates, owns (or within three years,
did own) 10% or more of an entity&rsquo;s voting stock. The statute could prohibit or delay mergers or other takeover or change in control
attempts and, accordingly, may discourage attempts to acquire us even though such a transaction may offer our stockholders the opportunity
to sell their stock at a price above the prevailing market price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Acquisitions
of Controlling Interest</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada&rsquo;s
&ldquo;acquisition of controlling interest&rdquo; statutes (NRS 78.378 through 78.3793, inclusive) contain provisions governing the acquisition
of a controlling interest in certain Nevada corporations. These &ldquo;control share&rdquo; laws provide generally that any person who
acquires a &ldquo;controlling interest&rdquo; in certain Nevada corporations may be denied voting rights, unless a majority of the disinterested
stockholders of the corporation elects to restore such voting rights. These laws would apply to us as of a particular date if we were
to have 200 or more stockholders of record (at least 100 of whom have addresses in Nevada appearing on our stock ledger at all times
during the 90 days immediately preceding that date) and do business in the State of Nevada directly or through an affiliated corporation,
unless our Charter or Bylaws in effect on the tenth day after the acquisition of a controlling interest provide otherwise. These laws
provide that a person acquires a &ldquo;controlling interest&rdquo; whenever a person acquires shares of a subject corporation that,
but for the application of these provisions of the NRS, would enable that person to exercise (1) one-fifth or more, but less than one-third,
(2) one-third or more, but less than a majority, or (3) a majority or more of all of the voting power of that corporation in the election
of its directors. Once an acquirer crosses one of these thresholds, shares that it acquired in the transaction that took it over the
threshold and shares that it acquired within the 90 days immediately preceding the date when it acquired or offered to acquire a controlling
interest become &ldquo;control shares&rdquo; to which the voting restrictions described above apply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Su_005"></A>DESCRIPTION
OF PREFERRED STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
of our Preferred Stock may be issued in one or more series, and our Board is authorized to determine the designation and to fix the number
of shares of each series. Our Board is further authorized to fix and determine the dividend rate, premium or redemption rates, conversion
rights, voting rights, preferences, privileges, restrictions, and other variations granted to or imposed upon any wholly unissued series
of our Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the issuance of shares of a series of Preferred Stock, our Board will adopt resolutions and file a certificate of designation with
the Secretary of State of the State of Nevada. The certificate of designation will fix for each series the designation and number of
shares and the rights, preferences, privileges, and restrictions of the shares including, but not limited to, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    voting rights, if any, of the Preferred Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    rights and terms of redemption;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    dividend rate(s), period(s), and/or payment date(s) or method(s) of calculation applicable to the Preferred Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    dividends are cumulative or non-cumulative and, if cumulative, the date from which dividends on the Preferred Stock will accumulate;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    relative ranking and preferences of the preferred stock as to dividend rights and rights upon the liquidation, dissolution, or winding
    up of our affairs;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    terms and conditions, if applicable, upon which the Preferred Stock will be convertible into Common Stock, another series of Preferred
    Stock, or any other class of securities, including the conversion price (or manner of calculation) and conversion period;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    provision for redemption, if applicable, of the Preferred Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    provisions for a sinking fund, if any, for the Preferred Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    liquidation preferences, if any, for the Preferred Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    limitations on the issuance of any class or series of Preferred Stock ranking senior to or on a parity with the class or series of
    Preferred Stock as to dividend rights and rights upon liquidation, dissolution, or winding up of our affairs; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other specific terms, preferences, rights, limitations, or restrictions of the Preferred Stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the terms listed above, we will set forth in a prospectus supplement, information or document incorporated by reference,
related free writing prospectus, or other offering materials, as applicable, the following terms relating to the series of Preferred
Stock being offered:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of shares of the preferred stock offered, the liquidation preference per share, the conversion rights, and the offering price
    of the Preferred Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    procedures for any auction and remarketing, if any, for the Preferred Stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    listing of the Preferred Stock on any securities exchange; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    discussion of any material and/or special United States federal income tax considerations applicable to the Preferred Stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Su_006"></A>DESCRIPTION
OF DEBT SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description, together with the additional information we include in any applicable prospectus supplements or any related free
writing prospectus or other offering materials, as applicable, summarizes the material terms and provisions of the debt securities that
we may offer under this prospectus. While the terms we have summarized below will apply generally to any future debt securities we may
offer pursuant to this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the
applicable prospectus supplement. If we so indicate in a prospectus supplement, the terms of any debt securities offered under such prospectus
supplement may differ from the terms we describe below, and to the extent the terms set forth in a prospectus supplement differ from
the terms described below, the terms set forth in the prospectus supplement or any related free writing prospectus or other offering
materials, as applicable, shall control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may sell from time to time, in one or more offerings under this prospectus, debt securities, in one or more series. These debt securities
that we may issue include senior debt securities, senior subordinated debt securities, subordinated debt securities, convertible debt
securities, and exchangeable debt securities. We will issue any such senior debt securities under a senior indenture that we will enter
into with a trustee to be named in the senior indenture. We will issue any such subordinated debt securities under a subordinated indenture,
which we will enter into with a trustee to be named in the subordinated indenture. We use the term &ldquo;indentures&rdquo; to refer
to either the senior indenture or the subordinated indenture, as applicable. The indentures will be qualified under the Trust Indenture
Act of 1939, as amended (the &ldquo;Trust Indenture Act&rdquo;), as in effect on the date of the indenture. We use the term &ldquo;debenture
trustee&rdquo; to refer to either the trustee under the senior indenture or the trustee under the subordinated indenture, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary description, together with the additional information we may include in any applicable prospectus supplement, information
or document incorporated by reference, related free writing prospectus, or other offering materials, as applicable, does not purport
to be complete and is subject to, and qualified in its entirety by reference to, the form of indenture filed as an exhibit to the Registration
Statement of which the prospectus is a part, as it may be supplemented, amended, or modified from time to time, as well as the notes
and supplemental agreement relating to each series of debt securities that will be incorporated by reference as exhibits to the Registration
Statement that includes the prospectus or as exhibits to a Current Report on Form 8-K if we offer debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indenture does not limit the amount of debt securities that may be issued thereunder, and each indenture provides that the specific terms
of any series of debt securities shall be set forth in, or determined pursuant to, an authorizing resolution and/or a supplemental indenture,
if any, relating to such series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue the debt securities issued under the indentures as &ldquo;discount securities,&rdquo; which means they may be sold at a discount
below their stated principal amount. These debt securities, as well as other debt securities that are not issued at a discount, may be
issued with &ldquo;original issue discount,&rdquo; or &ldquo;OID,&rdquo; for U.S. federal income tax purposes because of interest payment
and other characteristics or terms of the debt securities. Material U.S. federal income tax considerations applicable to debt securities
issued with OID will be described in more detail in any applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will describe in the applicable prospectus supplement, the related free writing prospectus, or other offering materials, as applicable,
the terms of the series of debt securities being offered, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    title or designation;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    aggregate principal amount and any limit on the aggregate principal amount that may be issued;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    maturity date or dates on which principal will be payable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    form of the debt securities of the series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.45in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    applicability of any guarantees;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    or not the debt securities will be secured or unsecured, and the terms of any secured debt;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the debt securities rank as senior debt, senior subordinated debt, subordinated debt, or any combination thereof, and the terms of
    any subordination;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt securities will be issued is a
    price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration
    of the maturity thereof, or, if applicable, the portion of the principal amount of such debt securities that is convertible into
    another security or the method by which any such portion shall be determined;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date interest will begin to
    accrue, the dates interest will be payable, and the regular record dates for interest payment dates or the method for determining
    such dates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    right, if any, to defer payment of interest and the maximum length of any such deferral period;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    applicable, the date or dates after which, or the period or periods during which, and the price or prices at which, we may, at our
    option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those
    redemption provisions;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory sinking fund or analogous
    fund provisions or otherwise, to redeem, or at the holder&rsquo;s option to purchase, the series of debt securities and the currency
    or currency unit in which the debt securities are payable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple
    thereof;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    place or places where payments will be payable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the debt securities of that series shall be issued in whole or in part in the form of a global security or securities, the terms
    and conditions, if any, upon which such global security or securities may be exchanged in whole or in part for other individual securities;
    and the depositary for such global security or securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the indenture will restrict our ability to pay dividends or will require us to maintain any asset ratios or reserves;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if,
    other than the full principal amount thereof, the portion of the principal amount of debt securities of the series that shall be
    payable upon declaration of acceleration of the maturity thereof;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    we will be restricted from incurring any additional indebtedness;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.45in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
    to or changes in the events of default with respect to the securities and any change in the right of the trustee or the holders to
    declare the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
    to or changes in the provisions relating to satisfaction and discharge of the indenture;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
    to or changes in the provisions relating to the modification of the indenture both with and without the consent of holders of debt
    securities issued under the indenture;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    interest will be payable in cash or additional debt securities at our or the holders&rsquo; option and the terms and conditions upon
    which the election may be made;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if any, and principal amounts
    of the debt securities of the series to any holder that is not a &ldquo;United States person&rdquo; for federal tax purposes;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    restrictions on transfer, sale, or assignment of the debt securities of the series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    discussion on any material or special U.S. federal income tax considerations applicable to a series of debt securities; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other specific terms, preferences, rights, or limitations of, or restrictions on, the debt securities, any other additions or changes
    in the provisions of the indenture, and any terms that may be required by us or advisable under applicable laws or regulations.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue debt securities that provide for an amount less than their stated principal amount to be due and payable upon declaration of
acceleration of their maturity pursuant to the terms of the indenture. We will provide you with information on the federal income tax
considerations and other special consideration applicable to any of these debt securities in the applicable prospectus supplement, related
free writing prospectus, or other offering materials, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Conversion
or Exchange Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will set forth in the applicable prospectus supplement, related free writing prospectus, or other offering materials, as applicable,
the terms on which a series of debt securities may be convertible into or exchangeable for shares of our Common Stock, shares of our
Preferred Stock, or other securities. We will include provisions as to settlement upon conversion or exchange and whether conversion
or exchange is mandatory, at the option of the holder, or at our option. We may include provisions pursuant to which the number of shares
of our Common Stock, shares of our Preferred Stock, or our other securities that the holders of the series of debt securities receive
would be subject to adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidation,
Merger, or Sale; No Protection in Event of a Change of Control or Highly Leveraged Transaction</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
we provide otherwise in the prospectus supplement, information or document incorporated by reference, related free writing prospectus,
or other offering materials, as applicable, applicable to a particular series of debt securities, the indenture will contain covenant
that restricts our ability to merge or consolidate, or sell, convey, transfer, or otherwise dispose of our assets as an entirety or substantially
as an entirety, unless we are the surviving corporation or the successor to or acquirer of such assets (other than a subsidiary of ours)
expressly assumes all of our obligations under the indenture or the debt securities, as appropriate. In addition, we cannot complete
such a transaction unless immediately after completing the transaction, no event of default under the indenture, and no event that, after
notice or lapse of time or both, would become an event of default under the indenture, has occurred and is continuing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
we provide otherwise in the prospectus supplement, information or document incorporated by reference, related free writing prospectus,
or other offering materials, as applicable to a particular series of debt securities, the debt securities will not contain any provisions
that may afford holders of the debt securities protection in the event we have a change of control or in the event of a highly leveraged
transaction (whether or not such transaction results in a change of control), which could adversely affect holders of debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Events
of Default Under the Indentures</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
we provide otherwise in the prospectus supplement, information or document incorporated by reference, related free writing prospectus,
or other offering materials, as applicable to a particular series of debt securities, the following are events of default under the indentures
with respect to any series of debt securities that we may issue:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    we fail to pay interest when due and our failure continues for a period of 90 days; <I>provided</I>, <I>however</I>, that a valid
    extension of an interest payment period by us in accordance with the terms of any indenture supplement thereto shall not constitute
    a default in the payment of interest for this purpose;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.45in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same shall become due and payable
    whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established
    with respect to such series; <I>provided</I>, <I>however</I>, that a valid extension of the maturity of such debt securities in accordance
    with the terms of any indenture supplement thereto shall not constitute a default in the payment of principal or premium, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    we fail to observe or perform any other covenant or agreement contained in the debt securities or the indenture, other than a covenant
    specifically relating to another series of debt securities, and our failure continues for 90 days after we receive written notice
    of such failure, requiring the same to be remedied and stating that such is a notice of default thereunder, from the trustee or holders
    of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    specified events of bankruptcy, insolvency, or reorganization occur as to us.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
event of default with respect to a particular series of debt securities (except as to certain events of bankruptcy, insolvency, or reorganization)
necessarily constitutes an event of default with respect to any other series of debt securities. The occurrence of an event of default
may constitute an event of default under any bank credit agreements we may have in existence from time to time. In addition, the occurrence
of certain events of default or acceleration under the indenture may constitute an event of default under certain of our other indebtedness
outstanding from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an event of default with respect to debt securities of any series at the time outstanding occurs and is continuing, then the trustee
or the holders of at least 25% in principal amount of the outstanding debt securities of that series may, by a notice in writing to us
(and to the debenture trustee if given by the holders), declare to be due and payable immediately the principal (or, if the debt securities
of that series are discount securities, that portion of the principal amount as may be specified in the terms of that series) of and
premium and accrued and unpaid interest, if any, on all debt securities of that series. Before a judgment or decree for payment of the
money due has been obtained with respect to debt securities of any series, the holders of a majority in principal amount of the outstanding
debt securities of that series (or, at a meeting of holders of such series at which a quorum is present, the holders of a majority in
principal amount of the debt securities of such series represented at such meeting) may rescind and annul the acceleration if all events
of default, other than the non-payment of accelerated principal, premium, if any, and interest, if any, with respect to debt securities
of that series, have been cured or waived as provided in the applicable indenture (including payments or deposits in respect of principal,
premium or interest that had become due other than as a result of such acceleration). We refer you to the prospectus supplement, information
or document incorporated by reference, related free writing prospectus, or other offering materials, as applicable, relating to any series
of debt securities that are discount securities for the particular provisions relating to acceleration of a portion of the principal
amount of such discount securities upon the occurrence of an event of default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the terms of the indentures, if an event of default under an indenture shall occur and be continuing, the debenture trustee will be
under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of
the applicable series of debt securities, unless such holders have offered the debenture trustee reasonable indemnity. The holders of
a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method, and place
of conducting any proceeding for any remedy available to the debenture trustee, or exercising any trust or power conferred on the debenture
trustee, with respect to the debt securities of that series, provided, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    direction so given by the holder is not in conflict with any law or the applicable indenture; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
    to its duties under the Trust Indenture Act, the debenture trustee need not take any action that might involve it in personal liability
    or might be unduly prejudicial to the holders not involved in the proceeding.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
holder of the debt securities of any series will only have the right to institute a proceeding under the indentures or to appoint a receiver
or trustee, or to seek other remedies if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    holder previously has given written notice to the debenture trustee of a continuing event of default with respect to that series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made written request,
    and such holders have offered reasonable indemnity to the debenture trustee to institute the proceeding as trustee; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    debenture trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount
    of the outstanding debt securities of that series (or at a meeting of holders of such series at which a quorum is present, the holders
    of a majority in principal amount of the debt securities of such series represented at such meeting) other conflicting directions
    within 60 days after the notice, request, and offer.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium,
if any, or interest on, the debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will periodically file statements with the applicable debenture trustee regarding our compliance with specified covenants in the applicable
indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Modification
of Indentures; Waiver</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and the debenture trustee may change the applicable indenture without the consent of any holders with respect to specific matters, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    evidence the succession of another corporation to us and the assumption by any such successor of our covenants in such indenture
    and in the debt securities issued thereunder;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    add to our covenants or to surrender any right or power conferred on us pursuant to the indenture;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    establish the form and terms of debt securities issued thereunder;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    evidence and provide for a successor trustee under such indenture with respect to one or more series of debt securities issued thereunder
    or to provide for or facilitate the administration of the trusts under such indenture by more than one trustee;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    cure any ambiguity, to correct or supplement any provision in the indenture that may be defective or inconsistent with any other
    provision of the indenture or to make any other provisions with respect to matters or questions arising under such indenture; provided
    that no such action adversely affects the interests of the holders of any series of debt securities issued thereunder in any material
    respect;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 81pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    add to, delete from, or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue,
    authentication, and delivery of securities under the indenture;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    add any additional events of default with respect to all or any series of debt securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    supplement any of the provisions of the indenture as may be necessary to permit or facilitate the defeasance and discharge of any
    series of debt securities, provided that such action does not adversely affect the interests of any holder of an outstanding debt
    security of such series or any other security in any material respect;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    make provisions with respect to the conversion or exchange rights of holders of debt securities of any series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    pledge to the trustee as security for the debt securities of any series any property or assets;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 81pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    add guarantees in respect of the debt securities of one or more series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    change or eliminate any of the provisions of the indenture, provided that any such change or elimination becomes effective only when
    there is no security of any series outstanding created prior to the execution of such supplemental indenture that is entitled to
    the benefit of such provision;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    provide for certificated securities in addition to or in place of global securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    qualify such indenture under the Trust Indenture Act;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
    respect to the debt securities of any series, to conform the text of the indenture or the debt securities of such series to any provision
    of the description thereof in our offering memorandum or prospectus relating to the initial offering of such debt securities, to
    the extent that such provision, in our good faith judgment, was intended to be a verbatim recitation of a provision of the indenture
    or such securities; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    make any other change that does not adversely affect the rights of holders of any series of debt securities issued thereunder in
    any material respect.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under the indentures, the rights of holders of a series of debt securities may be changed by us and the debenture trustee with
the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series
(or, at a meeting of holders of such series at which a quorum is present, the holders of a majority in principal amount of the debt securities
of such series represented at such meeting) that is affected. However, the debenture trustee and we may make the following changes only
with the consent of each holder of any outstanding debt security affected:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">extending
    the fixed maturity of the series of debt securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reducing
    the principal amount, reducing the rate of, or extending the time of payment of interest, or any premium payable upon the redemption
    of any debt securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reducing
    the principal amount of discount securities payable upon acceleration of maturity;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">making
    the principal of or premium or interest on any debt security payable in currency other than that stated in the debt security;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">impair
    the right to institute suit for the enforcement of any payment on any debt security when due;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    applicable, adversely affect the right of a holder to confer or exchange a debt security; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reducing
    the percentage of debt securities, the holders of which are required to consent to any amendment or waiver.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
for certain specified provisions, the holders of at least a majority in principal amount of the outstanding debt securities of any series
(or, at a meeting of holders of such series at which a quorum is present, the holders of a majority in principal amount of the debt securities
of such series represented at such meeting) may on behalf of the holders of all debt securities of that series waive our compliance with
provisions of the indenture. The holders of a majority in principal amount of the outstanding debt securities of any series may, on behalf
of the holders of all the debt securities of such series, waive any past default under the indenture with respect to that series and
its consequences, except a default in the payment of the principal of, premium, or any interest on any debt security of that series or
in respect of a covenant or provision, which cannot be modified or amended without the consent of the holder of each outstanding debt
security of the series affected; <I>provided</I>, <I>however</I>, that the holders of a majority in principal amount of the outstanding
debt securities of any series may rescind an acceleration and its consequences, including any related payment default that resulted from
the acceleration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Discharge,
Defeasance, and Covenant Defeasance</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
can discharge or decrease our obligations under the indenture as stated below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may discharge obligations to holders of any series of debt securities that have not already been delivered to the trustee for cancellation
and that have either become due and payable or are by their terms to become due and payable, or are scheduled for redemption, within
one year. We may effect a discharge by irrevocably depositing with the trustee cash or government obligations, as trust funds, in an
amount certified to be enough to pay, when due, whether at maturity, upon redemption or otherwise, the principal of, and any premium
and interest on, the debt securities and any mandatory sinking fund payments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise provided in the applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus,
or other offering materials, we may also discharge any and all of our obligations to holders of any series of debt securities at any
time, which we refer to as defeasance. We may also be released from the obligations imposed by any covenants of any outstanding series
of debt securities and provisions of the indenture, and we may omit to comply with those covenants without creating an event of default
under the trust declaration, which we refer to as covenant defeasance. We may effect defeasance and covenant defeasance only if, among
other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    irrevocably deposit with the trustee cash or government obligations denominated in the currency of the debt securities, as trust
    funds, in an amount certified to be enough to pay at maturity, or upon redemption, the principal (including any mandatory sinking
    fund payments) of, and any premium and interest on, all outstanding debt securities of the series; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    deliver to the trustee an opinion of counsel from a nationally recognized law firm to the effect that the holders of the series of
    debt securities will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the defeasance or covenant
    defeasance and that defeasance or covenant defeasance will not otherwise alter the holders&rsquo; U.S. federal income tax treatment
    of principal, and any premium and interest payments on, the series of debt securities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the case of a defeasance by us, the opinion we deliver must be based on a ruling of the Internal Revenue Service issued, or a change
in U.S. federal income tax law occurring, after the date of the indenture, since such a result would not occur under the U.S. federal
income tax laws in effect on that date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we may discharge or decrease our obligations under the indenture as described in the two preceding paragraphs, we may not avoid, among
other things, our duty to register the transfer or exchange of any series of debt securities, to replace any temporary, mutilated, destroyed,
lost, or stolen series of debt securities or to maintain an office or agency in respect of any series of debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registered
Global Securities and Book Entry System</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
debt securities of a series may be issued in whole or in part in book-entry form and will be represented by one or more fully registered
global securities. We will deposit any registered global securities with a depositary or with a nominee for a depositary identified in
the applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering
materials and registered in the name of such depositary or nominee. In such case, we will issue one or more registered global securities
denominated in an amount equal to the aggregate principal amount of all of the debt securities of the series to be issued and represented
by such registered global security or securities. This means that we will not issue certificates to each holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
and until it is exchanged in whole or in part for debt securities in definitive registered form, a registered global security may not
be transferred except as a whole:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
    the depositary for the registered global security to its nominee;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
    a nominee of the depositary to the depositary or another nominee of the depositary; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
    the depositary or its nominee to a successor of the depositary or a nominee of the successor.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering materials,
as applicable, relating to a series of debt securities will describe the specific terms of the depositary arrangement involving any portion
of the series represented by a registered global security. We anticipate that the following provisions will apply to all depositary arrangements
for debt securities:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ownership
    of beneficial interests in a registered global security will be limited to persons that have accounts with the depositary for such
    registered global security, these persons being referred to as &ldquo;participants,&rdquo; or persons that may hold interests through
    participants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
    the issuance of a registered global security, the depositary for the registered global security will credit, on its book-entry registration
    and transfer system, the participants&rsquo; accounts with the respective principal amounts of the debt securities represented by
    the registered global security beneficially owned by the participants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    dealers, underwriters, or agents participating in the distribution of the debt securities will designate the accounts to be credited;
    and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ownership
    of beneficial interest in the registered global security will be shown on, and the transfer of the ownership interest will be effected
    only through, records maintained by the depositary for the registered global security for interests of participants, and on the records
    of participants for interests of persons holding through participants.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
laws of some states may require that specified purchasers of securities take physical delivery of the securities in definitive form.
These laws may limit the ability of those persons to own, transfer, or pledge beneficial interests in registered global securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">So
long as the depositary for a registered global security, or its nominee, is the registered owner of the registered global security, the
depositary or such nominee, as the case may be, will be considered the sole owner or holder of the debt securities represented by the
registered global security for all purposes under the indenture. Except as stated below, owners of beneficial interests in a registered
global security:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">will
    not be entitled to have the debt securities represented by a registered global security registered in their names;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">will
    not receive or be entitled to receive physical delivery of the debt securities in the definitive form; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">will
    not be considered the owners or holders of the debt securities under the relevant indenture.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
each person owning a beneficial interest in a registered global security must rely on the procedures of the depositary for the registered
global security and, if the person is not a participant, on the procedures of a participant through which the person owns its interest,
to exercise any rights of a holder under the indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
understand that, under existing industry practices, if we request any action of holders or if an owner of a beneficial interest in a
registered global security desires to give or take any action that a holder is entitled to give or take under the indenture, the depositary
for the registered global security would authorize the participants holding the relevant beneficial interests to give or take the action,
and the participants would authorize beneficial owners owning through the participants to give or take the action or would otherwise
act upon the instructions of beneficial owners holding through them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will make payments of principal and premium, if any, and interest, if any, on debt securities represented by a registered global security
registered in the name of a depositary or its nominee to the depositary or its nominee, as the case may be, as the registered owners
of the registered global security. Neither we nor the trustee, or any other agent of ours or the trustee will be responsible or liable
for any aspect of the records relating to, or payments made on account of, beneficial ownership interests in the registered global security
or for maintaining, supervising, or reviewing any records relating to the beneficial ownership interests.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that the depositary for any debt securities represented by a registered global security, upon receipt of any payments of principal
and premium, if any, and interest, if any, in respect of the registered global security, will immediately credit participants&rsquo;
accounts with payments in amounts proportionate to their respective beneficial interests in the registered global security as shown on
the records of the depositary. We also expect that standing customer instructions and customary practices will govern payments by participants
to owners of beneficial interests in the registered global security held through the participants, as is now the case with the securities
held for the accounts of customers in bearer form or registered in &ldquo;street name.&rdquo; We also expect that any of these payments
will be the responsibility of the participants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the depositary for any debt securities represented by a registered global security is at any time unwilling or unable to continue as
depositary or stops being a clearing agency registered under the Exchange Act, we will appoint an eligible successor depositary. If we
fail to appoint an eligible successor depositary within 90 days, we will issue the debt securities in definitive form in exchange for
the registered global security. In addition, we may at any time and in our sole discretion decide not to have any of the debt securities
of a series represented by one or more registered global securities. In that event, we will issue debt securities of the series in a
definitive form in exchange for all of the registered global securities representing the debt securities. The trustee will register any
debt securities issued in definitive form in exchange for a registered global security in the name or names as the depositary, based
upon instructions from its participants, shall instruct the trustee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Information
Concerning the Debenture Trustee</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
debenture trustee, other than during the occurrence and continuance of an event of default under the applicable indenture, undertakes
to perform only those duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture,
the debenture trustee under such indenture must use the same degree of care as a prudent person would exercise or use in the conduct
of his or her own affairs. Subject to this provision, the debenture trustee is under no obligation to exercise any of the powers given
it by the indentures at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the
costs, expenses, and liabilities that it might incur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Payment
and Paying Agents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
we other indicate in the applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus,
or other offering materials, we will make payment of the interest on any debt securities on any interest payment date to the person in
whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record
date for the interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated
by us, except that unless we otherwise indicate in the applicable prospectus supplement, information or document incorporated by reference,
related free writing prospectus, or other offering materials, we will make interest payments by check which we will mail to the holder.
Unless we otherwise indicate in a prospectus supplement, information or document incorporated by reference, related free writing prospectus,
or other offering materials, as applicable, we will designate the corporate trust office of the debenture trustee as our sole paying
agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement, information
or document incorporated by reference, related free writing prospectus, or other offering materials, any other paying agents that we
initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the
debt securities of a particular series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
money we pay to a paying agent or the debenture trustee for the payment of the principal of or any premium or interest on any debt securities
which remains unclaimed at the end of two years after such principal, premium, or interest has become due and payable will be repaid
to us, and the holder of the security thereafter may look only to us for payment thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Governing
Law</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indentures and the debt securities will be governed by and construed in accordance with the laws of the State of New York, except to
the extent that the Trust Indenture Act is applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subordination
of Subordinated Debt Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
obligations pursuant to any subordinated debt securities will be unsecured and will be subordinate and junior in priority of payment
to certain of our other indebtedness to the extent described in a prospectus supplement, information or document incorporated by reference,
related free writing prospectus, or other offering materials, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outstanding
Debt Securities</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of April 8, 2024, we had the following debt securities outstanding:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828024003865/ex10101_icgjanonefourthame.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Fourth Amendment to</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Secured Revolving Line
    of Credit Promissory Note, amendment dated February 7, 2024, issued to Isaac Capital Group LLC [filed as Exhibit 10.101
    to the Company&rsquo;s Form 10-K filed April 8, 2024 (File No. 0-19621) and incorporated herein by reference]. </FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828024003865/ex10102_livejanonefirstame.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of First Amendment to Promissory Note in favor of Live Ventures Incorporated, dated February 7, 2024 [filed as Exhibit
    10.102 to the Company&rsquo;s Form 10-K filed April 8, 2024 (File No. 0-19621) and incorporated herein by reference].</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828024003865/ex10103_janonepromissoryno.htm" STYLE="-sec-extract: exhibit">Form
    of Promissory Note in favor of Isaac Capital Group LLC, dated February 7, 2024 [filed as Exhibit 10.103 to the Company&rsquo;s Form
    10-K filed April 8, 2024 (File No. 0-19621) and incorporated herein by reference].</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828024003865/ex10104_janonepromissoryno.htm" STYLE="-sec-extract: exhibit">Form
    of Promissory Note in favor of Live Ventures Incorporated, dated February 7, 2024 [filed as Exhibit 10.104 to the Company&rsquo;s
    Form 10-K filed April 8, 2024 (File No. 0-19621) and incorporated herein by reference].</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/862861/000162828024015260/ex10106_janonepromissoryno.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Promissory Note in favor of Jon Isaac, dated March 4, 2024 [filed as Exhibit 10.106 to the Company&rsquo;s Form 10-K filed
    April 8, 2024 (File No. 0-19621) and incorporated herein by reference].</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Su_007"></A>DESCRIPTION
OF WARRANTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue warrants to purchase debt securities, shares of our Common Stock, shares of our Preferred Stock, or any combination of these
securities. We may issue the warrants independently or together with any underlying securities, and the warrants may be attached or separate
from the underlying securities. We may also issue a series of warrants under a separate warrant agreement to be entered into between
a warrant agent and us. The warrant agent will act solely as our agent in connection with the warrants of such series and will not assume
any obligation or relationship of agency for or with holders or beneficial owners of warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description is a summary of selected provisions relating to the warrants that we may issue. The summary is not complete. When
warrants are offered in the future, a prospectus supplement, information, or document incorporated by reference, related free writing
prospectus, or other offering materials, as applicable, will explain the particular terms of those securities and the extent to which
these general provisions may apply. The specific terms of the warrants as described in the applicable prospectus supplement, information
or document incorporated by reference, related free writing prospectus, or other offering materials will supplement and, if applicable,
may modify or replace the general terms described in this section.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
summary and any description of warrants in the applicable prospectus supplement, information or document incorporated by reference, related
free writing prospectus, or other offering materials is subject to and is qualified in its entirety by reference to all the provisions
of any specific warrant document or agreement, which we will file with the SEC for incorporation by reference into this prospectus. See
&ldquo;Available Information&rdquo; and &ldquo;Incorporation of Certain Information by Reference&rdquo; for information on how to obtain
a copy of a warrant document when it is filed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
we refer to a series of warrants, we mean all warrants issued as part of the same series under the applicable warrant agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Terms</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering
materials may describe the terms of any warrants that we may offer, including but not limited to the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    title of the warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    total number of warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    price or prices at which the warrants will be issued;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    currency or currencies that investors may use to pay for the warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    date on which the right to exercise the warrants will commence and the date on which the right will expire;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the warrants will be issued in registered form or bearer form;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">information
    with respect to book-entry procedures, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    applicable, the minimum or maximum amount of warrants that may be exercised at any one time;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    applicable, the designation and terms of the underlying securities with which the warrants are issued and the number of warrants
    issued with each underlying security;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    applicable, the date on and after which the warrants and the related underlying securities will be separately transferable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    applicable, a discussion of material United States federal income tax considerations;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    applicable, the terms of redemption of the warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    identity of the warrant agent, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    procedures and conditions relating to the exercise of the warrants; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other terms of the warrants, including terms, procedures, and limitations relating to the exchange and exercise of the warrants.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrant
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue the warrants in one or more series under one or more warrant agreements, each to be entered into between a bank, trust company,
or other financial institution as warrant agent, and us. We may add, replace, or terminate warrant agents from time to time. We may also
choose to act as our own warrant agent or may choose one of our subsidiaries to do so.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrant agent under a warrant agreement will act solely as our agent in connection with the warrants issued under that agreement. The
warrant agent will not assume any obligation or relationship of agency or trust for or with any holders of those warrants. Any holder
of warrants may, without the consent of any other person, enforce by appropriate legal action, on its own behalf, its right to exercise
those warrants in accordance with their terms. Until the warrant is properly exercised, no holder of any warrant will be entitled to
any rights of a holder of the warrant property purchasable upon exercise of the warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form,
Exchange, and Transfer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue the warrants in registered form or bearer form. Warrants issued in registered form, <I>i.e.</I>, book-entry form, will be represented
by a global security registered in the name of a depository, which will be the holder of all the warrants represented by the global security.
Those investors who own beneficial interests in a global warrant will do so through participants in the depository&rsquo;s system, and
the rights of these indirect owners will be governed solely by the applicable procedures of the depository and its participants. In addition,
we may issue warrants in non-global form, <I>i.e.</I>, bearer form. If any warrants are issued in non-global form, warrant certificates
may be exchanged for new warrant certificates of different denominations, and holders may exchange, transfer, or exercise their warrants
at the warrant agent&rsquo;s office or any other office indicated in the applicable prospectus supplement, information or document incorporated
by reference, related free writing prospectus, or other offering materials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the exercise of their warrants, holders of warrants exercisable for debt securities will not have any of the rights of holders of
the debt securities purchasable upon such exercise and will not be entitled to payments of principal (or premium, if any) or interest,
if any, on the debt securities purchasable upon such exercise. Prior to the exercise of their warrants, holders of warrants exercisable
for shares of Common Stock or shares of Preferred Stock will not have any rights of holders of the shares of Common Stock or the shares
of Preferred Stock purchasable upon such exercise and will not be entitled to dividend payments, if any, or voting rights of the shares
of Common Stock or the shares of Preferred Stock purchasable upon such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise
of Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
warrant will entitle the holder to purchase for cash an amount of securities at an exercise price that will be stated in, or that will
be determinable as described in, the applicable prospectus supplement, information or document incorporated by reference, related free
writing prospectus, or other offering materials. Warrants may be exercised at any time from the initial exercise date and time through
and including the close of business on the expiration date set forth in the applicable prospectus supplement, information or document
incorporated by reference, related free writing prospectus, or other offering materials. After the close of business on the expiration
date, unexercised warrants will become void. Warrants may be redeemed as set forth in the applicable prospectus supplement, information
or document incorporated by reference, related free writing prospectus, or other offering materials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
may be exercised as set forth in the applicable prospectus supplement, information or document incorporated by reference, related free
writing prospectus, or other offering materials. Upon receipt of payment and the warrant certificate properly completed and duly executed
at the corporate trust office of the warrant agent or any other office indicated in the prospectus supplement, information or document
incorporated by reference, related free writing prospectus, or other offering materials, as applicable, we will forward, as soon as practicable,
the securities purchasable upon such exercise. If less than all of the warrants represented by such warrant certificate are exercised,
a new warrant certificate will be issued for the remaining warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Su_008"></A>DESCRIPTION
OF RIGHTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue rights to purchase our debt securities, shares of our Common Stock, or shares of our Preferred Stock. These rights may be issued
independently or together with any other security offered hereby and may or may not be transferable by the stockholder receiving the
rights in such offering. In connection with any offering of such rights, we may enter into a standby arrangement with one or more underwriters
or other purchasers pursuant to which the underwriters or other purchasers may be required to purchase any securities remaining unsubscribed
for after such offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
series of rights will be issued under a separate rights agreement that we will enter with a bank or trust company, as rights agent, all
of which will be set forth in the relevant offering material. The rights agent will act solely as our agent in connection with the certificates
relating to the rights and will not assume any obligation or relationship of agency or trust with any holders of rights certificates
or beneficial owners of rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description is a summary of selected provisions relating to rights that we may offer. The summary is not complete. When rights
are offered in the future, a prospectus supplement, information, or document incorporated by reference, related free writing prospectus,
or other offering materials, as applicable, will explain the particular terms of those securities and the extent to which these general
provisions may apply. The specific terms of the rights as described in a prospectus supplement, information or document incorporated
by reference, related free writing prospectus, or other offering materials, as applicable, will supplement and, if applicable, may modify
or replace the general terms described in this section.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
summary and any description of rights in the applicable prospectus supplement, information or document incorporated by reference, related
free writing prospectus, or other offering materials is subject to and is qualified in its entirety by reference to the rights agreement
and the rights certificates. We will file each of these documents, as applicable, with the SEC and incorporate them by reference as an
exhibit to the Registration Statement of which this prospectus is a part on or before the time we issue a series of rights. See &ldquo;Available
Information&rdquo; and &ldquo;Incorporation of Certain Documents by Reference&rdquo; above for information on how to obtain a copy of
a document when it is filed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering
materials may describe:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    the case of a distribution of rights to our stockholders, the date of determining the stockholders entitled to the rights distribution;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    the case of a distribution of rights to our stockholders, the number of rights issued or to be issued to each stockholder;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    exercise price payable for the underlying debt securities, shares of our Common Stock or shares of our Preferred Stock upon the exercise
    of the rights;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number and terms of the underlying debt securities, shares of our Common Stock or shares of our Preferred Stock that may be purchased
    per each right;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which the rights are transferable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    date on which the holder&rsquo;s ability to exercise the rights shall commence, and the date on which the rights shall expire;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which the rights may include an over-subscription privilege with respect to unsubscribed securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    applicable, the material terms of any standby underwriting or purchase arrangement entered into by us in connection with the offering
    of such rights; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other terms of the rights, including, but not limited to, the terms, procedures, conditions, and limitations relating to the exchange
    and exercise of the rights.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
provisions described in this section, as well as those described under &ldquo;&mdash;Description of Debt Securities&rdquo; and &ldquo;&mdash;Description
of Capital Stock&rdquo; above, will apply, as applicable, to any rights we offer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Su_009"></A>DESCRIPTION
OF UNITS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue units composed of (i) our debt securities, (ii) shares of our Common Stock, (iii) shares of our Preferred Stock, (iv) warrants
to purchase our debt securities, shares of our Common Stock, or shares of our Preferred Stock or any combination of these securities,
and (v) rights to purchase our debt securities, shares of our Common Stock, or shares of our Preferred Stock in any combination. We will
issue each unit so that the holder of the unit is also the holder of each security included in the unit. As a result, the holder of a
unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may
provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified
date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description is a summary of selected provisions relating to units that we may offer. The summary is not complete. When units
are offered in the future, a prospectus supplement, information, or document incorporated by reference, related free writing prospectus,
or other offering materials, as applicable, will explain the particular terms of those securities and the extent to which these general
provisions may apply. The specific terms of the units as described in a prospectus supplement, information or document incorporated by
reference, related free writing prospectus, or other offering materials, as applicable, will supplement and, if applicable, may modify
or replace the general terms described in this section.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
summary and any description of units in the applicable prospectus supplement, information or document incorporated by reference, related
free writing prospectus, or other offering materials is subject to and is qualified in its entirety by reference to the unit agreement,
collateral arrangements, and depositary arrangements, if applicable. We will file these documents with the SEC for incorporation by reference
into this prospectus, as applicable. See &ldquo;Available Information&rdquo; and &ldquo;Incorporation of Certain Information by Reference&rdquo;
for information on how to obtain a copy of a document when it is filed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other offering
materials may describe:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those
    securities may be held or transferred separately;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    provisions for the issuance, payment, settlement, transfer, or exchange of the units or of the securities composing the units;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    the units will be issued in fully registered or global form; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other terms of the units.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
applicable provisions described in this section, as well as those described under &ldquo;Description of Debt Securities,&rdquo; &ldquo;Description
of Capital Stock&rdquo; and &ldquo;Description of Warrants,&rdquo; will apply to each unit and to each security included in each unit,
respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Su_010"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated in the applicable prospectus supplement, information or document incorporated by reference, related free writing
prospectus, or other offering materials, as applicable, we intend to use the net proceeds from the sale of securities for general corporate
purposes, which may include capital expenditures, working capital and general and administrative expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Su_011"></A>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may sell the securities through underwriters or dealers, through agents, directly to one or more purchasers, through a rights offering,
or otherwise. We will describe the terms of the offering of the securities in a prospectus supplement, information or document incorporated
by reference, related free writing prospectus, or other offering materials, as applicable, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    name or names of any underwriters, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    purchase price of the securities and the proceeds we will receive from the sale;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    underwriting discounts and other items constituting underwriters&rsquo; compensation;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    public offering price;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    discounts or concessions allowed or reallowed or paid to dealers; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    securities exchange or market on which the securities may be listed.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Only
underwriters we name in the prospectus supplement, information or document incorporated by reference, related free writing prospectus,
or other offering materials, as applicable, are underwriters of the securities offered thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
distribution of securities may be effected, from time to time, in one or more transactions, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">block
    transactions (which may involve crosses) and transactions on The Nasdaq Capital Market or any other organized market on which the
    securities may be traded;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases
    by a broker-dealer as principal and resale by the broker-dealer for its own account pursuant to a prospectus supplement, information
    or document incorporated by reference, related free writing prospectus, or other offering materials, as applicable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary
    brokerage transactions and transactions in which a broker-dealer solicits purchasers;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
    &ldquo;at the market&rdquo; to or through a market maker or into an existing trading market, on an exchange or otherwise; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.9in; text-align: justify; text-indent: -0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
    in other ways not involving market makers or established trading markets, including direct sales to purchasers.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities may be sold at a fixed price or prices, which may be changed, or at market prices prevailing at the time of sale, at prices
relating to the prevailing market prices, or at negotiated prices. The consideration may be cash or another form negotiated by the parties.
Agents, underwriters, or broker-dealers may be paid compensation for offering and selling the securities. That compensation may be in
the form of discounts, concessions, or commissions to be received from us or from the purchasers of the securities. Dealers and agents
participating in the distribution of the securities may be deemed to be underwriters and compensation received by them on resale of the
securities may be deemed to be underwriting discounts and commissions under the Securities Act. If such dealers or agents were deemed
to be underwriters, they may be subject to statutory liabilities under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also make direct sales through subscription rights distributed to our existing stockholders on a pro rata basis, which may or may
not be transferable. In any distribution of subscription rights to our stockholders, if all of the underlying securities are not subscribed
for, we may then sell the unsubscribed securities directly to third parties or may engage the services of one or more underwriters, dealers,
or agents, including standby underwriters, to sell the unsubscribed securities to third parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
or all of the securities that we offer though this prospectus may be new issues of securities with no established trading market. Any
underwriters to whom we sell our securities for public offering and sale may make a market in those securities, but they will not be
obligated to do so and they may discontinue any market making at any time without notice. Accordingly, we cannot assure you of the liquidity
of, or continued trading markets for, any securities that we offer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agents
may, from time to time, solicit offers to purchase the securities. If required, we will name in the applicable prospectus supplement,
information or document incorporated by reference, related free writing prospectus or other offering materials, as applicable, any agent
involved in the offer or sale of the securities and set forth any compensation payable to the agent. Unless otherwise indicated, any
agent will be acting on a best efforts basis for the period of its appointment. Any agent selling the securities covered by this prospectus
may be deemed to be an underwriter, as that term is defined in the Securities Act, of the securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
underwriters are used in an offering, securities will be acquired by the underwriters for their own account and may be resold, from time
to time, in one or more transactions, including negotiated transactions, at a fixed public offering price, or at varying prices determined
at the time of sale, or under delayed delivery contracts or other contractual commitments. Securities may be offered to the public either
through underwriting syndicates represented by one or more managing underwriters or directly by one or more firms acting as underwriters.
If an underwriter or underwriters are used in the sale of securities, an underwriting agreement will be executed with the underwriter
or underwriters at the time an agreement for the sale is reached. The applicable prospectus supplement, information or document incorporated
by reference, related free writing prospectus, or other offering materials will set forth the managing underwriter or underwriters, as
well as any other underwriter or underwriters, with respect to a particular underwritten offering of securities, and will set forth the
terms of the transactions, including compensation of the underwriters and dealers and the public offering price, if applicable. The prospectus,
and the applicable prospectus supplement, information or document incorporated by reference, related free writing prospectus, or other
offering materials will be used by the underwriters to resell the securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a dealer is used in the sale of the securities, we or an underwriter will sell the securities to the dealer, as principal. The dealer
may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale. To the extent required,
we will set forth in the prospectus supplement, information or document incorporated by reference, related free writing prospectus, or
other offering materials, as applicable, the name of the dealer and the terms of the transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may directly solicit offers to purchase the securities and may make sales of securities directly to institutional investors or others.
These persons may be deemed to be underwriters within the meaning of the Securities Act with respect to any resale of the securities.
To the extent required, the prospectus supplement, information or document incorporated by reference, related free writing prospectus,
or other offering materials, as applicable, will describe the terms of any such sales, including the terms of any bidding or auction
process, if used.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agents,
underwriters, and dealers may be entitled under agreements that may be entered into with us to indemnification against specified liabilities,
including liabilities incurred under the Securities Act, or to contribution to payments they may be required to make in respect of such
liabilities. If required, the prospectus supplement, information or document incorporated by reference, related free writing prospectus,
or other offering materials, as applicable, will describe the terms and conditions of such indemnification or contribution. Some of the
agents, underwriters or dealers, or their affiliates may be customers of, engage in transactions with or perform services for us, our
subsidiaries, or affiliates in the ordinary course of business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the securities laws of some states, the securities offered by this prospectus may be sold in those states only through registered or
licensed brokers or dealers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
person participating in the distribution of Common Stock registered under the Registration Statement that includes this prospectus will
be subject to applicable provisions of the Exchange Act, and the applicable SEC rules and regulations, including, among others, Regulation
M, which may limit the timing of purchases and sales of any of our Common Stock by any such person. Furthermore, Regulation M may restrict
the ability of any person engaged in the distribution of our Common Stock to engage in market-making activities with respect to our Common
Stock. These restrictions may affect the marketability of our Common Stock and the ability of any person or entity to engage in market-making
activities with respect to our Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
persons participating in an offering may engage in over-allotment, stabilizing transactions, short-covering transactions, and penalty
bids in accordance with Regulation M under the Exchange Act that stabilize, maintain, or otherwise affect the price of the offered securities.
If any such activities occur, they will be described in the applicable prospectus supplement, information or document incorporated by
reference, related free writing prospectus, or other offering materials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent required, this prospectus may be amended or supplemented from time to time to describe a specific plan of distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
securities we offer other than shares of Common Stock will be new issues of securities with no established trading market. Any underwriters
may make a market in these securities but will not be obligated to do so and may discontinue any market making at any time without notice.
We cannot guarantee the liquidity of the trading markets for any securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Su_012"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated in the applicable prospectus supplement, Clark Hill PLC, Los Angeles, California, will provide opinions regarding
the validity of any securities offered by this prospectus. Clark Hill PLC may also provide opinions regarding certain other matters.
The legality of the securities for any underwriters, dealers, or agents will be passed upon by counsel as may be specified in the applicable
prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Su_013"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of the Registrant as of and for the year ended December 30, 2023, incorporated by reference in this prospectus,
have been audited by Hudgens, LLC, an independent registered public accounting firm, as stated in its report incorporated by reference
herein, and have been incorporated in reliance upon the authority of such firm as experts in accounting and auditing. This report
on the consolidated financial statements contains an explanatory paragraph regarding the Company&rsquo;s ability to continue as a going
concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Registrant as of and for the year ended December 31, 2022, incorporated by reference in this
prospectus, have been audited by Frazier &amp; Deeter, LLC, an independent registered public accounting firm, as stated in their report.
Such consolidated financial statements are incorporated by reference herein, and have been incorporated in reliance upon the firm given
their authority as experts in accounting and auditing. This report on the consolidated financial statements contains an explanatory paragraph
regarding the Company&rsquo;s ability to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="form424b5_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Up to $5,000,000</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Common Stock</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS
SUPPLEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>H.C. Wainwright &amp; Co.</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
date of this prospectus supplement is June 21, 2024.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 65; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>form424b5_001.jpg
<TEXT>
begin 644 form424b5_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  V .T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^D/OTI:C
ME;8I)Z 9H JZAJ%GI=G)=WLR0P)]YV-82_$+PN=N-43D@#Y3W_"O._&^H:YK
MUY(QTR^@TNV)*!HB V.KM7%C&Y.!]]>WN*Y)XAJ5K'U>!R&G6H>UJ3U\NGJ?
M3\;!T#J<@C(/K4E06_RVT7^X/Y5+N%=9\J][(=13=P/2C</6@0ZBF[AC-&X8
MS0 ZBF[ABC>,9SQ0 ZBF[A06XXH &.#5.ZU*SL_]?.B'TZG\JR/$&N/;N;2U
M8"3'SR==OL/>N8CBEN9]J*\DK<XSD_G7@XW-E3G[*BN:1Z.'P/M(\]1V1V)\
M3Z9G'F.?HAJQ;ZUI]TP6.X4-Z-P:Y8>'=3*;O)4>Q?FJ%U9SVDGEW$31L>F>
MA^AKA>:8VE[U2G[OHSI6"PT](3U/2,C&:=7%Z+K<EI,D%PY:!C@,>J'_  KL
M]PQG->]@L;3Q4.>&YYE>A*A+ED.HINZES7<8"T4W<*7-"U 6BDS1F@!:,4F:
M0MBE<!U%56O[=6*F50PX(-60<BDI)[,;36XM-8 CGFES1VJA&-XH&/"VJ$$Y
M^S/CGVKYTCZ1_P"\O\Q7T9XI_P"15U3_ *]G_E7SG'TB_P!Y?YBN'%/5'VW#
M7\"K_70^FXVVP1Y( "*<GZ5Y1XJ^)-Y<7LMGH<P@MHV*M<XRSD=2OH*[CQC?
M2:=X'O+B,XD,*HI';=@?UKQ'1M,.J:Q9:;&VWSI I;T4=3]<5K7J2348]3BR
M3 T9JIBJZNH]'MIN3Q^)M>BF\U-8O?,ZG]X3CZC%;ES\1]:N]&BMUN6AO$ER
M9X0,2)CH1V.:]=TW0--TJS2UM;.%8U&#E02WN37G7Q1T#3]/CM=0M8%AEGE\
MN14&%88SG'K43IU(0;4CJP^/P6-Q,:3HVUT>GY$_PW\0:QJ^OW5OJ%_)<1+;
M[@K <'/TJ[\3=<U31Y=-73KU[82!]^T YQC'6L#X3DGQ/>8Z_9?_ &:M#XP?
M\?&D_23^E-2E[#FN14H4O[95-17+VZ;&+IGQ'UC3[6\-S.;RX? @\X +&.<D
MX'/:L6\\6Z_>R>9/J]R,G@(=BCV %=!\,M!L-9U.[GO8A-]E"F-'Y7)[GUZ5
MZQ>:+I][926LUG T3*1MV#CZ5,(5)QNV:XK&X' XIPC1N]+^7H>.>'_'^KZ5
M?1B]NI;RS9@LBRG+*#W!]O2O:Y+E5LGN5.5$>\'U&*^:+N(6\MS"O*Q.\?X
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M(906D88R3Z@5,J_/!I(VPF3+!8J-2I522>G<Z;X3?\C/=_\ 7K_[-5_XO_\
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:]T5,J*H^4 ?2BBE&$5JD/F;W'4M%%4!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>form424b5_002.jpg
<TEXT>
begin 644 form424b5_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "O 7<# 2(  A$! Q$!_\0
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M ,<YKSO3?BE:W_C(Z5Y*)ILLK6]O>;CEY5Z@CH >QH ]&HIH/-.R* "BBB@
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MUK&CT#05$UJC@&= I3S.<>WO5R/1 M_9W/VJ5UME955^2<\=: -D'-%(*6@
MHHHH **** "BBB@ HHHH **** &LH92IY!&.:Q6\,612WC1Y4B@SMC#?*<G/
M(K;S10!ROBFT@C.FS+$!*;R,;AP<5U0ZUSGBW_5Z9_U^QUT= "T444 %%%%
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MI#TKF_&O_((MO^ON/^= &.WWC1FAOO'ZT<TP+?AG_D9KW_KV3^==E7&^&?\
MD9;S_KV3^==E0 444AH ,"CBL^76]/@>X62Y56M@#*/[N>E1_P#"0:;Y<;&Y
M&UQD''0>I]* ,_Q?_J]*_P"O^+^==)7->+71XM)VN#_I\1'/:NE[&@#%M/\
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MR,'(ZBF_9H,*/)CPO*_*.* .6\47RS-I,/DRJ3>Q'<R_+Z]:ZWM7.>+N(M+
MZ?;XN/QKH_6@#%M/^1LU+_KC'6W6)9_\C7J7_7&.MN@!DW^ID_W36;X=_P"0
M+#]6_F:TIO\ 4R?[IK-\.?\ (%A^K?S- &K7.^-/^1=?_KJG\ZZ*N>\9_P#(
MO/\ ]=4_G0!AFDZTM)0!9T#_ )&C_MV/\Z[6N*T#_D9_^W8_SKM,T +1110
M4@.30>E<_KG]JO<P)8>>JD?-(A&U.>X/)H ;XM_U6F?]?L==!)_JW^AKD_%
MOP^E[WA-O]LC'0A\UUDG^K?_ '30!F>'/^0)#_O-_,UK5D^'?^0+#_O-_,UK
M4 8_B3_D&I_UW3^=:XK(\2?\@Q/^N\?\ZUZ %KC?$G_(S6O_ %[-_.NQKCO$
M?_(RVO\ U[-_.CJ!3[_A3A]X?6FCI]*4?>'UI]0-GP5_R!9?^OF3^==)7-^"
MO^0-+_U\R?SKI*0!1110!1U/3XM3MQ!*2 &#JP[,.E9[>'D^S/;I>3)'(V^3
M&,EL]?:M>XN8;:,R32!$!QD^]1I?VCVC72SH8%SNDSP,=<T 8NK:%8Q>'+E&
MB#^5"Q4].?7BM;2!_P 2>S_ZXK_*H-7GBG\.W<L4BLCP,58'@C%6-(_Y UG_
M -<5_E0!3TG_ )"VL?\ 79?Y5M5C:3_R%M8_Z[+_ "K9H K:A_R#[C_KFW\J
MBT;_ ) ]I_US%2ZA_P @^X_ZYM_*HM&_Y ]I_P!<Q2 O5S7C7_D$VW_7W'_.
MNEKFO&O_ "";;_K[C_G0!CM]XTGO2MUH-,"YX9_Y&:]_Z]D_G78UQOAG_D9;
MWK_Q[)_.NR% !1110 AI-Q Z51UA+N3394LI'CG.-K)C(]<9KF_LWB@QJI=L
M 8B(D&X'/63U&/2@#0\7']UI6?\ G_B_G71^M<AXG6_#Z499(&M_MT60JD-G
MZUUX[T 8UG_R-6H_]<8ZVJQ;/_D:]2_ZXQ5M4 ,F_P!3)_NG^59OAW_D"P_5
MOYFM*;_4R?[I_E6;X=_Y L/U;^9H U:Y[QG_ ,B])_UU3^==#7/>,_\ D7G_
M .NJ?SH Q#2444 6- _Y&@C_ *=C_.NUKB]!_P"1H_[=C_.NTH **** "DQ2
MU!-=00,JRRHA;[NYL9H PO%O^JTS_K^CKH9/]6_T-<]XL(,6F$$?\?L?>N@D
M(\M^?X30!F^'/^0+#_O-_,UK5D^'"/[%AY'WF_F:U<CU% &1XD_Y!J?]=T_G
M6N*R/$9!TU.1_KT_G6OD>HH *X[Q)_R,UK_U[-_,5V.1ZBN.\2$?\)-;<C_C
MV;^= %,=Z</O?C2=,\TJ_>'/>@#8\%?\@63_ *^9/YUTE<WX+(_L:7D?\?,G
M\ZZ/(H 6B@'-% %'5-.BU.V$$I8!7#JR]0P.156VT5+6&: S-)%.&,J,,[F;
MJ:TIYX;:,RS2*B+U9CQ40O[0VOVH7$?D]-^>,T 8^KZ)8Q^&986CWBWMV6,D
MD$"M31P/[&LO^N*_RJOJ]U!<>';V2*9'0PM@@U/I$B?V/9_.O^I7O[4 5M*_
MY"VK_P#75?Y5LUB:4Z?VMJ_S+_K5[^U;/F)_?7\Z (-0_P"0?<?]<V_E46C?
M\@>T_P"N8I^H2)_9UQ\Z_P"K;O[5%H\B?V/:?.O^K'>@"^:YOQK_ ,@FV_Z^
MX_YUT?F)_?7\ZYOQHZG2;;#K_P ?<??WH R&^\:*&*[C\PZ^M)E?[P_.@"YX
M9_Y&:]_Z]D_G795QGAIU'B:]RR_\>R=_>NQ\Q.SKGZT .HI :6@ Q3<=:4G%
M037EO;NJ33(C/]T$]: ,/Q?_ *K2O^O^+^=='7-^+F'DZ5R/^/\ B_G71[AG
MJ/SH Q[/_D:]2_ZXQ5M5BV9'_"5:ER/]3%_6MG<O]X?G0 V;_4R?[I_E6;X<
M_P"0)#]6_F:T9F!AD&1]T]_:LWPZR_V+!R.K=_<T :U<[XS_ .1=?_KJG\ZZ
M'<O]X?G7/>,V'_"//R/]:G?WH Q#0:"1N/(_.CCU'YT 6- '_%3\_P#/L?YU
MVM<5H! \4$9'_'L>_O79[QGJ/SI .HHHH *P]7\/+JMQYOGM&6B\EQC.5SGC
MT/O6Y13 QKCPW87GE_:$D?R\%09#@$=#3_\ A'[0]6G/UE-:U% &/%X;T^&,
M1QB95'82FG_\(_9_WI_^_IK5HH YO6-+TRPTJYO+B.>6*!/,*><><5@W&LV-
MIID%_)87C1RR(H5)SD;O6N\N+>*Y@>&:-7C<893T(J.33[6:.*.2"-TB(**1
MPN!@<4 </<:]HT5]<6MO!=W"PQ+()EGPKDG&T?2K]O8Z7?:U]BO;*6.]6#S$
M;SRX*'MD=*WO^$<T@0>2-/A$>"N ,<$Y/ZU8L]+L[!F:W@5&8 %NI('N: ,_
M_A$M)_YXR?\ ?PTO_"):2.D4G_?PUN44 8L'A?3;9"D*2QH26(60]35RTTN"
MSE,D1E+$8^=R15ZB@ %(:6B@"AJFFIJ=J(79EVNLBL.S#I6=_P (RH@\@73[
M3)YQ.!_K,]?I[5T%)WH Q8?"^GK;>3<(T^6+L68C)/7@=JE7PWI:J%6V(4#
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868M%M89EE02[E.1F0]:TJ* "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>form424b5_003.jpg
<TEXT>
begin 644 form424b5_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "M ($# 2(  A$! Q$!_\0
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MR.M1)8!;1XC<W.Z1A,SB3!/&,?2@#L]P'!(H;&.W/K7%Q:8R6]S'-?7,PNU
M.Y\;2IX(]ZC&GS*%$FH74A!\Q&+XV^WTH ZS3+6>TMW2XF,K-(S@YZ ]JO U
MR-G%)8WL=P;NXFVJ=R._#9K7_MH@D>0./]K_ .M0!;U.UN+RU$=M=&VD#JV\
M#.0#R/QJXO"C-9/]LD_\L!_WU_\ 6I#K1'_+ ?\ ?7_UJ -BBL?^VS_S[C_O
'K_ZU% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>form424b5_004.jpg
<TEXT>
begin 644 form424b5_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $! 4L# 2(  A$! Q$!_\0
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M>W2@#URN?\<?\B-K?_7E)_Z#705S_CC_ )$;6_\ KRD_]!H ;X#_ .1#T/\
MZ\X_Y5T!KG_ ?_(AZ'_UYQ_RK/\ BG<SV?PWUFXMIGAE2(%71BI'(Z$4 8/Q
MO'_%)Z=_V$H?YUZ3;Y%M$ /X%Z_2OC^2:ZO_ "4OM5U.X@W(P1Y"S*>_!X!]
M*W/"VIZDOCK0X1K.I2PM>A&CGF."N>!C^= 'U4.E+2#O2T %%%% !1110!YY
M+_R7BW_[ [?^A5Z$*\]E_P"2\6__ &!V_P#0J]"% "T444 )S7/>,M,TW4_#
MMS_:FG/?PP*95@CSN9ATQBL[XH:IJ&C^"Y[O3+IK:Z$\2K* #C+ '(JG'H/Q
M EB20>,[0!@&Q_9X_P : /+;#P3<6\VF:SJVCW5WI.J3>7)IZ.Q>W7/R%O45
M]$6-G;Z?90VEI&([>%0D:#HH]*XO_A'?B#C_ )'.S_\ !>/\:AT6_P#%&G?$
M*WT#6M7@U"":R>Y#1VXC((8 "@"2#_DN5U_V"%_]"KOZX"#_ )+E=?\ 8(7_
M -"KOZ "BBB@ HHI* %KSSXF_P#(6\&_]A9?Y5Z'7GGQ-_Y"W@W_ +"R_P J
M /0AWI:0=Z6@ HHHH **** "FMT-.IIZ4 >'ZW;Z_JVJW.?"L^F1+*=MU81_
MO9 #][=7J?A".6+PU:QS&^\Q00?MQ!F_X%BN4\=JS>(K7[99Z[=6 M^%TUBH
M1\]6QUKK/"2Q+X<MO(MKVWBYVI?$F4<]\T+8#5:T@>ZCN6B0S1J520CE0>N*
MK0:)IEK-/+!86\;W Q,R1@%P>H-66O+=+I+5YXQ<.I98RPW,!U./2J]MK>EW
M<\T-O?V\DD )D59!\@'4FD@);#3;+3(/)L;6*WCSDK&N!FN.\0?\E:\*C_IW
MN/Y5V-IJ5EJ"N;.\@N APQB<-CZXKCO$'_)6O"G_ %[W'\J8CO:Y_P <?\B-
MK?\ UY2?^@UT%8'C16?P3K2HI9C9R  #)/!H&,\!_P#(AZ'_ -><?\JR_BW_
M ,DPUOK_ *H?S%:O@96C\"Z&KJ586: J1@CBLKXM$_\ "L=:Z?ZH=?J* /GF
M%9OL=D&BMC;F/Y=^ A7(W<CDCU]*T?#HD'CO0ODA"B_4,81P>N/PQTK'A:U-
MK9J8F#!,,RN=Y/N.F?0=#WK4\,- ?'6A")2I-\N"[9(^G]:!'U<*6D%+0,**
M** "BBB@#SR7_DO%O_V!V_\ 0J]"%>>R_P#)>+?_ + [?^A5Z$* %HHHH X+
MXP_\B!-_U\P?^C!7<6O_ !Z0_P#7-?Y5P_QA_P"2?S?]?,'_ *&*[BU_X\X?
M^N:_RH D-<'=_P#);]._[ \O_H8KO37!7?\ R6_3O^P/+_Z&* &P?\ERNO\
ML$+_ .A5W]<!!_R7*Z_[!"_^A5W] !1110!!=7,-I \]Q,D42#+.YP!]37-3
M^,!'XVL]#CABDM+BU:Y^V"484#MZ5NZQIUGJVF3V5_#Y]K*I$D?]X5\[S>$+
MF47/B.TTB]CT.UN?LXTPR-YKQ9PQ'<<]J0'T=:7EM?1>=:3QS19QOC;<,UPO
MQ,_Y"W@W_L++_*NJ\,:3IVD:#;6^E6C6MJR"186SE2W/.>]<K\3/^0KX._["
MR_RI@>A#O2T@[TM !1110 4444 %-89!%.I#TH Y6X\.:VDC'2_$UQ!$Y+>7
M/$LH7/H:T-(T:[L9VN;[5[F_N&79\X"(H]E'%<IX_O=2L=2M95.H_85 *"Q7
M.Y\\[_PZ5T_A*349?#UN^J;_ +2Q9AY@P^S/R[O?%" P[O2;:T^)EA?+'(S7
M%K,9Y&8L ,=!Z"N8L;K2=?O=3>T1M/BMK66VM8(H&\QU)^>1O7V%>OE 2#M&
M?7%-6WB0Y6-%/J% H X/P$'BAU*UL(K>2VB11;WHMO)\U\=&'?![UB0_\)1_
MPM?P[_PDWV'=Y$_D?8R>F.<YKUE4"C 4 >U<+X@_Y*UX5_Z]KC^5 '>#I7%>
M-]0\7Z7%/?:+'IITZVMS)-]HR78CDX%=INK!\:\^!]<_Z\Y/_030!E^ ]1\5
M:M91:CK::<EC<0+);K;9W#/8YIOQ:_Y)CK?7_5#I]16GX%_Y$/0_^O./^59?
MQ:P?ACK8S_RR'\Q0!\XQN\EC9P&4>2J;5+$!-K?>P<9QZ^G:M3PNS#QWH2>9
MO4WR9V]..!_]:LJ".5X+2);?]]L +*/F);[I(Z9],<>M:OAE'C\>:$KPE,WR
M@%AR".M CZP'>EI!WI:!A1110 4444 >>2_\EXM_^P.W_H5>A"O/9?\ DO%O
M_P!@=O\ T*O0A0 M%%% &#XN\.1^*M"?2Y+B2!6D23S$&3\K9Q6U$OEQ(@YV
MJ%S7+^.;/7)=,>\T?7&TT6D3RR*L0;S<#('/2N>^%K^)=;TNT\0ZIXA>YMID
M=39F(  YQG- 'IAK@[O_ )+?IW_8'E_]#%=Y7!W?_);]._[ \O\ Z&* &P?\
MERNO^P0O_H5=_7 0?\ERNO\ L$+_ .A5W] !2-TI:1NE '&:WXYDL-;FT;2]
M$O-5U"W19)8XF"A4;H<GK5'_ (3KQ+V^'VI8_P"NR4FCC_B]WB#_ +!T/\Z]
M"Q0!Y\_C[Q+&I=O &IA5!9CYZ< 5E>+-;M_$4'@+5;566*YU-6"MU4XP17IV
MH<:==?\ 7%_Y&O#[/_D2_AQ_V%CT_P!YJ />!WI:0=Z6@ HHHH **** "D;A
M2:6D/2@#R'79=4AUZ34(=3\31P3J56&WLPXCP>GTKO/!:+'X7ML&^8L69FOE
MVRL2>217)^)/%3VOC$KI/B'3+9XK?9<0WK'9G/8#O77^$-6FUSP[!?W,D,DK
ME@SPJ0C8.,C/:A; 6F\1:8FN)HOVI6OWC:3REYVJ.I)[52MO&^A7,EVJ73*+
M5&D=W0JK*#@E2?O#/I5._P!$;_A-K&\MK15B:VG6>91_&1@;C7'MX6UO4+&.
MP-B\#:=:2QB1R-L[,VY0OUH0'I&B^(;#Q!!)+8O)^Z;:Z2H4=2>F0?4<US&O
M_P#)6O"O_7M<?RJYX8LM0FU#6-3N+::P^UI%%"DF"X*+@MCZUS,>CZGI/Q6\
M.KJ>O3:LTEO.4:6,)L^F* /1M>9H] U&1&*LMM(58=0=IKY/@GU;4-+\R?Q#
M<*LAV-!+,QW(>KG_ &>V.M?5_B#_ )%S4_\ KUD_]!-?(VG-&-("N)2WGAOD
M8!<<]CSN]^E %]9M7TYHD36KJ*.*1%6 3GY1D87CCD<U] ?$\D_"35"<DFU3
M)_*OG3*!XP0P.]?NG"_>'0'D#'6OHOXG?\DCU3T^R)_2@#Y\@>(V=E&;W"A-
MI+@^4 <9QCD#U_2M/PT\?_"=:$$N3+_IZ],XXR,G/Z>U4;<W/DV100>?L7.T
M#S">-NX'C/I^M:.@&4^.]!,WEY_M 8P!NSSGI^M CZI'>EI!2T#"BHKFXBM(
M))YW"11J6=ST4#O7*_\ "S_!>,_\)!:X^IH Z^BH+2[@OK2*ZMI!)#*H9&'<
M&IB: //9?^2\6_\ V!V_]"KT(5Y[*1_POBW_ .P.W_H5>A"@!:**:_ /L,T
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M$KX<?]A8_P#H35[?J'_(-NO^N+_RKQ"S_P"1*^''_86/_H34 >[CO2T@[TM
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M1N(8-7N9(Y9E+HD<3.=HZDX' KS$_$WPNWQ57Q +N8Z<NG?9VE$+</NS@C%
M'N,<211JD:*B*,*JC  JAK6MZ?X?TV34-4N%M[6/&Z0@GKVXK)\,^/M \7SS
MP:-=/+)"H9U>,H0#QD9%=#<6=M>V[074$<T3=4D4,#^!H X:'XI^ [K4HFAU
M&-[R3$2.(#N.3TSBN^4UYMX,T;3/^$^\8K_9]MBWNH?)'E#]W\F?E]*]+Q0
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MEV]K"UPCQ!92@W ;QWKH_!O_ ")>C?\ 7G'_ .@BL/XM?\D[OO\ KI%_Z&*
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M ,EG\/?]@V:M74O^1:US_KY/_H2UE:C_ ,EG\/?]@V:@#T*O*_"G_)=_%O\
MU[1_TKU/< <9%>5^%"/^%Z^+3GC[/'S^5 'JN*6FA@>X_.G4 %%%% !1110
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M (U_Y'WP3_U]2?\ H- &EJ7_ "+6N?\ 7R?_ $):RM1_Y+/X>_[!LU:NI?\
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M"GA[^P]'BM9R))E=G&3N\K=_"I/.!0!T(S2T44 %%%% !1110 4444 %%%%
M!112;J %I*PY?&7AN&9XI-;L4D0D,K3 $$<&FCQMX8/37;#_ +_"@!GBGPK;
M>);+:S&"]BRUM=1G#1MZ9Z[3W%:6C6+Z?H]K:R1Q+)%& XA&%W=R/K5#_A-?
M#!_YCVG],_Z\5<&OZ2;!+\:A;_9';:LV\;2?3- &3XW357T;_B7*SPJ^;N.-
MMLKQ=PA[&N8\+>&]+\1+<WN;N73E(2T:28K*%_CC?G)7/8UW8\1:-)!-,NI6
MWEP@&1M_W?K4.BW6A22SIH\MLS.?-E6$]2>^*2 U+>WCMHDAA18X8U"HJC@
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10!1113 04M%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>form424b5_005.jpg
<TEXT>
begin 644 form424b5_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $/ 8D# 2(  A$! Q$!_\0
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M#F?[%@RH0Y?*CM\QH UJ**,T %%)D>M+0 4444 %%%% !1110 4444 %%%%
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M&U@#70VUE;V[%X8]I/!.2:ZJ4915FSY_&UJ=:KSTH<J[%H&EI!2UJ<84444
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M "C H Y:R\()9W<4JW>Y$D$K?N\.SC_:[ ^E=.HYI<"E Q0*P4444#"BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW5C:10RJS%HR<C ]Z]E'2N.M2G1ERS6H"FLG68],G^SKJ">8T<@DA09+%AZ
M5J]ZQ[;YKG4[R0?OXF,:G&2J@9&*S IVFG:#9WMLZVCV\Z.[Q-("!N;KS72
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MT6!@6CB) .X<5Y_]@OO^?"ZX_P"F+?X5]%7FIW/]JW5I:I;QI9QK)(9N/,#
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M5U"L&4$<@C-5[=X[BVBG1,+(H<9&#@U8 XQ6R5E8\J<N>3EW'4444R0HHHH
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+N* * '4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>form424b5_006.jpg
<TEXT>
begin 644 form424b5_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (: 84# 2(  A$! Q$!_\0
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M+]S_ -_A1_PTG8?]"_<_]_A_A7SLW6@4 ?1/_#2EA_T+]S_W^%'_  TI8?\
M0OW/_?X5\[$<\48.* /HG_AI.P_Z%^Y_[_"C_AI2P_Z%^Y_[_"OG84E 'T5_
MPTG8_P#0OW/_ '^'^%'_  TG8?\ 0OW/_?X5\[#B@G- 'T3_ ,-*6'_0OW'_
M '^'^%)_PTG8_P#0OW'_ '^'^%?.W6GJ"Q '7W- 'T-_PTG8_P#0O7'_ '^'
M^%'_  TI8_\ 0OW'_?X?X5\]2(T;E6P2/2F8H ^B?^&D[#_H7[C_ +_"C_AI
M.P_Z%^Y_[_#_  KYUQ4D:EB !DGB@#Z)'[1EHR;QX<NROKYHI@_:1LF;:/#U
MSGT\X?X5X(UW)'&8-V1]T_3_ !HM! ;D,'VJHZ$9)/M0![\W[1MHHRWARY '
M_38?X4S_ (:2L/\ H7KG_O\ +7@%X\GVAM^>>>1C(JN&VME0/QH ^A_^&D[#
M_H7[C_O\*OZ)\?[/6M<LM,30YXVNI5B#F4$+GOBOFAFW')P/I70^ _\ D?-$
M_P"OM/YT ?;8Z5Q7Q#^(,/@"TLKF>QDNQ=2,@".%VX&<UVM>(?M)#_B0Z)_U
M\O\ ^@T 1?\ #25@.GAZY_[_  H_X:3L?^A?N?\ O\*\N\(^'?#M[X:U'6O$
M%S>116MQ' BVV/FW GG--\4:#H4?ANSU_P .7%PUG+.UM)#=*!(K@9R#W&*
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MI4=<;M@ZT 80K;TG3(IH1>2RY5#R@'-8SE2Q(& 3P!VJ6&ZE@5EC<J&ZC^M
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MQ[T8]Z #<:-QHQ[T8]Z 'I/(BLJN0K=0.]'F<8VCCO3,44 /WER QP!TK?\
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M:CKEAI=FUW=7 6!6V%T!?!_"I=.U&VU:PAOK*42V\R[DD (##\:P+#P_>1>
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M1_\ OU/_ /%4HAT\,")]&_[]3_\ Q5;WD0<?O)__  .2@00;A^\FZ_\ /\E
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MG5C(47:,AB.!^%>23$BTFSNR\<@ 'RY+?=X_B&.W\?7BO2?@[_R2[1O]Q_\
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M[7[.XU?0OM$UV0%NT&3O!X!YJ]X[U+6]+T:&;0HGDD+[6V1[ST^48],T =:
M >!7FGQ"'_%Q? 0_Z?'_ )5T-]=ZLXMY;:66&5+)IIU\O*%P,;<=<Y.:\^U;
M4]2U'Q?\/9+ZQDA_TI_WTCY,K=.G4#OS0!2\?6\$_P 8IO.@24I81O$&7<=^
M>-H/!;T!X]:J'3K-Q@Z?%MP1CR5'RYRWX;NIZ@\#BM#QPVWXOWPQG?I2I[ $
M]6]0.ZCDCI5-5 8D&,X(;A""=JX')[^AZ <')H C-C;,P+Z>A<DM\UN@.XC#
M<#C(7J.@'(YKH?@[#%!XL\41P1I'$JP[%087&#C'M[GFN?0!8@@$)RBKE48
M -D<'G'H.H/)XKH_A&=_C/Q8V,%C$Q!Y(Z]3T)]2.* /81TH/2CM0>E &7;?
M\C)??]<(OZUJUE6W_(R7W_7"+^M:M !WKQ_P^7'B?QELBF?_ (FIYCLEF ^0
M=STKU\UXIID)D\5>,& LS_Q,R#Y\LRG[HZ!#@_SH Z_?/_S[77_@H3_&@-.6
M'^C774?\PA*R?LQXXTK_ ,";O_&@6WSCC2NH_P"7F[_QH U/A22=&UC((/\
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MO/\ P9I_A2B:Z#+^[O.H_P"8FG^%=!OO?^>'_DB/\:!)>[@/L_I_RXC_ !H
MR/A,2=#U<L&#'5[C.Y]Q[=^]>@5P7PN).EZV6&#_ &Q<9&W;CIV[5W>[!Q0
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M')'%=& *K65E!8VD5K;1B.")=J(!PHJSTH 7 J.1TC&7=4&<9)Q1)(J*68X
M&2:X+5O%NFZ]>V^A+827EG>$I*X8QNC*V/E'7(.#].: -#4?&BQ:Q!9Z9"+]
M1N$X@.YPP. H';W)XXKKTR4!(P<<C/2N<\->#[#P\S3)B>^8%6NF4!V4G.#C
MJ?>NE'2@ P/2D-!-8VM^(++1%B%W*4DG5O)!!VNP&=N>@- #M;UZST:QDFFG
MA\W#"*-Y -[ 9QGM4/A76;O6M-:>\M&@D5@,E2JOD9RH/.!G&>^*Y:QT"P\<
MO;>(9H#"DI(N[1OWD<V!@,I['MFO0H(UAA2)%"HBA54= !T% $@%! S2BB@
MHHHH 0C-&WWI:* &[:, =:=4,TH2//5B#M7."Q]!0 LLL<4+RR.$C0;G9C@
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M!BEH **** $()/% &#2T4 %%%% !1110 4444 %(1FEHH 0+SFEHHH ****
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MH^)K#3)+2.3SIY+OYHH[>(NVSCYR!T49&30!M9%&:\\M/B%J-[XA?3+?2X)
M;F6V0K(Q:,J.'D&.%-(_Q"U&PTZ*_P!5TVV2![UK0^1*6(V!MQ_\=X% 'HF1
M2UQ>F>+]1DUK2[#5M-AM5U6%YK1HI"Y&WG:_O@@UV2G(H =1110 $XHS2&N
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M21;ET\PR2.TY+3$\'>3]X5HZ;X5TS2=1DOK-)(V==HC\P^6@/7"]NE;G%!H
MB2VACEDE2-1))C>P'+8Z9KF;KX>>'KRYNI9H)F%PVYH_.;8C9R2J] 21S75Y
M&<44 9FKZ#8ZY8Q6E]&7ABF29%#8PR'*_K5'4/!VD:C'.)HI5>>X%R98Y"KK
M(!C<I'3BNAXI: ,_2-'L]$L([*RC*0H2?F8LS$]6)[DUH444 %%%% !1110
M5B>(K&ZO;:T%H\H:*[CE=8WV[D!Y!]1[5M9%5;V_M;!(VNIEB61Q&FX_>8]
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M0>1TK5TGQ+X?UR=X--O;>YD0;F5%Z#\10!E6]WJ<>AQQRZO9O>[296!_B)Z
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M<C[V[%=U+86MQ<I<R0JTZ(463H54\D5YOX2>VNO&4&JB-6O-0B>2XA1'46C
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M_P#H^2@#E]:8G4O ^23_ ,3RZZG_ *:5[[7@6L@_VGX'_P"PY=?^C*]\R!0
MM131M)&ZJQ0L" PZC/>I:* .9T7P9I^C7[ZFS37FJ2+M>\N&RY'H . *K7_B
M#4;7QU9Z6L"_V?(@$C%3G)!^;/M@#\:ZXU&R*QW$#.,9(YQ0!P$_BS6;=M1D
MC>UO+6UN@F8U*N4QRJCN1Q]3FL[PGJLVL?&'6;F?3;G3V&FQJL=QC<RYX;CI
MFO3A#""V(X\DY.%'6N$L/^2Y:OW_ .)3%_Z%0!Y5X<57L[[=C_C^G3_6;!C>
M2>/_ &?MTK78.#O4M\PR0L>_#=.G\/'\';[U9GA1G-G>J@;_ )"TIX4$;LG
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M8.-<M/:^F_\ 285JZ!_R%I?]RQ_DU &=IVE:?IWC_P .-9V4,#O+?*S1KM+
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MVO?^$TMO/MFD:)OLOW2X^;\Z[7PGI/B;3#<_\)#KL>J>9M\K9%L\O'6NHHH
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MD=!W![XQ76Z'X;L=$1GABC:XD.9)@F,]N!_#]!QF@"MX2\*0>&=-$495[J0
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(>G% ".P49)
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5%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>form424b5_007.jpg
<TEXT>
begin 644 form424b5_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $A E(# 2(  A$! Q$!_\0
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M_:4W^E#R_FX'RC<<\5U'PI9!X,6%)G9HKF4-;N#NM,MGR3GGY0>M '=4444
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MU75I3M^WB[MX(V!4ML"[F;J>_%5[?P/J,=@]NJP0-)K$MWOC;E8F! /U&>E
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M7\0G4?[3T@Z>MO-LA))_>+V/Z4 =;1BA3D4M !BDI:* "BBB@ HHHH ****
M"FG(.13J* .%7PSXLL+[4GTC7;"&UN[I[D)-:EV0MC//X5M>%?#9\.:=-%)>
MR7MU=3M<7-Q(,%Y&ZX'8>@K?[4N* *>HZE::592WM].L%M$ 7D;H,\"LNX\9
M:!:M<K-J2*;7;Y_RD["W0'CK6AK&F1:QI-SIT[%8[A-C, "1[C/>N:U+X?6F
MHSS7#7TT4KJ C1H/DX .?[V1Z],T ==%=0SHLD4BNK*&4J>H/>I@<UY+-I<&
M@_&_P];6#S1Q3Z<_G+YA(DV\#(Z=J]:% "T444 %&*** $Q2XHHH ,48HHH
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M?\EY\+_]>$W\S7IPKQQAK'_"[O#!U=K<M_9KF,1 [AQ\V_WSZ5[&* "BBB@
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M.E;WAKQSHOBNXN(-+EF:6W57E66(H0IZ'F@#IJ::4=*1NM 'D7CP_9_'4=Y
MET\D$<;O$LNPS#/_ "S'H.^*N^(KVVU_7X+.YO;2S"B)H8[B,[LNNX@MD':<
M8QTH\67=M#\1[(32><X$8",&Q 2>Q' S[U>\::M)I6MQ";PYIMW#-%F.\N9
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MEYYW =3Q796FU+"  J0L8 *#C&.PH Q?'W_(@:[_ -><G\JC^'/_ "3O0/\
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M.I)X P?XNWIWKTCPIS/\3.X^U2?^BS7$:!A?#^G!2K#R.H@*_7@]?<?Q]NE
M%=O#H4E?[;U<<$Y-RWR 'EB.I"]#CDGIQ4=YH+VUC<S)JFM,\:M@?;/X@N0O
M7KWSTQQUKH"<2H%!8Y&"'Q@]@#_!_O'[GW35+5L'2+T?*%\AP#Y1.1C.<?\
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M.3GK7FO_  N?QU_T&#_W[% 'U]C'88JFN?[8<<8\D?SKY,_X7/XZ_P"@R?\
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M]>TH7LJ"-512N57T%>^GH:X?Q!X9U&^\96>K6:1J(D5?.DD)"8_V,=?0C\:
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M% !@4FT>E+10 FT#M2T44 %%%% !2;1Z4M% ";1Z4;1Z4M% ";1Z4;1Z4M%
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M/C[6"1SYRC'K\HYK%10SCCI79"A&44[D:GNS_%;PL@R;BXQZB TP?%KPF?\
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M4B%JR&23)Y)J-\%>.M5C.'D*@GY:DB)=@!T]:V4&CH4DA-I+8[BKL=MOB;#
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M7IOO'M[(5V[=/*]<_P 8J*\TT1*UM#Z1HHHKD("BBB@ HHHH **** "BBB@
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M''^C2_S%=#6L(\JL=,+VU"DHS15%GSOXSO4@^(&KHV!^^'7_ '145C>0R/\
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M"LZB35S.,NAZR#Q2TE+7*:!1113 **** "BBB@ HHHH **** "BBB@ HHHH
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M87V'Q%_T&K7_ , __LJ0V/B+_H-6O_@'_P#95O4E &#_ &?XA_Z#-K_X!?\
MV5+]@\1?]!FU_P# +_[*MVC% K(P[32-075X[^_U".X,4;1QI'!Y?7J3R:W
M*6B@84A'%+10!YSK?PIMM:\0W>KMJLT3W#!C&(P0N!BIK7X9K;01P'6;B2&-
MBR1L@PI/4BN_HJ_:2M:Y+BGN<WIWABYTV7,6KS&/))C9 0:U4L)5+'[2=QZG
M;5^BIYF]R?9Q,%O#K&X>87K[F.<[>14IT+.S$X^4Y)V#+'WK9HHNQ.E!]#..
MG2EL^>O_ 'Q3OL$O_/9?^^*OT47N+V,.QDWNFW<\&+>[CBF!R)&BW ?AFJ9T
MKQ">FMVP_P"W(?XUT5%(I4X+H<]_9GB$K@ZW;?7[$/\ &@:7X@ Q_;=M_P"
M0_QKH:* ]G'L<[_9?B#/_(;MO_ (?XTX:9KX_P"8S:_^ 0_QKH** 4(KH8/]
MG>(.VL6O_@%_]E1_9_B#_H,6O_@%_P#7K>Q1B@KE1A?V?X@_Z#%K_P" ?_V5
M!T_7S_S%[7_P#_\ KUNXI<4!RHYN31=:DSG5K4$^EF/\:I3>$M3G^]J]N#ZB
MS _K78XHI60E!'#+X&U-6!&O+QT'V4?XU:T7P=/IGB9M;NM3^TS&V-LJ+"$
M!8'/7GI778I:2BEL4DD(.E+115#"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBBD 4444P"B
MBB@ HHHH *2BB@ I:** "BBB@ HHHH **** "BBB@ HHHH ****0!1113 *2
MBB@ HHHH *6BB@ HHHH 0T444 +1110 4444 %%%% !1110 4444 %%%% !1
9110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>form424b5_008.jpg
<TEXT>
begin 644 form424b5_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &, 8(# 2(  A$! Q$!_\0
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M/T-<9&Q3&14H1?O$\>M2Y697*CK)/B3K2](+4_@:5/B3K#KG[/;?D:Y!BIR
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MGG^U*B0?ZT."I7TX/K0!JT5G6&MV.I2O%;2DRH,M&Z%6 ]<'M6@#F@!:***
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M/3!FC%8WA[Q5HWB>T\[2[Q)2OWXCPZ'T*]16SFM#F%HI"V* <T &*:1FGTE
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M_/6XO6W\^PZ"NTVY/6FR1B2-D).&&#CTH \ZT_0]*7XK:A"-.M1&EG&ZIY0
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M&K7V'XH?]!;1/^_+5V&C:I:ZOI%K?V6/(F3<H ^[ZK]0:T,4"//_ +#\4/\
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MO^#KR?Q#!-H=H;5\Q;M0%R5VHG&S8.O%<\FCWMU8Z7XE\.S:F)K:X55L+O\
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MR&>U?=\\98Y9"/2N7T71-5T?QKI^IV-S>WEAJ4)6Y6[3#PJ/N[CW(KTX 8H
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M#@2%#]UO>KOA#P7<Z;JEQJE_:6=B)81"+"T8O&0/XF+?>-=XBA%"J %'  &
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MTJZT3^WM'OV;RIDCW3B1NBRGN/\ :[5TGA3P9#9:+IYUFUAGU"V+-$S_ #M
MI/"9[XKM*04 (!QT-':G4AH X2Y\5ZMJOB2[T/0$M;::S&9'OP09/]Q>X]ZY
M35+6_P#&5S="?2B^LV4B6][:>=A8X\95X6[$GK7HGB/PG:>(5CFWR6FHP\P7
ML/#QG^H]JG\.^'(/#\$@622XNIVWW-U*<O*_J?;VH Q8?!4U]X3MM)US4)+B
M6-U?S2H,B '(0-UXZ9KLXD$:*@Z* !GKQ3Z* "BBB@ HHHH **** "BBB@ H
MHHH **** "@T4C D<4 <_K_C'2?#\BPW3S2SL-WDVT9D=5_O$#H*Y37/%O\
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$ '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>form424b5_009.jpg
<TEXT>
begin 644 form424b5_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $U A$# 2(  A$! Q$!_\0
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MZO;&<6A)B0' YXYQ0!YG>Z1IW@[XR>&+?PR3!'?HPO($D+*R<_,?\:>5^W^
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M&*,#@^AJ8=*^??A7J_B2XU^33_/M=-2YG.I2PRQ'?=1MW3T%?0(Z4 +1110
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M#;GQ/Y>A>$[S3+SR6/GRQ%5V]QFO7!TI@+BBBB@ HHHH \(U+_DYJT_W%_\
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M%"I+*/'NHC +!?*7 ]JDTWP7XD2:UNIO'&H3("KO$T:X8=2* /0J*;SZTZ@
MIDDBQ1EW=44=68X JO?:C9Z9!Y]]=16T6<;Y7VC-86IZ_P"$-7TZ:POM8T^6
MUF7;(GVD#(_ T ;@U&R[WMM_W]7_ !J2.\MIG"17,,C'LD@)KR^\\._"Y%@\
MF73CF95;%X?N]^]:^D67PWT+44O]-O-.@N4!57%WG@]>":5P/0%^N:6L>V\3
MZ#>7"P6VKV4LSG"HDP)/T%:PYI@.HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH Y;XAZS_ &%X"UB_5L.("D?^\WRC^=1?#31_[$\
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M ")UY_U_25ZC7E_P,_Y$Z[_Z_I*]0'2OCZGQ,_1:?P(****@T"BBB@ HHHH
MSM:NKZST:ZN-.M!>7D:9BMRVWS&],]JX;Q!K7BV86\*> [?4H6A6202R B.0
M]5P?3UKTCMFO*O%::_K?Q$.BQ^))-"T^.T$L#1D SL3SU]*0&QX+U/Q&^I&R
MOO!<&B6&PMYL3#ENPP*[T&N$\)>%=3T?63<WGC2YUB/RROV:1AC/KP:[L4P'
M4444 %%%% 'A&I?\G-6G^XO_ *#7,?';_DI!_P"O./\ K73ZE_R<U:?[B_\
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MCXJ>.[O.<2QP@_2O5*\M^%'S^)?'$GKJF,_A7J5 !3>U.IO:@#YN\0?\E/\
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MM%%=) 4444 %(:6D[4 <]XZ_Y$76_P#KT?\ E7*>!B?^$$T;G_EW6NK\=?\
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MR=<^)^(_/\X_C!1117.>*=7\%_\ D=_$?_7"/^=>VUXE\%_^1W\1_P#7"/\
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MR.VA?]>\G\ZY.NL^,/\ R.^A?]>\G\ZY2N?$_$?G^<?QD)1117.>*=7\%_\
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M_0D6_P#W_P#_ *]'_"7?%7_H2+?_ +__ /UZ]7HH \H_X2[XJ_\ 0CV__?\
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MO-':WN5%[C]VC=@373QRI(BNC*R,,JP/!%>'#5+#1XV\/Z_J$&N^#]2<BVU
M2B22V<G@/W'L:ZOP/:>)/#&L_P!@3 ZIX<>,RV6H!LF)?[C'O3 ]*S124M
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M7%C>W<JW76*5OE7WQW/O3 J^#O &F:-?)K5A<Z@EM,F^#3YG(2WW\D8KO0*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% "&E%%% !1110 4444 %%%% !1110
/ 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>form424b5_010.jpg
<TEXT>
begin 644 form424b5_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $[ 94# 2(  A$! Q$!_\0
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MM=-FO8Q%>Q/#YBN!T8>A_K5WP'X)D\%PZG')J37S7US]H,C)M8<<Y]37944
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M6_;!LDLQ:BV\OICOFLS4_ &IOXVN_$>CZQ#:O>0B&=;BV$K(!WC)Z5Z%28H
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MR["<'TK9T3Q7I'B&:6+3;KS7B +KM(X/2K52#V9RU,)7I)N<&D;HI:XW2/'
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M.T9S0!1_M_2MJG[?#@JA!R>CG"G\3TH?7]*C!=[^%0 Y))/1#A_R-7OLT/\
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M2Z[>-9V<;+*MPC8:*13E2OJ<]JQO#_B3Q:?&::%XFL=.M%EM6GA:WD+%\'!
M^G>MWQEX;7Q3X>?3C=?99EE2>"8J"%D0Y7(/4>U 'C;>)(;A6@O/B%XH73G
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M\ B41RL^XNN."3WJY4<,4<$2Q1(J1H,*JC  ] *DI %%%%, /2FTX]*8QP*
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M[^ZTCPYX5M[:*YD@V7\2^<2IQN;CO7K&B1W,6BVB7D=M'<","1+88C4^B^U
M&B.E)CFEHH X'6_AL-5U#5)+?6[JSLM6*G4+1(U82E>X8\KFDUGX9P:C=SR6
M6KW6G6UY;1VM[!&JL)HTX7D_=..,UW^** .1\5:!I,?@[42=.MF>WL&CC=X@
MS*JK@<XKDOV>?^2?S?\ 7X_\A7H'C#_D3=9_Z\Y/_037GW[//_)/YO\ K\?^
M0H ]<HHHH 0CFO"_C+ _A_QMX=\6P+CRY%20COM.?Y&O<SUK@/C#HG]M?#^]
MVJ3+;8F3'7CK29<-['=VMPEU:PW$;!HY4#J1Z$9J:N ^#VN'6_AU8%VS-:9M
MI/7Y>GZ8KOZ9+T84444""BBB@ HHHH **** "BBB@ HHHH *H:Y_R -1_P"O
M67_T$U?K+U^XABT+4%DFC1FM9<!F S\IH \O_9T_Y$S4?^OS_P!E%>R5XO\
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M::P..M @R*&/!KAO')U[3;6XU:PU?R+:-5'V;R@<DG&<UG:IK>L>%M!DGO\
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M&=CA5!))["N?;QQX;'_,7ML X)W<"MN[(%I,3&90(V/EC^+CI^-?.3:U;_\
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M/:3V/@C1[6ZB>*>*V5'C<8*D=C7D%QJ5A=ZKJ@\2_$C4M-OX;R2/[/:-^Z5
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M\WH *Z+3?A]\2/ 5J)_#^N6]^BG+:>V=K#V#=_IBE;6YIS*UK'NP/K2FO+=
M^,NFS70TSQ19S:%J8X83 ^6Q]CVKTV&XBN(5FAE22)QE70Y!'UIF2)#]:\A)
M)_:9 _ZAG]*],U?5;?3+"::6XBB*H=N]@.:^;X_&6J?\+07Q [0_:A#Y3_+\
MNSV_"LY5%%V.NEA*M6/-%:;'U".O7-.KE]/\=>';]%\K58-QQD,VTY_&MJ75
M=/CLVNWO;9+=!EI6D&T?C5*2>QE.C4I_%%HNMTK!\6:Q<:'H<E[;+;&1#TN9
M BX[\^OM7":S\8FO[UM)\#:5-K%\?E^T;2(4/]?J<"LU_A%XC\86\EYXS\22
M_;'7,-M#S'#]1T/X53U,U9.YRWPQ^(L>@WMS83O:PV][?--+-,Y 4'K7O5CX
ML\/:C_QZ:W8R^PG&?UKP;X7?#C2]3?4-4U6XCELK&YDM9;>:/Y74?Q9SP:LZ
MSX0\+^(]:&G^#M&=9(SB2Z61A&OX5FVH'5"E+$:Q5DMWT/6/%/CRTT;%I8@7
MVI2<1P1'=C/0G%8NB^"-0UN^76_%TC2R'F*RS\L8]Q_2L6W^ J6J1W%IXGU"
MWOU&2Z $ ^W>IV\ _$O3EVZ;X\,T:G*I.IR?;)S2Y.9WD6L2J4.2DK/J^OR[
M&A\6_P"P8?!&I0%;)=26.,1H57S0N\=.^.M=?X8FT*2SC&D&Q,@AC\[[,%!S
MC^+%>#_$F?QQI6DX\5PZ'+]L BCGA0><-N#D$<XKK/A[\6_!_DPVE[9Q:-?E
M%2294'E2D<9R.F?>M$FCFDXM;NY[:*6J]M=6]W"MQ;31S0L,J\;!@?QJ<&F9
M"T49I,B@!:*,T4 (>E5;RPL]2@^SWMM%<0D@F.5 RY'?!JR35'5-;TW1;<W&
MIWT%K$!G,K@?D.] 'EWP<T/2;K3];FGTVTEDAU:41,T0)0 \ 'MBO7QUKR#X
M%:S8W</B&RAF!G_M![D#^]&QX(KV&@ HHHH **** "N#^*%I82^'[:ZOM;?2
M?LER)8KB&/?(7 .%0=<FN\KS;XC7VF2WFEV\&OZ;9:]8W GM;>\.4<D;<..V
M<\$T ,\!74MUK,3R>-KS51+9^>ME<VXC)0G ;Z@]J]'EFBBV>9(J;B NY@,G
MTKS;P-X+\0V6KV>I^(9K$#3[:2VM8K/G<)&W,S'^E=WK>B:?X@TY[#4X/.@<
MYP"05(Z$$<@T"/,[#0?&^ARZA!8^%/#MU:2W<L\+W,V7 8YP3CFO3=*EF%A;
M0WD5M;WOE RV\# JGT'I7'?\*QFC8):^,_$5O:@8\C[0&X]-Q&:Z'P[X.TOP
MVTLUK]HN+N4;9;JZF,DCCTR>@]A0,Z$'(I:0# I: # HQ110!B>,/^1-UG_K
MSD_]!->??L\_\D_F_P"OQ_Y"O0?&'_(F:S_UYR?^@FO/OV>?^2?S?]?C_P A
M0!ZY129]Z7\: "BC/O1GWH 8>M>9_&^:"+P,5D@:6620+%M&<'U->FGZUQ'Q
M,\)2^+/#Z0Q7WV3[,[3,=N=X"]*F6J-:+M-'A7PH\,:1XKU::SUY;UK>-!)!
MLD*Q9'4-]:^B=%\'>%]"5?[,TBRB8?\ +38&;\SS7D?P]^%2:I8+J<VMW<<!
M9E$$)VY(/<UVW_"K;F!B]GXFU",]E+9%9\TK72N=;H4;M3GRM>7^1Z.,%<#H
M.@'2E!R>17FB^"?&EHY:U\5LX'02@F@V'Q,LVW)J-G<J.BL,9HYWV$L'"7PU
M8DWQC^;PWI(_ZC%M_,UW[RI#'OD954 99CBOF7QW'XCU'Q#*NKWIAE78_D1$
M[%('!'O7;^$/ ^M>)-!MKG6O$=S+8G_56Z$@X]S0JMW9;ERR^5)*=5VB^N]S
MH/'&O^!-1MVL=6MXM4GQA5A7<ZGV8<BO.=$\/^/=.>ZG\&/?6^G$$I:WCCD>
MB@]3^5>W:+X+T+1$'V6QC\S_ )Z2#<Q]\FN@"XZ4XJ3=Y,RJ5,/%<M.-WW?^
M1\XZ!J>A7NL&U^(,VHVFIAL;+O*Q?GVK0&@^&T^-XL0L']D+IPG!,HV XSG=
MFO9O$'A?1/$MFUOK%A#<QX.'*_.GN&'(-?).J:1#;^.KG3[*QU.73XIL+ RM
MYSP@X/;..M5R1[&<L76E9N1ZGXH\0^#;^];2O"?ALZSJA^426ZE8U/KD=:71
M/@?K&JVIG\2ZNUKNY6R@.X+_ +QZ5Z_X7T+1=%TBW71=/2T@EC5\;,2'(S\Q
M/.?K6Y@<\4U"*V)>(JM<KDVCRBP^'WBGPM 8?#NKVZ0D[BAC S]35/Q-KWQ$
MT;26^TK;6^6&+N/G;[8]Z]C(JK>V-M?VK0W<*31X)VN,C-9NG;6+.NGCDVE5
M@FO2S/G#P-HNM:[J$NAKJP@T^>4W=W&!S)D\_C7T/H^AZ?H5DEI86ZQ1KU(Z
MM[D]ZXGX66=N(M4G$2"5;QXPX'(7/3Z5Z0!@<TJ2O&[W#,:D55=*EI'L %*1
M0 !2GI6YYIYU\9-*L+KP#J%]/:127=NJ"&5ERT>7 .*U8?A]X2O-"BM)= LA
M'-$C,4C"G=CKD<YJOXK^&>F>+]1:]OM1U*,/&J&"&8K&0/\ 9J]X1\$6GA"2
MY:VU'4+L3JJE;N<N$QZ>E '#7'PL\1>$[AKWP#X@FC3.3I]VV4;VSTJ2P^,E
MSHUT-.\<Z%<:7<@[3<Q(6B;WQ_@:]>./3-5-1TO3]6LVM=0LX;F!A@QRH&'Z
MT 1:7K.GZU:"ZTR^M[N)AE6B?=^=>7:AK_Q,MO'5OX:COM&$EY')/"Y@)"HN
M>#[X%6-4^#0L+MM2\$ZS<:+>#YO)WDQ-_A7FFM^,_&&@?$6RFUB&RDUNQA-J
MC _(X?@,<=^: /I+2&U&#18#KLUL;U5_?R0_+&3ZC/2N5\1?%[PEX?=H!>F_
MO.@M[,;SGT)Z"N8B^&WC+Q>1<>-/%#Q6['=]BL3A<>G''\Z[GPY\._"_A=1_
M9VE0^:.L\P\R0_B>E '"_P#"2_$WQP-N@:1'H.GOP+JZ^^1[9_H*EC^!<6H6
M\T_B/7[S4]4D0A9&8^7&WJ >M>OXXK"\3^*]-\(6,5YJ?VCR)'\L&&(N0?<"
M@#QWX*^")(M7NM=M]5DC:QNY+.2'8"LR#CGT]:^@!^E>#_"GQ[H^DKJ&FW,=
MZ;J_U-Y(%CMF;*L>"?2O=@>?I0 ^BBB@ HHHH 2OGGQ)<Z?!J?CFSU/PUJ%[
M?7TY%I=1VC.% 7"X;MSZ5]#TE 'GOP_\<Q:Q%8:&VE:K;W,%H!)-<VY6,E0
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M%5HUI\\58R!8ZN-N=7S@1Y_<+V.6/_ AQ[5'_9NM[' USDI(%/V<?*2V5/\
MP$<>];@ZTM6<QCFRU4S;O[6^3S=VWR!]W;C;^?S?I41T[6\*!K>,)&&/V=?F
M(.7/_ AQ[5NT4 8K6&KX;&LX)$F/]'7C)^7_ +Y''O3#INL_;/-_MP^1YN[R
MOLZ_=VXVY^O.:W:* ,5+#556/?JY<KL+$P 9Q][_ +Z'Y5\Y>)AX)U+X@@W6
ML3202I,;Z],;9$^3M&WVQCCTKZF(R*SSHNELQ+:99DG)),*Y/Z4 8V@1M>:)
M9S:+KGF::5/V<F+<?+V;54D\\-S^E7QI^L +_P 3K<0(L_Z.HR5^_P#]]?I6
MM!!%;Q+%#$D<:]%1< ?A4M &$=.UG80-<(.V0!OLZ]2V5/\ P$<>]-ETO5II
M\OK"F'S=YB:U4@IMP%_[Z^;-;]% &!;:-?P&)O[2B,BA S+:(N<$[NG3(Q^5
M/;3M9)4C6S@0LI'V=>7+95_P'&*W** *=E#<PF7[3=>?N?*?(%VC X_/G\:N
M444 %%%% !1110 4444 %%%% !1110 F12UXY\3/%MS=79L-)U&.VM-,NX!?
M2"7:TKLPQ&O? ')-1>*;J^U?6_%EU#K%Y;)X?LH9;!;:7:A=EW%F ^]GI0!Z
M9XP(_P"$-UG_ *\Y/_037G_[//\ R3^;_K\?^0J'Q;\6M*L/#@TG4(+IM0O]
M*67=$HV;I$]:XKX5_%?0O!7A9],U&WNWF-PT@:%01@@>] 'TO17D/_#1'A3_
M )\]1_[]C_&C_AH?PIC/V/4?^_8_QH ]>HKR'_AHCPG_ ,^>H_\ ?L?XT?\
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MB_LO^S_*^T;6V[\=,8S70-^T-X2=2K66H%2,$&,8/ZUE?\+=^&9Y_P"$:?\
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M2_A3!9?$;4?$,ZV,VG7*$1V1@XC)QSZ=OUKOM4U6QT:PDOM1NH[6UC^])(<
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MJUN-3/ M]W.>RYZ ^U:U]$]Y87-O#=-;R2(R+-'@M&2.OUKPJ'1+I-5T_P
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M<1KY\KN7V-@;@@/"C/I0 _POI.KZ3IS0:SK3ZK<%LB4QA JC@  ?K6\.!2
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M*SL[ ;0[=E0#  IUK\+6@U+[$^K3R>%(Y1<PZ23]V3/W2W4H#R!7HZ#
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MT"'P)+>>";#P]K.J7-R(9(Y9G."6VG(C!ZX!'6F!VB@'!X..A-/ P,4B *H
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61110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>form424b5_011.jpg
<TEXT>
begin 644 form424b5_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (+ 8,# 2(  A$! Q$!_\0
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MGH,9'K0!Q'L#UIO^<U)(I@E>-_O \TT_,0!P#0!&1S24]AR13<4 )24N*3%
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M3G-%*>M% #J*** *UZN^RF7U0BN7MT2%MK$@8[UU-V,VDO\ NFL!27CV",G
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MH\WS-,H..<'I5H7DV#M(;GFO([?7I8)%8IT[J>M:R>*C,<,[(">@H ]!;49
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MBDNC 9 ^E9F: Q QVH E>=GQDG([YJ,N2<DTF:2@ HHHH **** "BBB@#I/
M'_(_Z%_U^1_SKZ_\87W]F^$]2NP,F.$D"OD#P!_R/^A?]?D?\Z^KOB:2/AMK
MY'!%J<?F* /)9-8+Q&=W7:/3O7.WVN,R28. O3MFN/M_$[*@CEWE-@'T([U3
MN];DF5E4%0W:@!^M7[7$H#29[@5BEVY&31)(SMECS3* )(\-(H9L*2 3Z"NM
M^);E?&MQ&KY2.&%4(&  $&,5QZC)KM/&<)U;3=&\3PC='=P"VN,?P3QC!!^H
MP10!R4=RZC!/%:!U%KBW"M.8F1-H4#AJR#QT/%&: )S<R<<].E2QWTJ#J#Z9
MJE2CK0!UWA6"PUB[GT^YN?LM[.H%C,YQ$9?[C^F>@-9DT.K6MY=6LUK+'-:9
M%Q&5(\K!QSZ5GVD:R7,:SN\<)8!Y$7<5'J!WKV#7O%7A+4/AOJ5C8ZA=2:V\
M4227%U!LEN50\*2..* /(FO)64AF(%1-<.I(5^#[5"0YP-K?E2F.0#)1L#VH
M 'D9@0Q/O41JW'*K6I@,8R6W!QU^E5F!!.>M #1UKLOA\!)J.K6\A_<RZ5<"
M3/3  (_4"N. KM?#\8T7P3K>O3?*]ZO]FV8SRQ)!D;Z  #ZF@#BCT%)2FDH
M*ZOX:?\ )2- _P"OM:Y2NK^&G_)2- _Z^UH ^TCUHH/6B@!U%%% '-^/O^1
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M=1ON$S?0\@U7Q2@<\G% %N*_"3K,]M"[J<\C /X5!+(9YGDV@%CG"]!5W2]
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M>1+:ZC!:GI;VML88\?10,_C7._\ "*^(?^@-?_\ ?AO\*]J_X:5A_P"A=?\
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MXRIVXP: (J*7!I* "BBB@ HHHH **** "BBB@ HHHH 4_6NJ^&O_ "4C0/\
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M!6U"'"83&['.:YZXC&<A0:ZZ\:&2?8I&?;I6-=P##*HVX]NM ''70*L3T!X
MK/U'3K74]+DM;E5*L.XY!]15[5<VY8ABQ^E8HU-=P!8@@X.X4 >0ZWHLVC7[
M02\KG*-ZC_&LLUZYKVFPZW:.A #KDJW<&O)YX7@F>)QAD)!H BHHHH ****
M.D\ ?\C_ *%_U^1_SK[0U+C3I^0/D-?%_@#_ )'_ $+_ *_(_P"=?:\T:S1/
M&PRK#!H \VEO9(7;'S<=5'2H3J1"EMV\^@XKL;O0;4QX *X/8]:PKW0[0,<9
MR.AS0!BC4(2I#D@]<FJ&HSPSX?S1ZXQR15N^TQ""@9EQW%8TMK';OAFSCU-
M%="[R.J$-DC)![5KV:;(MVX!MV369#)$LA".,C X%:]M+$RX(!YP?\: -6WD
M\U "2<#O3YC@8W#!_2K&F68>)I0/+@_CD<\?A[U-+>VMN&-C"&<<>;*,D_0=
MJ ,4:-?7.76%EC_OR':/UJI<Z+:H UUJ\$;#@K$ID/\ A6G<M-J$9:661W'.
M&/'Y52&GRSXC4 '/'% &1<Z3X>4#S+W4901R4B4 _G6/<:3X=*D,^K $YW82
MNKN=&>W.)@1Z9' JA-8^8C+&A..,&@#CKG2_"TL3(-4U:U&<;IK97 _*J/\
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MO]/\:]>_X:2TK_H W?\ W]6C_AI+2O\ H W?_?U: /(?^%5^-_\ H7;O]/\
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MVJ&"D<# JLUIODWLK!E[#FK[VQ60.!RW3CDU/;6[*1EBS.?3I0!G+;,%#("
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M2R1@B7! ^[72V6K97<S\U\X6'BK4[&1624,%[,.HKJM-^(<?F 7*/&#WZ@4
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M:*** ,/QA/\ 9?!^K3D#"6SDY^E?$=P0UQ(PZ,VX?C7VKX__ .1 US_KT?\
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MM.YB<]L]*\[N]:2)O++D(3_$W-:NN>([!XV$D@W/Z<UP]W>6EP<+O"]R1VH
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M-+_PJGQS_P!"Y>?D/\:]*_X:2N<9_P"$=B_[_G_"F_\ #2EQ_P!"]%_W_/\
MA0!YO_PJGQS_ -"Y>?D/\:/^%4^.?^A<O/R'^->D?\-*7'_0O1?]_P _X4?\
M-*7'_0O1?]_S_A0!YO\ \*I\<_\ 0N7GY#_&C_A5/CG_ *%R\_(?XUZ1_P -
M*7'_ $+T7_?\_P"%'_#2EQ_T+T7_ '_/^% 'F_\ PJGQS_T+EY^0_P :/^%4
M^.?^A<O/R'^->D?\-*7'_0O1?]_S_A1_PTI<?]"]%_W_ #_A0!YO_P *I\<_
M]"Y>?D/\:/\ A5/CG_H7+S\A_C7I'_#2EQ_T+T7_ '_/^%'_  TI<?\ 0O1?
M]_S_ (4 >;_\*I\<_P#0N7GY#_&C_A5/CG_H7+S\A_C7I'_#2EQ_T+T7_?\
M/^%'_#2EQ_T+T7_?\_X4 >=Q?"[QW#(DB^&[S<K!AE0>GXUVXF^+X  \,6_
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M%_W_ #_A0!QVK>$_BKK@VZCIVJ31CI%D*@_X"#BL@_"KQQV\-WGY#_&O2/\
MAI.X_P"A>B_[_G_"C_AI.Y_Z%V/_ +_G_"@#S;_A57CG_H6[S\A_C6S8^"/'
M<5B]A>^&;ZXM'Z*V,H?4<\5V'_#2=S_T+L7_ '_/^%'_  TG<_\ 0NQ?]_S_
M (4 >>7/PG\:)*?*\/7CQ]C@9_'FF0_"_P =P3)*GAR[WHP894$9'MFO1A^T
MG<_]"]%_W_/^%*/VDK@\_P#".QX_Z[G_  H HFX^+Y.3X7MO_!=%5/PYX/\
M'-S\3-+US6- EA472O-(D2QHH'? X%;)_:2N1_S+L7_?\_X5J>&OCW/X@\2:
M?I#:''$MW,(S)YQ.W/>@#V[&>:*7 /844 +1110!D>)\?\(OJ60"/(;K7SE%
M;O-"OEE>^>,!:^CO$J>9X9U%/6!A7@]III50!RPZ<T 9$EJ@95.W)&"?6@01
MW!^8D)T);BN@&D&-"=B\Y([\U3?3HPVV2-!NZ 'B@"BNG1Q(>A#< =Q5&:R
MCP\"@$G!R/S-=&-/1USCYE&,DU7FLG)P%5L'H>] ')3:>@3:4&".">PK%O-'
M7@IC _6O0)[!)(S'MP/3KBL:YL-K$D 8SC% ',V^DI#;,TZ*<]#GK[5SL\?E
MR,, 8/2O1$MXYX3"%YQWK N= E*N<8 )H Y7-&:EGA:"9HW&"#45 !FC-%%
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M:1NRI[$$4 44&^;( 4#@G%5)9XY6/RMCI["K6JZC'(LBD",1D9([YK&6]0;
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M'I62:]M\2Z'#J=M);R*@)&Y' Y4UXS=VTEG<R6\H(=&(/^- %>BBB@ HHHH
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M(^X]Q0!Y$1CK170>)/"=_P"'7CEE,=Q87'-M>VYW12CV/8^QYKGR,4 %%%%
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M[&L342;9L X4M\K=C]*\&LO%VLV10+=LZKT#\UT:_$BXNX!%?(2!QA>@]\T
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M*D9!&".HIM:FMVOV74)< ;'.1S670 5U?PT_Y*1H'_7VM<I75_#3_DI&@?\
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$ '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>form424b5_012.jpg
<TEXT>
begin 644 form424b5_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #N <(# 2(  A$! Q$!_\0
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M,ABEDC*I(/X21UKC[31M6AM+:U@T*SM[R!&!OFER-V.& '))/K18#I?*U_\
MY^K'_ORW^--*:\I -WIX)Z9B;_&N1.C^,7MC'#/<0OL43O)<AC*^[ED_N\4Z
M^\-Z\+IY$DNKF&&X#VRFXPP!3&<]^>U%O,#KO*U__GZL?^_+?XU&6UH,Z_;M
M.R@RP\LY7Z\URJ:%XGM[.T:2>\N6,3&>);K:PF)X8$_P^U:WA71M7LM1U*YU
MC9(URB LK9#8'-%O,1<74;YVVKK.CLWH!_\ 7JV$UY@"+JP(/3$3?XU@2^$3
MY_B!X;"!#=(HM64 $''/TJG<^'?%5K9FVTG4)4C,46X22;B2/O!3VHMY@=9Y
M6O\ _/U8_P#?EO\ &CRM?_Y^K'_ORW^-<O8:%XGEDMO[0OKGR(@[!%EVDG'R
MAB*QKJP\;6<5Q.9+E4>/#+'/N)?=V]..]%@/0?*U_P#Y^K#_ +\M_C1Y6O\
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MYUF^(/"\VN:;HMC("%M9$>9D?:5P.JGUS6!'X1\3MJ=X]U-#*DDBA9T?:7C
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MM8"<$+6JBC)MG46_B_Q"V-VI2'\!6[9>)=5,1DGU#IT! YKE+6'C)& .YJW
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M'.:0,[33?B/XYN90'UZ<C_<%=5!XU\5A?WFLRD_[HKD-.LTMT&<9/>NEL8;
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M: &X)],],T <A;^'O%<>L/<O.PD<1@3+/\H"GG<O<D5Z(@^49P3BG  CBG4
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MA&-KB#:K3S,OD<?Q@]2>]>@$@T#% ")PB@XS@9Q3LCVKS+Q2\R^([C;-(JX
M 5C@5E)/<9_X^)OQ<U:A<5['L.?<49]Q7DJSS_\ />7_ +[-2QRW'4S2[?\
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M^-Q"@3<9SSC\*VM!_:!FUG7K'33H,<8N91'O$Q.W/?I0![I12 \FEH ****
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M^NW]*XNNT^*__)3-;_Z[?TKBZ!BYKH? G_(]Z)_U]I_.N=KHO G_ "/>B?\
M7VG\Z /MS'-+1W-% !1110 4'I110!S?BQ1Y.E?]A"+^M=%BN?\ %G^ITO\
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M 6BDR*6@#F_#/_(7\1_]?_\ [(*Z0=*YGPT?^)QXD_Z__P#V05TH- "T444
M%%%% !1110!S\?\ R/,W_7@O_H9K?%8"?\CS-_UX+_Z&:WQ20D%+24M PI&I
M:*8'):UH>HWGB2WOK9VV1[>'D_=@ _-E>YK7O;/4;B7=;:H;9,8V>2&S[Y-:
MF*,4FAIM;'FVL;X-4FBN+PS2@#+^0HS51)CCY9B/^V*U8\4G'B.X_#^59B2'
M-:J":'[>2':EI6I76IPW$.M!(=G*B,9!],5'+-K5CN$ELE[;X^_"<2#ZBK<4
ME74D]#4/#JSY6=:S*;LIQ32.4LM5A@=DD5XV+9Q(N#^M:$VK_:,$.#@8%:]Q
M!!<\3PQR ]=RUD3^'].<DHDD3>L;XKFC0K4G>%F=4L3A*[]^Z(1K&W D*MVQ
MMJ*34HG)+1@*>PXI4\.LCY@OYT/^VH:B3PU=RL"=1C/^]#52>(EI)&L5@T[Q
MGJ5H+^W@,C,P&[[H!J(:QYLA$22OSP$4XK1B\-WJ?=OK4>Y@S4XTG454*=7*
M+_=BA K2DI4XVL<]=4YRYG-%+[>^0QM+E5'7Y#4;:O;9;_2BA[AC@BKIT-7/
M^D7]Y-[&3;G\J>NA:4JX-FC$]V.3^=;<U1[(QC]6CK)W,"359)&86JO,3_%C
M JF\%Y=/BX;"G^!.GYULWOAJ&-3)9W$L)_N9ROY5CI%JEN3F..?'=6P:ETV_
MB9LL=3IJU**0?9UBX1"N/3I5B)O[S<>M,2\D:)O,C,;+_ PZU4-["04+E6ZD
M5HK+8Y95G4=Y.Y=E$;$[7)JE)(8G&"<$^E-%U&<@,"/8TU[I-RAL>P%2V)-'
MT9HYSH]F?6%?Y5?JAHQSHMD0,?N5_E5^LSF>X4444 %%%% "4AIU!H P/$=E
MK5Y' -&OEM65LR$CJ/ZU6M?#VKVUY<70U\&>X"^;_HBXR!CBNGQ10!Y#KOP'
ML?$&L7.JW^OW?VBX;<^R! /RK U+X!>'-,@W3^)[B*1\B(2HB[F["O;=8EU"
M'2YI-,MXY[M5)1)#@$UY_9> M3\17D.I^)-0D96Y:UQ@I_L_2@#FK+]G+2IK
M.&2?7;L2L@+"-$90?8]ZTM,_9]TW2-3MM0M=?O//MY!(FZ%",CUKUNSM(;&V
MBMK>/9%&-J*.PJS0!A?V;KW_ $'U_P# 1:R-7\$7NMW=M=7FOMYEL&";+5 ,
M-US79FL/Q#XITSPW:B6_F =O]7$/O/\ 2@#FV^'DB*S-X@=449)-LG%9^C^"
MY=5@EE7Q'$X65D5K>%'!4>OH:7R-;\?W,,LLALM)&2LENY!;V8'K7=Z'H5CH
M%E]EL(!&A.YV Y<^IH Y*?X8R3PR1/K\NUQM.+9.E;]KH>LV=K#;Q:_^[B0(
MN;1,X P*Z.D/2@#F+[P[JVHI )]?XAE69<6J?>%6_P"SM=X_XGX_\!$J_J.J
MV6EVK7%[<)#&!U9L$_3UKA+GQ/=^-5FTKP^9K.)U*F]*9(/MZ"D!LI)K4NN_
MV?'XDLW"1DRJ($\Q6[#;GIBM/^S=>_Z#Z_\ @(M4O"_@RV\/QQS32&\U/;MD
MO)!\Q'I74BF!S%GX<U6QGNYX=?.^ZE\V3-HF-V,<?E6]9Q7,5LL=S<">8?>D
MV!<_A5JB@ HHHH **** "BBB@#GT/_%<3<?\N*_^AFM_M6/?:#'>ZB+]+RZM
MI_*\HF!\ KG/>F?\(]-_T&]2_P"_@_PI ;=+6'_PCTW_ $&]2_[^#_"C_A'I
MO^@WJ7_?P?X4P-RBL/\ X1Z;_H-ZE_W\'^%'_"/3?]!O4O\ OX/\* -NBL3_
M (1Z;_H-ZE_W\'^%'_"/3?\ 0;U+_OX/\* ,K6O"5[J>K2W45Q"B/C 8'-4E
M\"Z@#S=6_P"1KH?^$>E_Z#>I?]_!_A2_\(]-_P!!O4O^_@_PIIM":3,)/!5^
MI_X^8/R-3)X0OE_Y>8?R-:__  CTW_0;U+_OX/\ "C_A'IO^@WJ7_?P?X4^=
MBY49W_"*W7>>'\C1_P (G<'K-%^1K1_X1Z;_ *#>I?\ ?P?X4'P[,?\ F-ZE
M_P!_!_A1SL.5&?\ \(I..DT7ZTA\+71_Y;Q?K6A_PCLW_0;U+_OX/\*7_A'I
MO^@WJ7_?P?X4<\@Y49W_  BMWC_CXB_(TQO"5XW_ "\Q?D:U/^$>F_Z#>I?]
M_!_A1_PCTW_0;U+_ +^#_"CGD'*C&;P=>]KF#\C3#X+O^OVJ#\C6Y_PCTW_0
M;U+_ +^#_"C_ (1V7_H-ZE_W\'^%/GD'*C!D\$Z@Z%?M4'/L:H?\*[U+.1=V
MV?7!KK?^$=E_Z#>I?]_!_A1_PCTW_0;U+_OX/\*F[&<?_P *XU,GF]M3^!IT
M?PVN0^Z26T<GU4UUW_".RG_F-ZE_W\'^%'_".R_]!O4O^_@_PHN%CA[OX53S
M-OBEM$;Z$4RS^$<BSYO)X)$_V-P-=U_PCTH_YC>I?]_!_A1_PC\O_0;U+_OX
M/\*+C-:TMQ:VD-NO2- H_"IZP_\ A'IO^@WJ7_?P?X4?\(]-_P!!O4O^_@_P
MI ;E%8?_  CTW_0;U+_OX/\ "C_A'IO^@WJ7_?P?X4 ;E%8?_"/3?]!O4O\
MOX/\*/\ A'IO^@WJ7_?P?X4 ;E%8?_"/3?\ 0;U+_OX/\*/^$>F_Z#>I?]_!
M_A0!N45A_P#"/3?]!O4O^_@_PH_X1Z;_ *#>I?\ ?P?X4 ;9&10 <UB?\(]-
M_P!!O4O^_@_PH_X1Z;_H-ZE_W\'^% &Y16'_ ,(]-_T&]2_[^#_"C_A'IO\
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2RXN=QSNG8$CV% %ZBBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>form424b5_013.jpg
<TEXT>
begin 644 form424b5_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !) <(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#U[6-2N;2Z
M6.$J%VY.16?_ &[?Y^^G_?-2^(?^/]?]P5DU^<YGCL33Q,H1FTCW<-0IRIIR
M1H_V[?\ ]^/_ +YI?[=O_P"^G_?-9M%>;_:>+_G9T_5J7\J-'^W;_P#OI_WS
M5.Y\875K=+;M#+(S_=,<>0:BJG<VTTM[9SQO&%A+%E8')R,<5T8?,J_-:I-V
M(EAJ=M(FE:>,)+NT%SY\,:@X8/P5.<<BI#XID#;?MEOG./O"N+E\(O<[5N)H
M7C4AB@# /R3R1]?TJPWAR;['-:PSV\4<LH?(CR548P/TKT'BK_#69E[&/\IU
MH\3RL'*W=L0GWCD<4R3Q:8D9VO;8*O/4&N&A\,/J5@1<E8MLC*(MI7>N[/S?
M7MBKK>%B T<,T,-ODE8PA.,@#&?2AXCE=G6=P]C'^0ZY/%$SX/VFW 8X4Y!W
M4D_BF>WN;>"615>X8K'\O&?>N:L=#N+.]:X,MLX=OF38<*..1[\5)J>CW-_.
MTR70B>-D:WZX!4Y^;UK%8R7M+>U=BO80MK$Z3_A)Y@Y!N[?(.W!(Z^E.B\1W
M4V[RIX7V'#;><&N-E\*K=31RW30R;9WF,8W*OS=^.XK1TW39[.\N[B>>.4W&
MWY43:!BBKBW&#<*S;%&A!O6)TG]NW_\ ?3_OFC^W;_\ OI_WS6=R>O6C%>;_
M &GB_P"=F_U:E_*C1_MV^_OI_P!\TO\ ;M]_?3_OFLW%&*/[3Q?\[#ZM2_E1
MH_V[?_WT_P"^:7^W;_\ O)_WS6;BCD4?VGB_YV'U:E_*B6\\875G/'"R/*\B
MEU$4>>!UIT7C#SXXWCOK?$@RN3@_0CUK'O+.\EO[>ZM)84\I'7]X"?O=ZSH?
M#)MH9XXIXCO\LJS)SN4Y)/US7JPQKE33E5:9A+#Q3TB==_PD\V]$%W;[WY11
MU85+_;M__>C_ "KA[?29[;6H-V)1$0PPA )YY![8STKI^I)!KFQ.-KT[<E1L
MN%"F]XHT?[=O_P"^G_?-0W7B6[L[:2>0AE09(1<G\*J8JKJ-J][IT]JK*IE7
M;ELX -84LQQ#FN>;L4\-3MI%%ZU\9-=;@MQ''(K;6CD #*<9J2Z\5SVE@UX6
M66)<<Q#.<\5RLWA6W:$P6XCAA:U\@@9+%L@DY]#BISH/EZ-]@M)! , !,DQ#
MD'IUKT98S5.-5VN8K#Q_E-D>.)7WA5D\Q'"-$8_G7C@_2GVGC66[DB10\33
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MRY%*ME2>OIP: .O[T8K)T/6TUJ*9T@>%HF"LC,#U&1TK7% !BC%%% !1112
M****8!1163XAO)['0KNXM9EBG2/,;.NX;O3'>@#5SS1FN3D\330Z_8Z=)+'Y
M4T7ERR[<;9R,CGICVJ"QUW59-0MM/O)XEF;S'26./*7,8'!']T@]10!V=(>H
MKBE\3ZB=-LYR\&\PF:4JG$I#[=BCL<<UO:/J%S>7>IQ7+Q-]FN=B>6,84@$
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M4>@_*K6=)_9$\$^Y[CI>N:9K+2_V=>1W'EXW[,\9K4'2O,_A6!]JUC@#B/\
MD:],'2O=I3]I!3[G#*/*["T445J2%%%% !1110 4444 %%%% !1110 4444
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MPKNAUI:\RKE.%JS<Y1U9O'$5(JR9P9T3Q*?^7/3_ /O^W^%,.A>)C_RYZ?\
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110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>form424b5_014.jpg
<TEXT>
begin 644 form424b5_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $. <(# 2(  A$! Q$!_\0
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M-0_Z \O_ '^3_&C^T-0_Z \O_?Y/\: -.BLS^T-0_P"@/+_W^3_&C^T-0_Z
M\O\ W^3_ !H TZ*S/[0U#_H#R_\ ?Y/\:/[0U#_H#R_]_D_QH TZ*S/[0U#_
M * \O_?Y/\:/[0U#_H#R_P#?Y/\ &@#3HK,_M#4/^@/+_P!_D_QH_M#4/^@/
M+_W^3_&@#3HK,_M#4/\ H#R_]_D_QH_M#4/^@/+_ -_D_P : -.BLS^T-0_Z
M \O_ '^3_&C^T-0_Z \O_?Y/\: -.BLS^T-0_P"@/+_W^3_&C^T-0_Z \O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^OB7_P!#-:=9.@QN--8&5B1/*"2!S\YK3V-_?/Z4 /HIFQO[Y_2C8W]\_I0
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MU%-R*,B@!U%-R*,B@!U%-R*"?3F@!V:*:#GVHR.YH&.HIN11D4"'44W(HR*
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M"=K_ . __P!>C[)X@_Z"=I_X#_\ UZW*,4K#]J^R^Y&']D\0?]!.T_\  ?\
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MD\0?]!.T_P# ?_Z]'V3Q!_T$[3_P'_\ KUN8HQ18/:OLON1A_9/$'_03M/\
MP'_^O1]D\0?]!.T_\!__ *];F*,46#VK[+[D8?V3Q!_T$[3_ ,!__KT?9/$'
M_03M?_ ?_P"O6YBBBP>U?9?<CD+O3M=-RQ:=)9&QY;K&<+^O%:2V?B *!_:=
MKQZV_P#]>MS:*4"CE7<N6(;5K+[C#^R>(/\ H)VG_@/_ /7H^R>(/^@G:?\
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MT9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H
M**,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T4 %%%%
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M_C1_PF,G_0M:Y_X#C_&JY:O\R^[_ ((O=[&W_:$?_/.;_O@T?VA'_P \YO\
MO@UB?\)C)_T+6N?^ X_QH_X3&3_H6M<_\!Q_C1RU?YE]W_!#W>QM_P!H1_\
M/.;_ +X-']H1_P#/.;_O@UB?\)C)_P!"UKG_ (#C_&C_ (3&3_H6M<_\!Q_C
M1RU?YE]W_!#W>QN#4(_^><O_ 'P::-33>04DQV^4\UAOXQDVD_\ "-ZWP">;
M<?XUQUEXUUP0Z5?36EW+'<SHKPI8@ AB1A6\SK^%9SA7=K2_ I<O8]/.H1_\
M\YO^^#2?VA'_ ,\YO^^#6)_PF,@X_P"$:US_ ,!Q_C1_PF,G_0M:Y_X#C_&M
M.6K_ #+[O^"3[O8V_P"T(_\ GG-_WP:/[0C_ .><W_?!K$_X3&3_ *%K7/\
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M'_!&^7L=%_:$?_/.;_O@T?VA'_SSF_[X-8G_  F,G_0M:Y_X#C_&C_A,9/\
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M ..T>Z'O>1=^WVG_ #]0?]_!534CHVH6;0Z@;6>!3O*.P(R._P!:;_9F@?\
M/O8_^.TR;1]!EB9!%9H2.&4J"#ZT>Z+W_(;HRZ!90O+IB6ML)L;]I"EL=,YY
MXR:T_M]I_P _4'_?P5EVVC:'%&?-2SED8Y9VV\_0=A4W]F:!_P ^]C_X[1[H
M_?\ (N_;[3_GZ@_[^"C[?:?\_4'_ '\%4O[,T#_GWL?_ !VC^S- _P"?>Q_\
M=H]T/>\B[]OM/^?J#_OX*/M]I_S]0?\ ?P52_LS0/^?:Q_\ ':/[,T#_ )][
M'_QVCW0][R+OV^T_Y^H/^_@H^WVG_/U!_P!_!5+^S- _Y]['_P =H_LS0/\
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M^_@JE_9F@?\ /O8_^.T?V9H.?^/:Q_\ ':/=#WO(N_;[3_GZ@_[^"C[?:?\
M/U!_W\%4O[,T#_GWL?\ QVC^S- _Y]['_P =H]T/>\B\+^T_Y^H/^_@K+UB/
MP]>B.;4H[6Z:/Y4)PS#)Y Q_GBIO[,T#_GWL?_':AGT?1FV/;_98)D;*NNW^
M5"Y0?,:>FV=E8V*0Z?#%#;<LB1#"\\YJW5.U>RM+=88[B/:OK("3[U-]KMO^
M?B+_ +[%26345#]KMO\ GXB_[[%'VNV_Y^(O^^Q0!2OO^0QI?^])_P"@UIUD
MW<T4NLZ6(Y4?#2?=8'^&M:@ HHHH **** "BBB@#.UK33JEBL4<HBFBE2>%V
M7< Z,&7([C(YK)'A</IX@FEB>:2XDN+B58L$ER253.2JYVYYY (KIR,TFT>E
M &3X?TJ;1].-O/=?:'+EMWS8_4DY/4\]36E+;PW  FB20#D!QG%2  =!7)>.
M-?N](M8XK/[1$SE7>YCMGE5%# %<@$ G/?MGVH U;;P[IHC;[1I]J\A=CDQ@
M\%B1^E3_ /"/:/\ ] RT_P"_0KG=,U:]N/$D):\D9;BYN(7LV  B2, J0,9!
MY&<]=U=I0!F_\(]H_P#T#+3_ +]"C_A'M'_Z!EI_WZ%:5% &;_PCVC?] RT_
M[]"C_A'M&_Z!EI_WZ%:5% &;_P (]H__ $#+3_OT*/\ A'M'_P"@9:?]^A6E
M10!F_P#"/:/_ - RT_[]"JT?AO2Q>SNVFVGEL$"#RQVSFE\2RWB:/(ME<1V]
MP\L2+(\FP %QD!L'!(R!QU-<@NOW[HSI>W$+6(C6.%Y%D^TN9_+?+8&\?PC&
M,'Z4 =O_ ,(]H_\ T#+3_OT*/^$>T?\ Z!EI_P!^A6E10!F_\(]H_P#T#+3_
M +]"C_A'M&_Z!EI_WZ%:5% &;_PCVC?] RT_[]"C_A'M'_Z!EI_WZ%:5% &;
M_P (]H__ $#+3_OT*/\ A'M'_P"@9:?]^A6E574)Y;;3[J>%-\D<3.BXSD@9
M H S[GPWI;F#RM-M!ME#/^['W<&K'_"/:/\ ] RT_P"_0KA]-UG4;IK2RN]2
MN8!=&.66<3H^T-$S *^T;"2,[3G '!KM?#U[/?\ A_3[JY8&:6%69L8W<?>_
M'K^- #_^$>T?_H&6G_?H4?\ "/:/_P! RT_[]"M*B@#-_P"$>T?_ *!EI_WZ
M%'_"/:,/^89:?]^A6E10!F_\(]H__0,M/^_0H_X1[1_^@9:?]^A6E10!F_\
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MWKMK*UZ[K=7$T+VA "I&J!E8+U![\_WJ .F_X1[1_P#H&6G_ 'Z%'_"/:/\
M] RT_P"_0K2HH S?^$>T?_H&6G_?H4?\(]HV<_V9:?\ ?H5I44 9O_"/:-_T
M#+7_ +]"C_A'M'_Z!EI_WZ%:5% &;_PCVC_] RT_[]"C_A'M'_Z!EI_WZ%:5
M9>O3W-OH5_+9R+'<)"S1NY "G'7)X_/B@!$T2SMM0MKBSM((=F[>40 X(X%:
MM>9?VYJ4CW=H;^]M+:U2>6&>=HS+(Z1JP1F&00"<D#J#BO1+&:2XLK>64;9)
M(U9UQT)'(H LT444 %%%% !1110 4444 %->-)4*2(KJ>JL,@TZB@"!;.U2Z
M>Z2VA6XD 5Y0@#L!T!/4U/110 4444 %%%% !1110!'/;PW,+PW$,<L3C#)(
MH96'N#UJ'^S;',!^Q6^;?_4GRE_=?[O''X5:HH **** "BBB@ HHHH ****
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M'_/G_P"/49U8?\^?_CU &C16=G5O^G/_ ,>I VK$_P#+G_X]0!I45G?\3?\
MZ<__ !ZC_B;_ /3G_P"/4 :-%9W_ !-_^G/_ ,>H_P")O_TY_P#CU &C16<3
MJPZ_8_\ QZDSJW_3G_X]0!I45G?\3<_\^?\ X]1_Q-_^G/\ \>H T:*SO^)O
M_P!.?_CU'_$W_P"G/_QZ@"[L&W&T8],5E:7X7T?1;F:XL++RY9EV.S2._P N
M<[1N)P,]A5C_ (F__3G_ ./49U;_ *<__'J )[RQM[^RDL[J%9+>1=K1G@$5
M!I^C6.ES7<UI!MENW#SN[L[2$# R6). .W2C.K?].?\ X]1_Q-_^G/\ \>H
MNF)" #&N!T&!Q08U*[2BD>A'%4O^)O\ ].?_ (]1_P 3?_IS_P#'J )H;"WM
M[NYN8HMLURRF9\DE]HP/P JW6=_Q-_\ IS_\>H_XF_\ TY_^/4 :-%9N[5C_
M ,^?_CU+G5_^G/\ \>H T:*SO^)O_P!.?_CU'_$W_P"G/_QZ@#1HK._XF_\
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M:=_SZI^M']C:=_SZI^M7J* */]C:=_SZI^M']C:=_P ^J?K5ZB@"C_8VG?\
M/JGZT?V-IW_/JGZU>HH H_V-IW_/JGZT?V-IW_/JGZU>HH H_P!C:=_SZI^M
M']C:=_SZI^M7J* */]C:=_SZI^M']C:=_P ^J?K5ZB@"C_8VG?\ /JGZT?V-
MI_\ SZI^M7J* */]C:?_ ,^J?K1_8VG_ //JGZU>HH H_P!C:=_SZI^M']C:
M=_SZI^M7J* */]C:=_SZI^M']C:=_P ^J?K5ZB@"A_8VG_\ /JGZT?V-I_\
MSZI^M7Z* */]C:=_SZI^M']C:=_SZI^M7J* */\ 8VG_ //JE70 !@=J6B@
:HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>form424b5_015.jpg
<TEXT>
begin 644 form424b5_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $E 94# 2(  A$! Q$!_\0
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M,T4 %%%% !11FC- !111F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[H3E4'V?;$8V R_K]35/R?&448-N24;!19I 64#LQ]_6@#.6+2O^@3XER/\
M:>CRM*Z?V1XE_P"^G_QKHM+D\3&]MFU,(B%L,D8X(VYR?QKJ!F@#S&<Z-;0O
M-/IGB..)?O,[/@#U/TKJ(_!FE31JZSW^U@"";IN1BKWBS)\)ZGS_ ,N[5I66
M?L-N<_\ +)?Y"@#"_P"$'TO!!FOSG_IZ:@>"-+!)\V_Y_P"GIJZ6B@#FO^$'
MTLC!FO\ _P "FH/@?2B"/-OL$8(^U-72T4 5K"Q@TVRAL[9=L,*[4!.<"K-%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 9^LV4FHZ->V<3 //"R*6Z9-8=FGC*SLK>V6WT9A#$L8
M)>3G Q768HQ0!S)E\:?\^NC?]_)*3S?&F>;71O\ OY)73TT]: .:\WQG_P ^
MNC?]_'H\WQI_SZZ-_P!_)*+OQ1=PZI=6-EH%Y?"V(5Y8F55R1G'/L:9_PE&L
M9_Y%#4?^_J?XT 2"7QGWM=&_[^/2>;XS[VNC'_MH],_X2C6/^A0U'_OZG^-'
M_"4:Q_T*&H_]_8_\: (=1U+QAIVGW%Y+:Z,8X4+D>8_:I;>\\8W-M#.EIHP6
M1 X'F/QD9K)\37FJ^(_#M[I+^%M3A^TQ[1(LR H?7K5K1]6U72-'M-.C\)ZF
MZ6T2QAGE0EL#J>: -'S?&?\ SZZ-_P!_'I/-\:?\^NC?]_'IG_"4:Q_T*&H_
M]_$_QH_X2C6,_P#(H:C_ -_$_P : )/-\:?\^NC?]_)*/-\9X_X]=&_[^25&
M?%&L$C_BD=1_[^)_C4NG>)Y[S6(]-O-%NM/EEC:2-IF5@VWJ.* $\WQG_P ^
MNC?]_)*!+XT_Y]=& ]/,DKI%Q3J ..U.V\8:IIMQ8R0:0B3KL+K(Y(!KJ[>,
MQ0QQDYV(%/O@5-10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 -[UQ&GGQ5K8NKJWURWMH5N9(DA-L&VJIQU
MKN._2N:\%J1I=WG_ )_I^W^U0!!_8_C'_H9[?_P"%']C^,?^AGMO_ (?XUUM
M% ')?V/XQ_Z&>V_\ A_C1_8_C'_H9[;_ , A_C76T4 <E_8_C'_H9[;_ , A
M_C1_8_C'_H9[;_P"'^-=;10!R7]C^,?^AGMO_ (?XT?V/XQ_Z&>V_P# (?XU
MUM% ')?V/XQ_Z&>V_P# (?XTATCQB ?^*GM_7_CS%==32.: .3\(K=VNH:]%
MJ5]'<W(N4S*JA ?W8[5T=WMN+62%+E8F9<!PPR*RM2\*Z%?W<M[>6:M.XS(^
MXKD#UQ7/_9?AT.#=V6?:X/\ C0!IR:!J#<IXEE5]FW=D<58GT>[E*!-<DC"!
M<$,,Y Y-8@M_AR/^7RR_\"#_ (T?9OAS_P _=E_X$'_&@#7&C7^Z-&\02,BR
M;V!(RX]*<VD:G(\CGQ"Z%G)"KC"@YP*Y;7(? 2:%?-:7=I]H$+;-EP<Y]N:L
MVD/P]:QMWEO++>8E+9N#UQSWH W6T3463YO$LV\'*G(I(="U",8/B28[CEOF
M%97V;X<_\_=E_P"!!_QH^S?#GK]KLO\ P(/^- '<QR(J*#.K$  G<.:Y'Q'%
M?7?C'1TTN_CM9_L\Y,C1B08X[53^S_#G.?MEEZ_\?!_QK:\.Z;X8$[7^A_9Y
MI$'EF6.3?@'M[4 0#2/&./\ D9K8_P#;F*7^Q_&/_0SVW_@$*ZM>M.H Y+^Q
M_&/_ $,]M_X!#_&C^Q_&/_0SVW_@$/\ &NMHH Y+^Q_&/_0SVW_@$/\ &C^Q
M_&/_ $,]M_X!#_&NMHH Y+^Q_&/_ $,]M_X!#_&HY]+\8PV\DO\ PD]L=B%@
M/L0YP/K78U!>_P#'A<?]<F_D: */AV\GU#0;*[N6#32Q NRC )^E:M8GA+(\
M+:=G_GE_6MN@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,O5M?
MT_16B6^G\MIB1&H4L3CKP*S_ /A.-"_Y^)?^_#?X4W5@&\;Z$K*"#'/P1GL*
MZ(0QX^XG_?(H P/^$XT+_GXE_P"_#_X4?\)OH?\ S\R_]^7_ ,*WC$F#B-,_
M05C.FLI*P2&U=&8[3@944 0'QMH; @7,H)& WD-Q^E<MX%UN#0=.OH=7U.6X
MDFO))8SY#?*A/';O7622ZFDQ3_0L XY ^:B:35D*K_H(QS(3C/MQ0 W_ (3C
M0E S<3<_],&_PH/CC0N/](FY_P"F#_X58EM]2D EMWM^57Y-H()[XJ[I\,RV
MJB[2,R>P% &4/'&A?\_$W_?A_P#"G)XVT*2>*+[4ZM(X1-\3 $GH.16\(D_Y
MYI^0KEO'?EP:+;R&,'9?0-\J9/WNP[F@#K <#GK2US/AKQ?%XDM+NYCL+JW2
M"Y:#;*F&..^.U;?V]?\ GE-_WP: *6K^(K'19X(;H3M+."42&(N2!UX%4?\
MA.-,Q_QZZG_X!/\ X4VZG$WCG2"JLO\ HTW##'I73@_6@#F?^$YTS_GUU/\
M\ G_ ,*#XWTS /V74\?]>3_X5TI_&LB[CUA+B2:VGB,1^[&PZ?C0!@ZWXIL=
M3T.^LK=-5@GGA:..5;-P58CCM67X8OM$T;PU8:??Z==W5W!&%EE;3F)9^_:N
MK$^I,T<8O[4L[=!U(]!3?ME_#=%&OK5XB6 QU7C@'WS0!F_\)!X9Y_XDESQ_
MU#3_ (4?\)!X9_Z ES_X+3_A6[;1ZT9U,]Q 8AC(5>3ZUK?G0!QG_"0^&?\
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M5=%TE+K3=%DOIS<)'Y"GDJ3R>*J^%OM%YIVJ@J]M,VH2,8V;)0Y!VY% "?\
M"=3?]"QK/_?D55U3Q;-J.F7-D/#FN1F>)HQ(D6"N1UZUT!T[51(SKJ>"P^Z1
MP*AECN4EB@?6#'*%"MQ]XT <MX3UVZ\.>&;+2IM!URYE@7#RO'DL2<^M;/\
MPG4W_0L:S_WY%: %V7@M1K"BX3*N&'W_ *5.-.U,,?\ B:G9V!7F@#%E\?\
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M- "6WBNZM8%A3POK!5>A8+G^=3_\)I>?]"MJWY+_ (UUU&<4 <C_ ,)I>?\
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MI3?^,^VBZ=_X$&NJP** ,7PMI]WIFBK;WPC6Y:621UC.0-S$\?G6UBD Q3J
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M/"UCJ-J=2N-2ACAEN[HS+'&VX*N,=:Z.@ HHHH **** "BBB@ HHHH ****
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MI'_03M/^_P O^-']O:1_T$[3_O\ +_C0!H4F*BM[RVNT+VT\<R@X+(V1FIJ
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MFFF_\^VI?^ CUT?XT9H XU]6BUKQ9H[6EK=A8!*9'F@9%4$#')KL4QCBE/-
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M#^)+;0]+NXM9U6XN9I;N62,_97^5">.W>NI_X3[P_G'VF?G_ *=I/\* (_\
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MU%8.DZ[=7FKS:;>Z:]G-'$)E)D#!E)QVK?% "#W_ )TOX&EHH 3\#1^!I:*
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M>;3;.Z0'5I6:(D>6<\T?VR_FB7_A%-2\P'=NVIU_.HVU-6))\(:AD]]B?XT
M6+619?']Q(GW6TY"/^^C73UR6C"[NO%EQ?R:9<6-L+-(5$V,D[L\ &NMYH *
M*** "BBB@ HHHH JW\K6]A<3)C?'$SKGU KFK!?$UYI5O?/K=I&)8EE*_9<A
M01GUKH]5'_$HO?\ K@__ *":I^'D$OA73$=<JUK&"/\ @(H RA!KMS$ZMXAL
MWC888-98X/'/-5M.TG5-(TVWL;'Q#I\5M$N(U%J!WY[UT%_:1PVK>3:+*7QO
M!XR!5.QTVRNG:.?2_)*J&7DXP?>@9$+3Q-)$9(O$%HZXX(M!C^=7_#=[<:EX
M?M+NZ93-(IWE5VC()'3\*T([>*TMC%!'M0 X45C>#1_Q2=CG'W6_]"- BG?C
M5M0\53V%GJS6,$%LDFU8@V2345SIVKVC1K<>+I(R_P!W-N.:OVHQX\U$_P#3
ME%Q^-;=Q9V]TH$\*2 =-PZ4 <DUGJNS<GBZ5LG'RVP)S4%KHES81R/;^*1 M
MQ(97Q;J-S'@D^]=3>6EO;6;/#:(67[JJ.]4+6)KJ:*.]TN-8B"%('W2#0!E?
M9=1#E3XT.X'! A6K4^B>((K665?%$I*(6 ^SKS@9K=&CZ<O2SBZYZ5->C&GW
M'''E-_(T 4_#MU-?>'[&ZN&W3R1 N<=3ZUK5A^$1_P 4MIIZGR1R?J:W* "B
MBB@ HHHH **** &DF@,2<5C>*+ZYT[0;BZM3MF4HJ$+N/+ ' [FLF;Q7-97D
M=CY+7-PS1H V$)R,D8]: .QI#7,-XO5WMHK>U,LMPP4#>/E^;;S^52Z1XE&N
M+>-'!);1Q E)W'RD9(S^&#0!T.3CWI Q)K T'4M0N]/$ER4D!\QHYA\I= ?E
M;;[UAZ=XQO-NR_, G2W>=AC:) 6 C(_4'WH [W-+VKC]/\7R75P7EMTCM)3$
M(6+_ # NI)W#MR*=)XV"V5Q=K: 10A "TG+LP)VC\ : .L)-(&:N0D\0W[Z;
M-=6^&D-]'%%&1CY6 .T_XU)'XM+L'$!"R,BL7;"1$[OO'ZC% '6@Y%+7&VOC
M.X%K;M=V:!R-TY23A06*KCU/'/I5NT\6-<3VMO+9-%->8:W7?G<F3D_AC/XT
M =*6.3S2;N!7&ZMXLN&@NHK& )(6,<$K/R2KA7R.W7BK%[J^IP>)H;. AH([
M=)9@R<;3G<Q;MC% '5[J,_\ ZZX.T\4WVJ)Y$=W##,]Z DAB(Q RDKP>IXZU
MNVNJWM]X4:\MEB-_Y;;03A68' (^O:@#H!2UQMMXR*P0YB>X$8"W4A 1E<YP
MH7OR.<<5;_X2]'N8(8K4OO022,''R+L+'\>,4 =/36;%<H?&;+/90FQ9WN5$
MN(FW;(R<*3[\\CM5C7M7NK*&U:/:DKK*[C.X'8I.,_7% '19SU[^E*/Q_&N(
MB\77:GS+BWD15AC<1LH!<E"W4=CBK[>*Y4E-O)9!+EA%Y4328WE^<Y]!TH Z
M<%CG(H+>_P"M<UI6NW4NK7%I=QKY1FE6&8-P-N,J?IGK3=>U>]TZ_3[)+'*B
MP/)+;%,LB@</GZG\: .G/(&:4'BN!_X2;58Y;B!KF!FLXQ.9 @Q<@D?(.>#S
MVJ>R\37EV8I'9D?[0F860 "-F*=1U.1S0!W.<T4Q"",J<CUSUI] !1110 44
M44 0W$27%O+ ^=DBE#CW&*YR'P9]GACAAU_6(XHU"H@G& !VZ5U&!GI1B@#F
M_P#A$Y?^ABUG_O\ C_"C_A$Y?^AAUG_O^/\ "NEHH YD^$I"#GQ#K)SQ_KQ_
MA6QI6FPZ1IEO86[.T4"[07.6]>35W%&* ,'5/"=AJNH&]EENX9R@0M!,4R!T
MS57_ (033_\ G_U7_P "C74T4 <M_P ()I__ $$-5_\  LTA\!Z>?^8AJO\
MX%FNJHH Y7_A!-/_ .@AJO\ X%'_  H;P'IS(RM?ZH0P((^U'I7544 5;"RA
MTZQ@L[<$0PJ$0$Y.*M48HH **** "BBB@ HHHH KW$,=Q&$E0.I()!]N163J
MGABRU:]ANY6DCECZM&<%OK[T44 7(M)L([IYDM(EE8ARX');UIR:79)'<HEN
M@2XR9E[-GK]*** %M-+LK*...V@6-44JH!/ /45')H^G3)B2RA;*>5RO\&<X
M_/FBB@!K:+IC1>6;*+84$>,?P@\"G2Z-ITML;=[.(P\'9CC*C _2BB@"<6%H
M$*BWC"A@^,?Q#H:B;2=/=E#6D9"D,!CC(Z9]:** $&C:<98W^QQ;D+%3CINZ
MT?V39I>VMXL0$EM&T40'10W7^5%% "_V38>=-/\ 98O-FQYC8^]CFIWM8)))
M2\2EI$".2/O+Z444 5KC2-/O(H_/M(FVJ N!@@#H,CZFI3IUH8GB^SH$D0*R
M@8! Z"BB@")='TY)K=ULXMT"8C./N_XTMMI&GVK%H+2-&))) ]>M%% #(M'T
MZ'R?+M$3RB73&<@GK^%/FTJUG%LC)A+=BZ*/H00?;FBB@![:99.I9K6,[1M'
M'8# 'ZTR;1].G\UIK2-S(H5B?1>F/2BB@0VXT>RGA,/DA%!SE.#G///O@4Z7
M2[&6]^W26J-<E-AD/4J.Q]J** &QZ)IB10*ME$!$Y>/ ^Z?ZTTZ'I[2K*L 0
MK*9B%X#-C'-%% S0MXEAC2-!A%& *FHHH **** "BBB@ HHHH **** "BBB@
; HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
